|
US6765087B1
(en)
*
|
1992-08-21 |
2004-07-20 |
Vrije Universiteit Brussel |
Immunoglobulins devoid of light chains
|
|
WO1994025591A1
(en)
*
|
1993-04-29 |
1994-11-10 |
Unilever N.V. |
PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE)
|
|
EP0739981A1
(en)
*
|
1995-04-25 |
1996-10-30 |
Vrije Universiteit Brussel |
Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
|
|
US20040248201A1
(en)
*
|
1996-06-27 |
2004-12-09 |
Serge Muyldermans |
Recognition molecules interacting specifically with the active site or cleft of a target molecule
|
|
EP0937140B1
(en)
*
|
1996-06-27 |
2007-09-26 |
Vlaams Interuniversitair Instituut voor Biotechnologie vzw. |
Antibody molecules which interact specifically with the active site or cleft of a target molecule
|
|
HUP0001634A2
(hu)
*
|
1996-10-10 |
2000-09-28 |
Cytel Corporation |
Szénhidrátok tisztítása ultraszűréssel, fordított ozmózissal és nanoszűréssel
|
|
US20030228310A1
(en)
*
|
1996-12-23 |
2003-12-11 |
Advanced Biotherapy, Inc. |
Treatment of skin diseases
|
|
BR9907241A
(pt)
*
|
1998-01-26 |
2000-10-17 |
Unilever Nv |
Biblioteca de expressão, processo para preparar a mesma, uso de uma fonte não imunizada de sequências de ácido nucleico, e, processos para preparar fragmentos de anticorpos e, para preparar um anticorpo
|
|
JP2002512776A
(ja)
*
|
1998-04-28 |
2002-05-08 |
スミスクライン・ビーチャム・コーポレイション |
免疫原性の低下したモノクローナル抗体
|
|
EP1169453A1
(en)
|
1999-04-22 |
2002-01-09 |
Unilever Plc |
Inhibition of viral infection using monovalent antigen-binding proteins
|
|
US6924359B1
(en)
|
1999-07-01 |
2005-08-02 |
Yale University |
Neovascular-targeted immunoconjugates
|
|
CA2379214A1
(en)
|
1999-07-27 |
2001-02-01 |
Unilever Plc |
Bleaching detergent compositions
|
|
WO2001019871A2
(en)
*
|
1999-09-16 |
2001-03-22 |
Unilever Plc |
Delivery system for antidandruff agent
|
|
EP1088892A1
(en)
*
|
1999-09-24 |
2001-04-04 |
Vlaams Interuniversitair Instituut voor Biotechnologie vzw. |
Recombinant phages capable of entering host cells via specific interaction with an artificial receptor
|
|
US6479280B1
(en)
|
1999-09-24 |
2002-11-12 |
Vlaams Interuniversitair Institutuut Voor Biotechnologie Vzw |
Recombinant phages capable of entering host cells via specific interaction with an artificial receptor
|
|
US7358096B1
(en)
|
1999-11-29 |
2008-04-15 |
Conopco, Inc. |
Immobilisation of proteins
|
|
EP1118669A3
(en)
*
|
1999-12-17 |
2001-08-29 |
Unilever Plc |
Production of camelid antibodies in plants
|
|
DE60138333D1
(de)
|
2000-03-14 |
2009-05-28 |
Unilever Nv |
Variabele Domänen der schweren Kette eines Antikörpers gegen menschliche Ernährungslipasen und deren Verwendungen
|
|
US6696620B2
(en)
*
|
2000-05-02 |
2004-02-24 |
Epicyte Pharmaceutical, Inc. |
Immunoglobulin binding protein arrays in eukaryotic cells
|
|
AU2001268855A1
(en)
|
2000-05-26 |
2001-12-03 |
National Research Council Of Canada |
Single-domain antigen-binding antibody fragments derived from llama antibodies
|
|
WO2002057445A1
(en)
*
|
2000-05-26 |
2002-07-25 |
National Research Council Of Canada |
Single-domain brain-targeting antibody fragments derived from llama antibodies
|
|
US20050196755A1
(en)
*
|
2000-11-17 |
2005-09-08 |
Maurice Zauderer |
In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
|
|
CN1306272C
(zh)
*
|
2000-11-17 |
2007-03-21 |
罗切斯特大学 |
筛选编码抗原特异性免疫球蛋白分子或其抗原特异性片段的方法
|
|
US20060064782A1
(en)
*
|
2000-12-18 |
2006-03-23 |
Conopco, Inc. |
Production of antibodies
|
|
ATE441668T1
(de)
|
2000-12-19 |
2009-09-15 |
Unilever Nv |
Stabilisierung von schwerkettigen kamelantikírpern durch kaliumsalze
|
|
ES2376454T3
(es)
*
|
2000-12-22 |
2012-03-14 |
Grad, Carole, Legal Representative Of Howard, Kaplan |
Librer�?as de expresión en fago de fragmentos vh humanos.
|
|
EP1363663B1
(en)
|
2001-01-12 |
2011-03-02 |
Novartis Vaccines and Diagnostics, Inc. |
Nucleic acid mucosal immunization
|
|
US7754208B2
(en)
*
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
|
US20030133939A1
(en)
|
2001-01-17 |
2003-07-17 |
Genecraft, Inc. |
Binding domain-immunoglobulin fusion proteins
|
|
US7829084B2
(en)
|
2001-01-17 |
2010-11-09 |
Trubion Pharmaceuticals, Inc. |
Binding constructs and methods for use thereof
|
|
US20050069538A1
(en)
*
|
2003-09-18 |
2005-03-31 |
Gregorio Aversa |
Therapeutic binding molecules
|
|
US20040058445A1
(en)
*
|
2001-04-26 |
2004-03-25 |
Ledbetter Jeffrey Alan |
Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB
|
|
US20050152902A1
(en)
*
|
2001-06-05 |
2005-07-14 |
Advanced Biotherapy, Inc. |
Treatment of diabetic retinopathy
|
|
US20040086508A1
(en)
*
|
2001-06-05 |
2004-05-06 |
Advanced Biotherapy, Inc. |
Treatment of organ transplant rejection
|
|
US6861056B2
(en)
*
|
2001-06-05 |
2005-03-01 |
Advanced Biotherapy, Inc. |
Compositions and methods for treating hyperimmune response in the eye
|
|
US20040062768A1
(en)
*
|
2001-06-05 |
2004-04-01 |
Advanced Biotherapy, Inc. |
Compositions and methods for treating hyperimmune response in the eye
|
|
JP2005289809A
(ja)
|
2001-10-24 |
2005-10-20 |
Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) |
突然変異重鎖抗体
|
|
CA2471116A1
(en)
*
|
2001-12-21 |
2003-07-03 |
Serge Muyldermans |
Method for cloning of variable domain sequences
|
|
JP2005517674A
(ja)
*
|
2002-01-03 |
2005-06-16 |
フラームス・インテルウニフェルシタイル・インステイチュート・フォール・ビオテヒノロヒー・ヴェーゼットウェー |
腫瘍の処置に有用な新規免疫コンジュゲート
|
|
WO2003057728A1
(en)
|
2002-01-10 |
2003-07-17 |
Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw |
A novel splice variant of myd88 and uses thereof
|
|
US7736657B2
(en)
|
2002-02-10 |
2010-06-15 |
Apoxis S.A. |
Fusion constructs containing active sections on TNF ligands
|
|
US20030219436A1
(en)
*
|
2002-03-15 |
2003-11-27 |
Ledbetter Jeffrey A. |
Compositions and methods to regulate an immune response using CD83 gene expressed in tumors and using soluble CD83-Ig fusion protein
|
|
ATE328906T1
(de)
*
|
2002-06-28 |
2006-06-15 |
Domantis Ltd |
Dual-specifische liganden mit erhöhter halbwertszeit
|
|
US9321832B2
(en)
|
2002-06-28 |
2016-04-26 |
Domantis Limited |
Ligand
|
|
EP2283869A3
(en)
|
2002-07-15 |
2012-06-27 |
Board of Regents, The University of Texas System |
Selected antibodies and duramycin peptides binding to anionic phospholipids and aminophospholipids and their use in the treatment of viral infections and cancer
|
|
ATE512364T1
(de)
|
2002-08-07 |
2011-06-15 |
Ablynx Nv |
Modulation der blutplättchen-adhäsion basierend auf dem oberflächen-exponierten beta-switch loop des blutplättchen-glycoproteins ib-alpha
|
|
ES2381617T5
(es)
|
2002-08-14 |
2016-02-24 |
Macrogenics, Inc. |
Anticuerpos específicos frente a FcgammaRIIB y sus procedimientos de uso
|
|
GB0219720D0
(en)
*
|
2002-08-23 |
2002-10-02 |
Univ Aberdeen |
Polypeptide
|
|
US20040052790A1
(en)
*
|
2002-09-18 |
2004-03-18 |
Advanced Biotherapy, Inc. |
Treatment of schizophrenia
|
|
US9320792B2
(en)
|
2002-11-08 |
2016-04-26 |
Ablynx N.V. |
Pulmonary administration of immunoglobulin single variable domains and constructs thereof
|
|
US20060034845A1
(en)
|
2002-11-08 |
2006-02-16 |
Karen Silence |
Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
|
|
JP2006519763A
(ja)
|
2002-11-08 |
2006-08-31 |
アブリンクス エン．ヴェー． |
治療用ポリペプチドの投与法およびそのためのポリペプチド
|
|
BRPI0316092B8
(pt)
|
2002-11-08 |
2021-05-25 |
Ablynx Nv |
anticorpos de domínio único direcionados contra o fator de necrose tumoral alfa e usos para os mesmos
|
|
GB0230203D0
(en)
*
|
2002-12-27 |
2003-02-05 |
Domantis Ltd |
Fc fusion
|
|
BRPI0406694B8
(pt)
|
2003-01-10 |
2021-05-25 |
Ablynx Nv |
polipeptídios terapêutico, seus homólogos, seus fragmentos, que são usados nas modulações da agregação plaquetária
|
|
EP1437764A1
(en)
*
|
2003-01-10 |
2004-07-14 |
S.O.I. Tec Silicon on Insulator Technologies S.A. |
A compliant substrate for a heteroepitaxy, a heteroepitaxial structure and a method for fabricating a compliant substrate
|
|
US7354584B2
(en)
|
2003-04-11 |
2008-04-08 |
Medimmune, Inc. |
Recombinant IL-9 antibodies
|
|
ES2315664T3
(es)
|
2003-06-30 |
2009-04-01 |
Domantis Limited |
Anticuerpos de dominio unico (dab) pegilados.
|
|
US7754209B2
(en)
|
2003-07-26 |
2010-07-13 |
Trubion Pharmaceuticals |
Binding constructs and methods for use thereof
|
|
SI3095793T1
(sl)
|
2003-07-28 |
2020-07-31 |
Genentech, Inc. |
Zmanjšanje izluževanja proteina A med afinitetno kromatografijo proteina A
|
|
CA2534661A1
(en)
|
2003-08-08 |
2005-02-17 |
Genenews Inc. |
Osteoarthritis biomarkers and uses thereof
|
|
WO2005081687A2
(en)
*
|
2003-09-30 |
2005-09-09 |
Centocor, Inc. |
Human hinge core mimetibodies, compositions, methods and uses
|
|
US20050112130A1
(en)
|
2003-11-05 |
2005-05-26 |
Bhat Neelima M. |
Enhanced B cell cytotoxicity of CDIM binding antibody
|
|
EP2251357A1
(en)
|
2003-11-07 |
2010-11-17 |
Ablynx N.V. |
Camelidae single domain antibodies VHH directed against epidermal growth factor receptor and uses therefor
|
|
DK1697399T3
(en)
*
|
2003-12-12 |
2017-03-06 |
Government Of The United States Of America As Repr By The Secr Of The Dept Of Health And Human Servi |
Human cytotoxic t lymphocyte epitope and its agonist epitope from the non-variable number of muc-1 tandem repeat sequences
|
|
US7785903B2
(en)
|
2004-04-09 |
2010-08-31 |
Genentech, Inc. |
Variable domain library and uses
|
|
WO2005105984A2
(en)
*
|
2004-04-12 |
2005-11-10 |
The Trustees Of The University Of Pennsylvania |
Culture conditions and growth factors affecting fate determination, self-renewal and expansion of mouse spermatogonial stem cells
|
|
WO2005121797A2
(en)
*
|
2004-06-04 |
2005-12-22 |
Genencor International, Inc. |
Screening method using antibody heavy chains
|
|
US20050276806A1
(en)
*
|
2004-06-15 |
2005-12-15 |
Advanced Biotherapy, Inc. |
Treatment of autism
|
|
US20050276807A1
(en)
*
|
2004-06-15 |
2005-12-15 |
Advanced Biotherapy, Inc. |
Treatment of acne
|
|
ES2523661T3
(es)
|
2004-07-22 |
2014-11-28 |
Erasmus University Medical Center Rotterdam |
Moléculas de unión
|
|
GB2416768A
(en)
*
|
2004-07-22 |
2006-02-08 |
Univ Erasmus |
Heavy chain immunoglobulin complexes
|
|
US20060177445A1
(en)
*
|
2004-08-16 |
2006-08-10 |
Boris Skurkovich |
Treatment of inflammatory skin diseases
|
|
US7563443B2
(en)
|
2004-09-17 |
2009-07-21 |
Domantis Limited |
Monovalent anti-CD40L antibody polypeptides and compositions thereof
|
|
KR20070084069A
(ko)
|
2004-10-08 |
2007-08-24 |
도만티스 리미티드 |
Ｔｎｆｒ1에 대한 단일 도메인 항체 및 이의 사용 방법
|
|
US7462454B2
(en)
*
|
2004-10-12 |
2008-12-09 |
Advanced Biotherapy, Inc. |
Treatment of herpes
|
|
WO2006040153A2
(en)
*
|
2004-10-13 |
2006-04-20 |
Ablynx N.V. |
Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease
|
|
WO2006047639A2
(en)
|
2004-10-27 |
2006-05-04 |
Medimmune, Inc. |
Modulation of antibody specificity by tailoring the affinity to cognate antigens
|
|
EP1836500B1
(en)
|
2005-01-14 |
2010-07-07 |
Ablynx N.V. |
METHODS AND ASSAYS FOR DISTINGUISHING BETWEEN DIFFERENT FORMS OF DISEASES AND DISORDERS CHARACTERIZED BY THROMBOCYTOPENIA AND/OR BY SPONTANEOUS INTERACTION BETWEEN VON WILLEBRAND FACTOR (vWF) AND PLATELETS
|
|
CA2595682A1
(en)
*
|
2005-01-31 |
2006-08-03 |
Ablynx N.V. |
Method for generating variable domain sequences of heavy chain antibodies
|
|
CA2599589A1
(en)
|
2005-02-07 |
2006-08-17 |
Genenews,Inc. |
Mild osteoarthritis biomarkers and uses thereof
|
|
CA2596506C
(en)
|
2005-02-09 |
2021-04-06 |
Avi Biopharma, Inc. |
Antisense composition and method for treating muscle atrophy
|
|
DK1863849T3
(da)
|
2005-03-11 |
2011-08-08 |
Syngenta Ltd |
Bekæmpelse af gnavere
|
|
EP1877101B1
(en)
|
2005-04-28 |
2016-11-16 |
Ventana Medical Systems, Inc. |
Enzymes conjugated to antibodies via a peg heterobifuctional linker
|
|
CA2606018A1
(en)
*
|
2005-04-28 |
2006-11-02 |
Ventana Medical Systems, Inc. |
Nanoparticle conjugates
|
|
RU2464276C2
(ru)
|
2005-05-18 |
2012-10-20 |
Аблинкс Н.В. |
Улучшенные нанотела против фактора некроза опухоли-альфа
|
|
LT2444424T
(lt)
|
2005-05-20 |
2018-10-25 |
Ablynx N.V. |
Pagerintos tm nanodalelės, skirtos agregacijos sąlygotų sutrikimų gydymui
|
|
DE102005023617A1
(de)
|
2005-05-21 |
2006-11-23 |
Aspre Ag |
Verfahren zum Mischen von Farben in einem Display
|
|
EP2586798A3
(en)
|
2005-07-25 |
2013-08-07 |
Emergent Product Development Seattle, LLC |
B-cell reduction using CD37-specific and CD20-specific binding molecules
|
|
WO2007027714A2
(en)
|
2005-08-31 |
2007-03-08 |
Schering Corporation |
Engineered anti-il-23 antibodies
|
|
JP2009507023A
(ja)
|
2005-09-01 |
2009-02-19 |
シェーリング コーポレイション |
自己免疫性眼炎症性疾患を処置するためのｉｌ−２３およびｉｌ−１７のアンタゴニストの使用
|
|
CA2623659A1
(en)
*
|
2005-09-27 |
2007-04-05 |
National Research Council Of Canada |
Targeted delivery of compounds using multimerization technology
|
|
AU2006297304B2
(en)
*
|
2005-09-29 |
2012-05-17 |
Medimmune, Llc |
Method of identifying membrane LG specific antibodies and use thereof for targeting immunoglobulin-producing precursor cells
|
|
US7526409B2
(en)
*
|
2005-10-07 |
2009-04-28 |
Oracle International Corporation |
Automatic performance statistical comparison between two periods
|
|
GB0521139D0
(en)
|
2005-10-18 |
2005-11-23 |
Univ Sheffield |
Therapeutic agent
|
|
AU2006304883A1
(en)
|
2005-10-21 |
2007-04-26 |
Genenews Inc. |
Method and apparatus for correlating levels of biomarker products with disease
|
|
GB0522460D0
(en)
*
|
2005-11-03 |
2005-12-14 |
Prendergast Patrick T |
Composition and method for the treatment of avian influenza
|
|
CN101535244B
(zh)
*
|
2005-11-23 |
2014-07-23 |
文塔納医疗系统公司 |
分子缀合物
|
|
US10183986B2
(en)
|
2005-12-15 |
2019-01-22 |
Industrial Technology Research Institute |
Trimeric collagen scaffold antibodies
|
|
WO2007082899A1
(en)
|
2006-01-17 |
2007-07-26 |
Vib Vzw |
Inhibitors of prolyl-hydroxylase 1 for the treatment of skeletal muscle degeneration
|
|
EP1976991A1
(en)
*
|
2006-01-24 |
2008-10-08 |
Domantis Limited |
Fusion proteins that contain natural junctions
|
|
TW200744634A
(en)
|
2006-02-21 |
2007-12-16 |
Wyeth Corp |
Methods of using antibodies against human IL-22
|
|
TWI417301B
(zh)
|
2006-02-21 |
2013-12-01 |
Wyeth Corp |
對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途
|
|
US7504106B2
(en)
*
|
2006-03-14 |
2009-03-17 |
Boris Skurkovich |
Method and composition for treatment of renal failure with antibodies and their equivalents as partial or complete replacement for dialysis
|
|
US20100226920A1
(en)
*
|
2006-03-27 |
2010-09-09 |
Ablynx N.V. |
Medical delivery device for therapeutic proteins based on single domain antibodies
|
|
WO2008054514A2
(en)
*
|
2006-04-21 |
2008-05-08 |
Wyeth |
Differential expression profiling analysis of cell culture phenotypes and the uses thereof
|
|
CA2649932A1
(en)
|
2006-05-02 |
2007-11-15 |
Actogenix Nv |
Microbial intestinal delivery of obesity related peptides
|
|
EP3805269A1
(en)
|
2006-06-12 |
2021-04-14 |
Aptevo Research and Development LLC |
Single-chain multivalent binding proteins with effector function
|
|
MX2008015771A
(es)
|
2006-06-14 |
2009-01-27 |
Macrogenics Inc |
Metodos para el tratamiento de padecimientos autoinmunes usando anticuerpos monoclonales con toxicidad reducida.
|
|
EP2505209A1
(en)
|
2006-06-26 |
2012-10-03 |
MacroGenics, Inc. |
Fcgamma-RIIB-specific antibodies and methods of the use thereof
|
|
CN101541950A
(zh)
|
2006-07-13 |
2009-09-23 |
惠氏公司 |
糖蛋白的产生
|
|
CA2661782C
(en)
|
2006-08-28 |
2019-04-16 |
La Jolla Institute For Allergy And Immunology |
Antagonistic human light-specific human monoclonal antibodies
|
|
NZ576195A
(en)
|
2006-10-10 |
2012-04-27 |
Az Univ Amsterdam |
Complement inhibition for improved nerve regeneration
|
|
GB0621513D0
(en)
|
2006-10-30 |
2006-12-06 |
Domantis Ltd |
Novel polypeptides and uses thereof
|
|
JP5576120B2
(ja)
*
|
2006-11-01 |
2014-08-20 |
ベンタナ・メデイカル・システムズ・インコーポレーテツド |
ハプテン、ハプテンコンジュゲート、その組成物ならびにそれらの製造および使用の方法
|
|
WO2008055924A1
(en)
|
2006-11-07 |
2008-05-15 |
Vib Vzw |
Diagnosis and treatment of t-cell acute lymphoblastic leukemia
|
|
AU2007325838B2
(en)
|
2006-11-22 |
2013-09-19 |
Bristol-Myers Squibb Company |
Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR
|
|
WO2008068280A1
(en)
*
|
2006-12-05 |
2008-06-12 |
Ablynx N.V. |
Peptides capable of binding to serum proteins
|
|
AR064333A1
(es)
|
2006-12-14 |
2009-04-01 |
Schering Corp |
Anticuerpo anti-tslp de diseno
|
|
EP2115004A2
(en)
|
2006-12-19 |
2009-11-11 |
Ablynx N.V. |
Amino acid sequences directed against gpcrs and polypeptides comprising the same for the treatment of gpcr-related diseases and disorders
|
|
EP2514767A1
(en)
|
2006-12-19 |
2012-10-24 |
Ablynx N.V. |
Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders
|
|
US9023352B2
(en)
|
2007-02-20 |
2015-05-05 |
Tufts University |
Methods, compositions and kits for treating a subject using a recombinant heteromultimeric neutralizing binding protein
|
|
CA2678218A1
(en)
*
|
2007-02-21 |
2008-08-28 |
Ablynx N.V. |
Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization
|
|
JP2010518856A
(ja)
|
2007-02-23 |
2010-06-03 |
シェーリング コーポレイション |
操作された抗−ＩＬ−２３ｐ１９抗体
|
|
JP2010518858A
(ja)
|
2007-02-23 |
2010-06-03 |
シェーリング コーポレイション |
操作された抗−ｉｌ−２３ｐ１９抗体
|
|
EP2056838B1
(en)
|
2007-02-28 |
2013-09-25 |
Merck Sharp & Dohme Corp. |
Combination therapy for treatment of immune disorders
|
|
EP2057194B1
(en)
|
2007-02-28 |
2013-03-20 |
Merck Sharp & Dohme Corp. |
Engineered anti-il-23r antibodies
|
|
US9012180B2
(en)
|
2007-03-02 |
2015-04-21 |
Wyeth Llc |
Use of copper and glutamate in cell culture for production of polypeptides
|
|
SI2308514T1
(sl)
|
2007-03-23 |
2013-09-30 |
To-Bbb Holding B.V. |
Konjugati za prenos zdravila preko krvno-moĹľganske pregrade
|
|
TW200902708A
(en)
|
2007-04-23 |
2009-01-16 |
Wyeth Corp |
Methods of protein production using anti-senescence compounds
|
|
EP2164868B1
(en)
|
2007-05-04 |
2015-03-25 |
Technophage, Investigação E Desenvolvimento Em Biotecnologia, SA |
Engineered rabbit antibody variable domains and uses thereof
|
|
SI3072525T1
(en)
|
2007-05-14 |
2018-06-29 |
Astrazeneca Ab |
Procedures for lowering the levels of basophiles
|
|
EP3561513A1
(en)
|
2007-05-23 |
2019-10-30 |
Ventana Medical Systems, Inc. |
Polymeric carriers for immunohistochemistry and in situ hybridization
|
|
ES2664218T3
(es)
|
2007-06-01 |
2018-04-18 |
Open Monoclonal Technology, Inc |
Composiciones y procedimientos de inhibición de genes de inmunoglobulinas endógenas y de producción de anticuerpos idiotípicos humanos transgénicos
|
|
WO2008157299A2
(en)
*
|
2007-06-15 |
2008-12-24 |
Wyeth |
Differential expression profiling analysis of cell culture phenotypes and uses thereof
|
|
US10214588B2
(en)
|
2007-07-03 |
2019-02-26 |
Ablynx N.V. |
Providing improved immunoglobulin sequences by mutating CDR and/or FR positions
|
|
US8329421B2
(en)
|
2007-07-13 |
2012-12-11 |
Ventana Medical Systems, Inc. |
Methods of predicting response of a neoplasm to an EGFR inhibitor and detecting interactions between EGFR and an EGFR regulatory protein
|
|
EP2170960B1
(en)
|
2007-07-13 |
2015-07-29 |
Bac Ip B.V. |
Single-domain antigen-binding proteins that bind mammalian igg
|
|
ES2657055T3
(es)
|
2007-08-09 |
2018-03-01 |
Wyeth Llc |
Uso de perfusión para mejorar la producción de un cultivo de células alimentado por lotes en biorreactores
|
|
EP2535349A1
(en)
|
2007-09-26 |
2012-12-19 |
UCB Pharma S.A. |
Dual specificity antibody fusions
|
|
TWI489993B
(zh)
|
2007-10-12 |
2015-07-01 |
Novartis Ag |
骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法
|
|
US8216571B2
(en)
|
2007-10-22 |
2012-07-10 |
Schering Corporation |
Fully human anti-VEGF antibodies and methods of using
|
|
JP5514399B2
(ja)
*
|
2007-11-02 |
2014-06-04 |
国立大学法人 岡山大学 |
無機硫黄化合物加水分解酵素の製造方法
|
|
WO2009056634A2
(en)
|
2007-11-02 |
2009-05-07 |
Novartis Ag |
Molecules and methods for modulating low-density-lipoprotein receptor-related protein 6 (lrp6)
|
|
EP2902495B1
(en)
|
2007-11-09 |
2019-12-25 |
The Salk Institute for Biological Studies |
Use of tam receptor activators as immunosuppressors
|
|
BRPI0819656A2
(pt)
|
2007-11-27 |
2015-06-23 |
Ablynx Nv |
Seqüências de aminoácidos contras citocinas heterodiméricas e/ou seus receptores e polipeptídeos compreendendo as mesmas
|
|
WO2009070642A1
(en)
|
2007-11-28 |
2009-06-04 |
Medimmune, Llc |
Protein formulation
|
|
WO2009086215A2
(en)
*
|
2007-12-21 |
2009-07-09 |
Wyeth |
Pathway analysis of cell culture phenotypes and uses thereof
|
|
EP2250196B1
(en)
|
2008-01-31 |
2012-12-26 |
The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services |
Engineered constant domain molecule of an antibody
|
|
DE112009000507T5
(de)
|
2008-03-05 |
2011-02-10 |
Ablynx Nv |
Neue Antigen-bindende Dimerkomplexe, Verfahren zu ihrer Herstellung und ihre Verwendung
|
|
GB0809069D0
(en)
|
2008-05-19 |
2008-06-25 |
Univ Leuven Kath |
Gene signatures
|
|
US9908943B2
(en)
|
2008-04-03 |
2018-03-06 |
Vib Vzw |
Single domain antibodies capable of modulating BACE activity
|
|
US8568717B2
(en)
|
2008-04-03 |
2013-10-29 |
Vib Vzw |
Single domain antibodies capable of modulating BACE activity
|
|
CN102056945A
(zh)
|
2008-04-07 |
2011-05-11 |
埃博灵克斯股份有限公司 |
针对Notch途径的单可变结构域
|
|
RU2531754C2
(ru)
|
2008-04-11 |
2014-10-27 |
ЭМЕРДЖЕНТ ПРОДАКТ ДИВЕЛОПМЕНТ СИЭТЛ,ЭлЭлСи,US |
Связывающееся с cd37 иммунотерапевтическое средство и его комбинация с бифункциональным химиотерапевтическим средством
|
|
WO2009127691A1
(en)
|
2008-04-17 |
2009-10-22 |
Ablynx N.V. |
Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
|
|
US9296810B2
(en)
|
2008-05-02 |
2016-03-29 |
Novartis Ag |
Fibronectin-based binding molecules and uses thereof
|
|
PE20091931A1
(es)
|
2008-05-22 |
2009-12-31 |
Bristol Myers Squibb Co |
Proteinas de dominio de armazon basadas en fibronectina multivalentes
|
|
CA2720728C
(en)
|
2008-06-05 |
2018-04-03 |
Ventana Medical Systems, Inc. |
Compositions comprising nanomaterials and method for using such compositions for histochemical processes
|
|
GB2461546B
(en)
*
|
2008-07-02 |
2010-07-07 |
Argen X Bv |
Antigen binding polypeptides
|
|
US8444976B2
(en)
|
2008-07-02 |
2013-05-21 |
Argen-X B.V. |
Antigen binding polypeptides
|
|
EP2321352B1
(en)
|
2008-07-18 |
2016-01-06 |
Bristol-Myers Squibb Company |
Compositions monovalent for cd28 binding and methods of use
|
|
US9034325B2
(en)
|
2008-07-22 |
2015-05-19 |
Ablynx N.V. |
Amino acid sequences directed against multitarget scavenger receptors and polypeptides
|
|
UA105009C2
(uk)
|
2008-08-05 |
2014-04-10 |
Новартіс Аг |
Композиції та способи, призначені для спрямованого впливу антитіл на білок с5 системи комплементу
|
|
US20100092470A1
(en)
*
|
2008-09-22 |
2010-04-15 |
Icb International, Inc. |
Antibodies, analogs and uses thereof
|
|
US20100136584A1
(en)
*
|
2008-09-22 |
2010-06-03 |
Icb International, Inc. |
Methods for using antibodies and analogs thereof
|
|
WO2010039533A2
(en)
|
2008-09-23 |
2010-04-08 |
Wyeth |
Methods for predicting production of activating signals by cross-linked binding proteins
|
|
MX345226B
(es)
|
2008-10-29 |
2017-01-20 |
Ablynx Nv |
Formulaciones de moleculas de union a antigeno de dominio sencillo.
|
|
JP6113404B2
(ja)
|
2008-10-29 |
2017-04-12 |
アブリンクス エン．ヴェー． |
単一ドメイン抗原結合分子の精製方法
|
|
CN102257131A
(zh)
|
2008-12-19 |
2011-11-23 |
先灵公司 |
用于哺乳动物细胞培养的给料添加剂及使用方法
|
|
ES2729320T3
(es)
|
2008-12-19 |
2019-10-31 |
Ablynx Nv |
Inmunización genética para producir inmunoglobulinas contra antígenos asociados a células tales como P2X7, CXCR7 o CXCR4
|
|
EP2387583B1
(en)
|
2009-01-14 |
2018-09-19 |
Ablynx N.V. |
Pulmonary administration of immunoglobulin single variable domains and constructs thereof
|
|
US20100189919A1
(en)
*
|
2009-01-27 |
2010-07-29 |
Xerox Corporation |
Imaging System And Process Using Monoclonal Antibodies
|
|
EP2394159B1
(en)
|
2009-02-04 |
2018-09-26 |
Molecular Innovations |
Assays for detecting prorenin, and antibodies used therein
|
|
WO2010100135A1
(en)
|
2009-03-05 |
2010-09-10 |
Ablynx N.V. |
Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof
|
|
EP2230515B1
(en)
*
|
2009-03-16 |
2014-12-17 |
Agilent Technologies, Inc. |
Passivation of surfaces after ligand coupling
|
|
JP6159528B2
(ja)
|
2009-03-24 |
2017-07-05 |
ワイス・エルエルシー |
高濃縮のタンパク質治療薬を生成するための膜蒸発
|
|
GB0905023D0
(en)
|
2009-03-24 |
2009-05-06 |
Univ Erasmus Medical Ct |
Binding molecules
|
|
MX2011010681A
(es)
|
2009-04-10 |
2012-01-20 |
Ablynx Nv |
Secuencias mejoradas de aminoacidos dirigidas contra il-6r y polipeptidos que comprenden el mismo para el tratamiento de enfermedades y trastornos relacionados con il-6r.
|
|
AR076402A1
(es)
|
2009-04-27 |
2011-06-08 |
Novartis Ag |
Composiciones y metodos para aumentar el crecimiento muscular
|
|
AU2010230311B9
(en)
|
2009-04-27 |
2012-09-20 |
Novartis Ag |
Composition and methods of use for therapeutic antibodies specific for the IL-12 receptore betal subunit
|
|
HUE053480T2
(hu)
|
2009-04-30 |
2021-06-28 |
Ablynx Nv |
Eljárás domén ellenanyagok elõállítására
|
|
EP2432499A2
(en)
|
2009-05-20 |
2012-03-28 |
Schering Corporation |
Modulation of pilr receptors to treat microbial infections
|
|
BRPI1010830A2
(pt)
|
2009-06-05 |
2023-11-14 |
Ablynx Nv |
Sequências de aminoácidos melhoradas direcionadas contra o vírus respiratório sencicial humano (hrsv) e polipetídeos que compreende os mesmos para prevenção e/ou tratamento de infecções do trato respiratório.
|
|
AU2010268690B2
(en)
|
2009-07-03 |
2011-11-10 |
Avipep Pty Ltd |
Immuno-conjugates and methods for producing them
|
|
HUE051430T2
(hu)
|
2009-07-10 |
2021-03-01 |
Ablynx Nv |
Eljárás variábilis domének elõállítására
|
|
JP5426026B2
(ja)
|
2009-07-28 |
2014-02-26 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
非侵襲性インビボ光学イメージング方法
|
|
AR077594A1
(es)
|
2009-07-31 |
2011-09-07 |
Organon Nv |
Anticuerpos completamente humanos para btla (atenuante de linfocitos b y t)
|
|
DK2464657T3
(en)
|
2009-08-10 |
2015-06-29 |
Morphosys Ag |
New screening strategies for the identification of antibodies or fragments thereof which bind an antigen with enzymatic activity
|
|
WO2011027132A1
(en)
|
2009-09-03 |
2011-03-10 |
Cancer Research Technology Limited |
Clec14a inhibitors
|
|
EP3438126B1
(en)
|
2009-09-03 |
2020-08-19 |
Ablynx N.V. |
Stable formulations of polypeptides and uses thereof
|
|
ES2788869T3
(es)
|
2009-09-03 |
2020-10-23 |
Merck Sharp & Dohme |
Anticuerpos anti-GITR
|
|
WO2011029823A1
(en)
|
2009-09-09 |
2011-03-17 |
Novartis Ag |
Monoclonal antibody reactive with cd63 when expressed at the surface of degranulated mast cells
|
|
GB201005063D0
(en)
|
2010-03-25 |
2010-05-12 |
Ucb Pharma Sa |
Biological products
|
|
UY32920A
(es)
|
2009-10-02 |
2011-04-29 |
Boehringer Ingelheim Int |
Moleculas de unión biespecíficas para la terapia anti-angiogénesis
|
|
US20110195494A1
(en)
|
2009-10-02 |
2011-08-11 |
Boehringer Ingelheim International Gmbh |
Dll4-binging molecules
|
|
WO2011042398A1
(en)
|
2009-10-09 |
2011-04-14 |
Ablynx Nv |
Immunoglobulin single variable domain directed against human cxcr4 and other cell associated proteins and methods to generate them
|
|
WO2011045079A1
(en)
|
2009-10-15 |
2011-04-21 |
Intercell Ag |
Hepatitis b virus specific human antibodies
|
|
US9340605B2
(en)
|
2009-10-22 |
2016-05-17 |
Universiteit Twente |
VHH for application in tissue repair, organ regeneration, organ replacement and tissue engineering
|
|
EA201792376A3
(ru)
|
2009-10-23 |
2018-08-31 |
Милленниум Фармасьютикалз, Инк. |
Молекулы анти-gcc антитела и соответствующие композиции и способы
|
|
WO2011051327A2
(en)
|
2009-10-30 |
2011-05-05 |
Novartis Ag |
Small antibody-like single chain proteins
|
|
ES2691717T3
(es)
|
2009-10-30 |
2018-11-28 |
Novartis Ag |
Bibliotecas universales del dominio de unión del lado inferior de tipo iii de la fibronectina de tipo III
|
|
WO2011051466A1
(en)
|
2009-11-02 |
2011-05-05 |
Novartis Ag |
Anti-idiotypic fibronectin-based binding molecules and uses thereof
|
|
PE20121646A1
(es)
|
2009-11-04 |
2012-12-02 |
Merck Sharp & Dohme |
Anticuerpo anti-tslp modificado por tecnicas de ingeneria genetica
|
|
JP2013509869A
(ja)
|
2009-11-05 |
2013-03-21 |
ノバルティス アーゲー |
線維症の進行の予測用バイオマーカー
|
|
WO2011064382A1
(en)
|
2009-11-30 |
2011-06-03 |
Ablynx N.V. |
Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
|
|
AU2010328046C1
(en)
*
|
2009-12-10 |
2018-01-18 |
Regeneron Pharmaceuticals, Inc. |
Mice that make heavy chain antibodies
|
|
WO2011072266A2
(en)
|
2009-12-11 |
2011-06-16 |
Atyr Pharma, Inc. |
Aminoacyl trna synthetases for modulating hematopoiesis
|
|
EP3309176B1
(en)
|
2009-12-14 |
2025-10-01 |
Ablynx N.V. |
Immunoglobulin single variable domain antibodies against ox40l, constructs and their therapeutic use
|
|
EP2513308B1
(en)
|
2009-12-17 |
2017-01-18 |
Merck Sharp & Dohme Corp. |
Modulation of pilr to treat immune disorders
|
|
US9315581B2
(en)
|
2009-12-23 |
2016-04-19 |
A Vipep Pty Limited |
Immuno-conjugates and methods for producing them
|
|
WO2011083141A2
(en)
|
2010-01-08 |
2011-07-14 |
Ablynx Nv |
Method for generation of immunoglobulin sequences by using lipoprotein particles
|
|
AR079944A1
(es)
|
2010-01-20 |
2012-02-29 |
Boehringer Ingelheim Int |
Anticuerpo neutralizante de la actividad de un anticoagulante
|
|
AU2011212442A1
(en)
|
2010-02-05 |
2012-08-09 |
Ablynx Nv |
Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same
|
|
US20120296403A1
(en)
|
2010-02-10 |
2012-11-22 |
Novartis Ag |
Methods and compounds for muscle growth
|
|
US9120855B2
(en)
|
2010-02-10 |
2015-09-01 |
Novartis Ag |
Biologic compounds directed against death receptor 5
|
|
PL2533761T3
(pl)
|
2010-02-11 |
2019-09-30 |
Ablynx N.V. |
Sposoby i kompozycje do wytwarzania aerozoli
|
|
EP2533814A2
(en)
|
2010-02-11 |
2012-12-19 |
Ablynx N.V. |
Delivery of immunoglobulin variable domains and constructs thereof
|
|
JP5726917B2
(ja)
|
2010-02-26 |
2015-06-03 |
ヴェンタナ メディカル システムズ， インク． |
ポリタグプローブ
|
|
AU2011222980B2
(en)
|
2010-03-03 |
2016-08-11 |
Ablynx N.V. |
Biparatopic Abeta binding polypeptides
|
|
WO2011117423A1
(en)
|
2010-03-26 |
2011-09-29 |
Ablynx N.V. |
Immunoglobulin single variable domains directed against cxcr7
|
|
WO2011117392A2
(en)
|
2010-03-26 |
2011-09-29 |
Universitaetsklinikum Muenster |
Substitute therapy for glucocorticoids
|
|
US9556273B2
(en)
|
2010-03-29 |
2017-01-31 |
Vib Vzw |
Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages
|
|
US9101674B2
(en)
|
2010-03-29 |
2015-08-11 |
Vib Vzw |
Targeting and in vivo imaging of tumor-associated macrophages
|
|
WO2011124612A1
(en)
|
2010-04-06 |
2011-10-13 |
Vib Vzw |
Specific delivery of agrochemicals
|
|
GB201105584D0
(en)
|
2011-04-01 |
2011-05-18 |
Imp Innovations Ltd |
Cancer methods
|
|
JP5822913B2
(ja)
|
2010-04-20 |
2015-11-25 |
ヴェンタナ メディカル システムズ， インク． |
２色発色性インサイツハイブリダイゼーション
|
|
US8980253B2
(en)
|
2010-04-26 |
2015-03-17 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-tRNA synthetase
|
|
EP2563381B1
(en)
|
2010-04-27 |
2017-08-09 |
aTyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl trna synthetases
|
|
CA2797271C
(en)
|
2010-04-28 |
2021-05-25 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl trna synthetases
|
|
JP5991963B2
(ja)
|
2010-04-29 |
2016-09-14 |
エータイアー ファーマ， インコーポレイテッド |
バリルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
|
|
JP6008838B2
(ja)
|
2010-04-29 |
2016-10-19 |
エータイアー ファーマ， インコーポレイテッド |
アスパラギニルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
|
|
US9068177B2
(en)
|
2010-04-29 |
2015-06-30 |
Atyr Pharma, Inc |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-tRNA synthetases
|
|
PT2563813E
(pt)
|
2010-04-30 |
2015-11-26 |
Alexion Pharma Inc |
Anticorpos anti-c5a e métodos para utilização dos anticorpos
|
|
EP2566496B1
(en)
|
2010-05-03 |
2018-02-28 |
aTyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of methionyl-trna synthetases
|
|
EP2566515B1
(en)
|
2010-05-03 |
2017-08-02 |
aTyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of arginyl-trna synthetases
|
|
EP2566495B1
(en)
|
2010-05-03 |
2017-03-01 |
aTyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-trna synthetases
|
|
US8877188B2
(en)
|
2010-05-04 |
2014-11-04 |
The Brigham And Women's Hospital, Inc. |
Detection and treatment of non-dermal fibrosis
|
|
CA2805267C
(en)
|
2010-05-04 |
2019-07-30 |
The Brigham And Women's Hospital, Inc. |
Detection and treatment of fibrosis
|
|
CN102985103A
(zh)
|
2010-05-04 |
2013-03-20 |
Atyr医药公司 |
与p38多-tRNA合成酶复合物相关的治疗、诊断和抗体组合物的创新发现
|
|
EP3345926B1
(en)
|
2010-05-06 |
2023-04-05 |
Novartis AG |
Compositions and methods of use for therapeutic low density lipoprotein-related protein 6 (lrp6) antibodies
|
|
US9290573B2
(en)
|
2010-05-06 |
2016-03-22 |
Novartis Ag |
Therapeutic low density lipoprotein-related protein 6 (LRP6) multivalent antibodies
|
|
RU2012148816A
(ru)
|
2010-05-07 |
2014-06-20 |
Ф. Хоффманн-Ля Рош Аг |
Метод диагностики для определения клеток ex vivo
|
|
WO2011143482A2
(en)
|
2010-05-14 |
2011-11-17 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-trna synthetases
|
|
MX2012013490A
(es)
|
2010-05-20 |
2013-01-29 |
Ablynx Nv |
Materiales biologicos relacionados con her3.
|
|
BR112012033119A2
(pt)
|
2010-06-22 |
2016-10-25 |
Univ Colorado Regents |
anticorpos para o fragamento c3d do componente do complemento 3.
|
|
WO2011161263A1
(en)
|
2010-06-25 |
2011-12-29 |
Ablynx Nv |
Pharmaceutical compositions for cutaneous administration
|
|
EP2588443A2
(en)
|
2010-07-02 |
2013-05-08 |
Ventana Medical Systems, Inc. |
Hapten conjugates for target detection
|
|
CA2805548A1
(en)
|
2010-07-02 |
2012-01-05 |
Vib Vzw |
The role of fragile x mental retardation gene and protein in cancer metastasis
|
|
CA2804416C
(en)
|
2010-07-12 |
2020-04-28 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-trna synthetases
|
|
GB201014715D0
(en)
|
2010-09-06 |
2010-10-20 |
Vib Vzw |
Nanobodies stabilizing functional conformational states of GPCRS
|
|
JP2013536175A
(ja)
|
2010-07-16 |
2013-09-19 |
アブリンクス エン．ヴェー． |
修飾された単一ドメイン抗原結合分子及びその使用
|
|
GB201012845D0
(en)
|
2010-07-30 |
2010-09-15 |
Vib Vzw |
Inhibition of dicer function for treatment of cancer
|
|
ES2612459T3
(es)
|
2010-08-02 |
2017-05-17 |
Regeneron Pharmaceuticals, Inc. |
Ratones que producen proteínas de unión que comprenden dominios VL
|
|
US9127028B2
(en)
|
2010-08-16 |
2015-09-08 |
Ventana Medical Systems, Inc. |
Substrates for chromogenic detection and methods of use in detection assays and kits
|
|
PL2606070T4
(pl)
|
2010-08-20 |
2017-06-30 |
Novartis Ag |
Przeciwciała dla receptora epidermalnego czynnika wzrostu 3 (her3)
|
|
WO2012023085A1
(en)
|
2010-08-20 |
2012-02-23 |
Wyeth Llc |
Cell culture of growth factor-free adapted cells
|
|
AU2011293294B2
(en)
|
2010-08-25 |
2016-03-24 |
Pangu Biopharma Limited |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Tyrosyl-tRNA synthetases
|
|
HUE036251T2
(hu)
|
2010-08-26 |
2018-06-28 |
Agrosavfe N V |
Kitinféle poliszacharid antigént kötõ fehérjék
|
|
WO2012025602A1
(en)
|
2010-08-26 |
2012-03-01 |
Vib Vzw |
Insect binding antibodies
|
|
US20120225081A1
(en)
|
2010-09-03 |
2012-09-06 |
Boehringer Ingelheim International Gmbh |
Vegf-binding molecules
|
|
US20120244141A1
(en)
|
2010-09-28 |
2012-09-27 |
Boehringer Ingelheim International Gmbh |
Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
|
|
EP2621953B1
(en)
|
2010-09-30 |
2017-04-05 |
Ablynx N.V. |
Biological materials related to c-met
|
|
JP2013543384A
(ja)
|
2010-10-05 |
2013-12-05 |
ノバルティス アーゲー |
抗−ｉｌ１２ｒベータ１抗体ならびに自己免疫性および炎症性疾患の処置おけるその使用
|
|
EP2632946B1
(en)
|
2010-10-29 |
2017-12-06 |
Ablynx N.V. |
Method for the production of immunoglobulin single variable domains
|
|
GB201018602D0
(en)
|
2010-11-04 |
2010-12-22 |
Vib Vzw |
MMP8 inactivating antigen binding proteins
|
|
MX343607B
(es)
|
2010-11-05 |
2016-11-11 |
Morphotek Inc |
Receptor alfa de folato como marcador de diagnóstico y pronóstico para cánceres que expresan receptor alfa de folato.
|
|
TWI619811B
(zh)
|
2010-11-08 |
2018-04-01 |
諾華公司 |
趨化細胞素受體結合多肽
|
|
WO2012084895A2
(en)
|
2010-12-20 |
2012-06-28 |
Universiteit Gent |
Crystal structure of flt3 ligand-receptor complex
|
|
US9598499B2
(en)
|
2010-12-30 |
2017-03-21 |
Institut National De La Santé Et De La Recherche Médicale (Inserm) |
Antigen binding formats for use in therapeutic treatments or diagnostic assays
|
|
CA2817374C
(en)
|
2010-12-30 |
2018-10-16 |
Ventana Medical Systems, Inc. |
Enhanced deposition of chromogens utilizing pyrimidine analogs
|
|
US9540443B2
(en)
|
2011-01-26 |
2017-01-10 |
Kolltan Pharmaceuticals, Inc. |
Anti-kit antibodies
|
|
EP2670779B1
(en)
|
2011-02-01 |
2017-08-02 |
Bac Ip B.V. |
Antigen-binding protein directed against epitope in the ch1 domain of human igg antibodies
|
|
WO2012106634A1
(en)
|
2011-02-03 |
2012-08-09 |
Alexion Pharmaceuticals, Inc. |
Use of an anti-cd200 antibody for prolonging the survival of allografts
|
|
EP2683290B1
(en)
|
2011-03-07 |
2018-11-07 |
F.Hoffmann-La Roche Ag |
Methods for in vivo testing of therapeutic antibodies
|
|
JP6385060B2
(ja)
|
2011-03-07 |
2018-09-05 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
治療的に活性な抗体のインビボにおける選択
|
|
WO2012122590A1
(en)
|
2011-03-14 |
2012-09-20 |
Cellmid Limited |
Antibody recognizing n-domain of midkine
|
|
CN103534359B
(zh)
|
2011-03-14 |
2016-07-06 |
文塔纳医疗系统公司 |
分析染色体易位的方法及其系统
|
|
WO2012130872A1
(en)
|
2011-03-28 |
2012-10-04 |
Ablynx Nv |
Method for producing solid formulations comprising immunoglobulin single variable domains
|
|
AU2012234284B2
(en)
|
2011-03-28 |
2015-10-08 |
Ablynx Nv |
Bispecific anti-CXCR7 immunoglobulin single variable domains
|
|
JP2014515740A
(ja)
|
2011-03-30 |
2014-07-03 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
抗凝固薬の解毒剤
|
|
KR20140018299A
(ko)
|
2011-03-30 |
2014-02-12 |
아블린쓰 엔.브이. |
Ｔｎｆ-알파에 대한 단일 도메인 항체를 이용하여 면역 장애를 치료하는 방법
|
|
CA2830806C
(en)
|
2011-03-31 |
2020-05-12 |
Merck Sharp & Dohme Corp. |
Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments
|
|
US20130078247A1
(en)
|
2011-04-01 |
2013-03-28 |
Boehringer Ingelheim International Gmbh |
Bispecific binding molecules binding to dii4 and ang2
|
|
US9527925B2
(en)
|
2011-04-01 |
2016-12-27 |
Boehringer Ingelheim International Gmbh |
Bispecific binding molecules binding to VEGF and ANG2
|
|
KR101970025B1
(ko)
|
2011-04-20 |
2019-04-17 |
메디뮨 엘엘씨 |
Ｂ7-ｈ1 및 ｐｄ-1과 결합하는 항체 및 다른 분자들
|
|
UA117218C2
(uk)
|
2011-05-05 |
2018-07-10 |
Мерк Патент Гмбх |
Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
|
|
US9534039B2
(en)
|
2011-05-09 |
2017-01-03 |
Ablynx N.V. |
Method for the production of immunoglobulin single variable domains
|
|
CN107903325B
(zh)
|
2011-05-16 |
2021-10-29 |
埃泰美德(香港)有限公司 |
多特异性fab融合蛋白及其使用方法
|
|
WO2012163887A1
(en)
|
2011-05-27 |
2012-12-06 |
Ablynx Nv |
Inhibition of bone resorption with rankl binding peptides
|
|
US9580480B2
(en)
|
2011-05-31 |
2017-02-28 |
Massachusetts Institute Of Technology |
Cell-directed synthesis of multifunctional nanopatterns and nanomaterials
|
|
CN103649123B
(zh)
|
2011-06-13 |
2017-05-24 |
Csl有限公司 |
抗g‑csfr抗体及其用途
|
|
WO2012172495A1
(en)
|
2011-06-14 |
2012-12-20 |
Novartis Ag |
Compositions and methods for antibodies targeting tem8
|
|
JP6164535B2
(ja)
|
2011-06-21 |
2017-07-19 |
フエー・イー・ベー・フエー・ゼツト・ウエー |
Ｇｐｃｒ：ｇタンパク質複合体に対して作製された結合ドメインおよびそれに由来する使用
|
|
IN2014CN00414A
(GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
|
2011-06-23 |
2015-04-03 |
Ablynx Nv |
|
|
JP2014525736A
(ja)
|
2011-06-23 |
2014-10-02 |
アブリンクス エン．ヴェー． |
ＩｇＥに対する免疫グロブリン単一可変ドメイン
|
|
ES2692519T3
(es)
|
2011-07-01 |
2018-12-04 |
Novartis Ag |
Método para tratar trastornos metabólicos
|
|
GB201112056D0
(en)
|
2011-07-14 |
2011-08-31 |
Univ Leuven Kath |
Antibodies
|
|
EP2731970B1
(en)
|
2011-07-15 |
2018-11-28 |
MorphoSys AG |
Antibodies that are cross-reactive for macrophage migration inhibitory factor (mif) and d-dopachrome tautomerase (d-dt)
|
|
KR102143506B1
(ko)
|
2011-08-17 |
2020-08-12 |
글락소 그룹 리미티드 |
변형된 단백질 및 펩티드
|
|
WO2013033073A1
(en)
|
2011-08-31 |
2013-03-07 |
Ventana Medical Systems, Inc. |
Expression of ets related gene (erg) and phosphatase and tensin homolog (pten) correlates with prostate cancer capsular penetration
|
|
GB201115529D0
(en)
|
2011-09-08 |
2011-10-26 |
Imp Innovations Ltd |
Antibodies, uses and methods
|
|
WO2013036130A1
(en)
|
2011-09-09 |
2013-03-14 |
Universiteit Utrecht Holding B.V. |
Broadly neutralizing vhh against hiv-1
|
|
EP2757875B2
(en)
|
2011-09-19 |
2023-03-22 |
Kymab Limited |
Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
|
|
US20140235492A1
(en)
|
2011-09-20 |
2014-08-21 |
Institut National De La Sante Et De La Recherche Medicate (Inserm) |
Methods for preparing single domain antibody microarrays
|
|
AU2012311443B2
(en)
|
2011-09-23 |
2016-12-01 |
Ablynx Nv |
Prolonged inhibition of interleukin-6 mediated signaling
|
|
WO2013045916A1
(en)
|
2011-09-26 |
2013-04-04 |
Kymab Limited |
Chimaeric surrogate light chains (slc) comprising human vpreb
|
|
WO2013045707A2
(en)
|
2011-09-30 |
2013-04-04 |
Ablynx Nv |
Biological materials related to c-met
|
|
US20130085139A1
(en)
|
2011-10-04 |
2013-04-04 |
Royal Holloway And Bedford New College |
Oligomers
|
|
WO2013054307A2
(en)
|
2011-10-14 |
2013-04-18 |
Novartis Ag |
Antibodies and methods for wnt pathway-related diseases
|
|
US9127056B2
(en)
|
2011-10-17 |
2015-09-08 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monospecific and bispecific human monoclonal antibodies targeting insulin-like growth factor II (IGF-II)
|
|
EP2771351B1
(en)
|
2011-10-28 |
2017-06-14 |
Patrys Limited |
Pat-lm1 epitopes and methods for using same
|
|
GB2496375A
(en)
|
2011-10-28 |
2013-05-15 |
Kymab Ltd |
A non-human assay vertebrate comprising human antibody loci and human epitope knock-in, and uses thereof
|
|
JP6411214B2
(ja)
|
2011-11-11 |
2018-10-24 |
ユーシービー バイオファルマ エスピーアールエル |
アルブミン結合抗体及びその結合断片
|
|
WO2013079606A1
(en)
|
2011-12-01 |
2013-06-06 |
Ventana Medical Systems, Inc. |
Automated dual stain of mirna and protein targets
|
|
WO2013079973A1
(en)
|
2011-12-02 |
2013-06-06 |
Di Cara Danielle Marie |
Antibodies against hgf - receptor and uses
|
|
GB201122047D0
(en)
|
2011-12-21 |
2012-02-01 |
Kymab Ltd |
Transgenic animals
|
|
UY34487A
(es)
|
2011-12-05 |
2013-07-31 |
Novartis Ag |
Anticuerpos para receptor de factor de crecimiento epidérmico 3(her3)
|
|
AU2012349736A1
(en)
|
2011-12-05 |
2014-06-26 |
Novartis Ag |
Antibodies for epidermal growth factor receptor 3 (HER3) directed to domain II of HER3
|
|
AU2012356170B2
(en)
|
2011-12-21 |
2016-06-16 |
Novartis Ag |
Compositions and methods for antibodies targeting Factor P
|
|
US10112988B2
(en)
|
2012-01-09 |
2018-10-30 |
Icb International, Inc. |
Methods of assessing amyloid-beta peptides in the central nervous system by blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an anti-amyloid-beta peptide
|
|
US10112987B2
(en)
|
2012-01-09 |
2018-10-30 |
Icb International, Inc. |
Blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an amyloid-beta peptide
|
|
WO2013108126A2
(en)
|
2012-01-16 |
2013-07-25 |
University Of Oslo |
Methyltransferases and uses thereof
|
|
JP6352812B6
(ja)
|
2012-01-20 |
2018-08-08 |
ジェンザイム・コーポレーション |
抗ｃｘｃｒ３抗体
|
|
WO2013113696A1
(en)
|
2012-01-30 |
2013-08-08 |
Vib Vzw |
Means and method for diagnosis and treatment of alzheimer's disease
|
|
WO2013121042A1
(en)
|
2012-02-16 |
2013-08-22 |
Vib Vzw |
PP2A SUBUNITS IN DNA REPAIR, THE PP2A B55α SUBUNIT AS NOVEL PHD2 INTERACTING PROTEIN, AND IMPLICATIONS FOR CANCER
|
|
MD4548C1
(ro)
|
2012-02-27 |
2018-08-31 |
Boehringer Ingelheim International Gmbh |
Polipeptide care se leagă de CX3CR1
|
|
US9592289B2
(en)
|
2012-03-26 |
2017-03-14 |
Sanofi |
Stable IgG4 based binding agent formulations
|
|
US10041950B2
(en)
|
2012-03-27 |
2018-08-07 |
Ventana Medical Systems, Inc. |
Signaling conjugates and methods of use
|
|
HRP20190817T1
(hr)
|
2012-03-30 |
2019-06-28 |
Boehringer Ingelheim International Gmbh |
Ang2-vezujuće molekule
|
|
US9156915B2
(en)
|
2012-04-26 |
2015-10-13 |
Thomas Jefferson University |
Anti-GCC antibody molecules
|
|
US9328174B2
(en)
|
2012-05-09 |
2016-05-03 |
Novartis Ag |
Chemokine receptor binding polypeptides
|
|
EP2855526B1
(en)
|
2012-05-24 |
2018-11-07 |
VIB vzw |
Anti-macrophage mannose receptor immunoglobulin single variable domains for targeting and in vivo imaging of tumor-associated macrophages
|
|
EP2687595B1
(en)
|
2012-07-19 |
2018-05-30 |
Laboratoire Français du Fractionnement et des Biotechnologies |
Method for purifying transgenic factor VII
|
|
CA2879542A1
(en)
|
2012-07-25 |
2014-01-30 |
Salk Institute For Biological Studies |
Regulating the interaction between tam ligands and lipid membranes with exposed phosphatidylserine
|
|
CN116574185A
(zh)
|
2012-07-25 |
2023-08-11 |
塞尔德克斯医疗公司 |
抗kit抗体及其用途
|
|
US9605074B2
(en)
|
2012-08-30 |
2017-03-28 |
The General Hospital Corporation |
Multifunctional nanobodies for treating cancer
|
|
UA118441C2
(uk)
|
2012-10-08 |
2019-01-25 |
Протена Біосаєнсиз Лімітед |
Антитіло, що розпізнає альфа-синуклеїн
|
|
CA2887682A1
(en)
|
2012-10-09 |
2014-04-17 |
Biogen Idec Ma Inc. |
Combination therapies and uses for treatment of demyelinating disorders
|
|
WO2014079819A1
(en)
|
2012-11-20 |
2014-05-30 |
Novartis Ag |
Optimized expression cassette for expressing a polypeptide with high yield
|
|
WO2014084859A1
(en)
|
2012-11-30 |
2014-06-05 |
Novartis Ag |
Molecules and methods for modulating tmem16a activities
|
|
HUE053669T2
(hu)
|
2012-12-05 |
2021-07-28 |
Novartis Ag |
Készítmények és eljárások EPO-t célzó antitestekre
|
|
WO2014087010A1
(en)
|
2012-12-07 |
2014-06-12 |
Ablynx N.V. |
IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE
|
|
JP6705650B2
(ja)
|
2012-12-14 |
2020-06-03 |
オープン モノクローナル テクノロジー，インコーポレイティド |
ヒトイディオタイプを有するげっ歯類抗体をコードするポリヌクレオチド及びそれを含む動物
|
|
CA2891686A1
(en)
|
2012-12-18 |
2014-06-26 |
Novartis Ag |
Compositions and methods that utilize a peptide tag that binds to hyaluronan
|
|
CA2894689A1
(en)
|
2012-12-19 |
2014-06-26 |
Amplimmune, Inc. |
Anti-human b7-h4 antibodies and their uses
|
|
AU2013204922B2
(en)
|
2012-12-20 |
2015-05-14 |
Celgene Corporation |
Chimeric antigen receptors
|
|
US9790277B2
(en)
|
2012-12-21 |
2017-10-17 |
The Johns Hopkins University |
Anti-H7CR antibodies
|
|
AR093984A1
(es)
|
2012-12-21 |
2015-07-01 |
Merck Sharp & Dohme |
Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
|
|
US9593157B2
(en)
|
2013-01-30 |
2017-03-14 |
Vib Vzw |
Chimeric polypeptides comprising G protein-coupled receptors and VHH antibodies
|
|
WO2014120916A1
(en)
|
2013-02-01 |
2014-08-07 |
Bristol-Myers Squibb Company |
Pegylated domain antibodies monovalent for cd28 binding and methods of use
|
|
AU2014214054B2
(en)
|
2013-02-05 |
2018-10-04 |
The Board Of Trustees Of The Leland Stanford Junior University |
Muscarinic acetylcholine receptor binding agents and uses thereof
|
|
CN117843785A
(zh)
|
2013-02-07 |
2024-04-09 |
Csl有限公司 |
Il-11r结合蛋白及其应用
|
|
BR112015017338B1
(pt)
|
2013-02-08 |
2022-11-29 |
Novartis Ag |
Anticorpo humano terapêutico isolado ou sua porção de ligação ao antígeno do mesmo, seu uso e seu processo de produção, composição farmacêutica, molécula de ácido nucleico isolada, vetor de clonagem ou de expressão e micro-organismo transgênico
|
|
EP2961773B1
(en)
|
2013-02-26 |
2019-03-20 |
Roche Glycart AG |
Bispecific t cell activating antigen binding molecules
|
|
WO2014133855A1
(en)
|
2013-02-28 |
2014-09-04 |
Caprion Proteomics Inc. |
Tuberculosis biomarkers and uses thereof
|
|
EP2972227B1
(en)
|
2013-03-12 |
2020-05-06 |
Ventana Medical Systems, Inc. |
Digitally enhanced microscopy for multiplexed histology
|
|
KR102313513B1
(ko)
|
2013-03-13 |
2021-10-15 |
프로테나 바이오사이언시즈 리미티드 |
Tau 면역치료제
|
|
EP3611189A1
(en)
|
2013-03-14 |
2020-02-19 |
Novartis AG |
Antibodies against notch 3
|
|
EP2968508B1
(en)
|
2013-03-15 |
2022-04-27 |
Sanofi Pasteur Biologics, LLC |
Antibodies against clostridium difficile toxins and methods of using the same
|
|
WO2014141192A1
(en)
|
2013-03-15 |
2014-09-18 |
Erasmus University Medical Center |
Generation of heavy chain-only antibodies
|
|
WO2014140376A1
(en)
|
2013-03-15 |
2014-09-18 |
Vib Vzw |
Anti-macrophage mannose receptor single variable domains for use in cardiovascular diseases
|
|
ES2769574T3
(es)
|
2013-03-15 |
2020-06-26 |
Michael C Milone |
Reconocimiento de células citotóxicas con receptores quiméricos para inmunoterapia adoptiva
|
|
CA2907397C
(en)
|
2013-03-15 |
2022-11-22 |
Anthrogenesis Corporation |
Modified t lymphocytes
|
|
WO2014146575A1
(en)
|
2013-03-19 |
2014-09-25 |
Beijing Shenogen Pharma Group Ltd. |
Antibodies and methods for treating estrogen receptor-associated diseases
|
|
AU2014273418B2
(en)
|
2013-04-29 |
2020-04-23 |
Biotalys NV |
Agrochemical compositions comprising antibodies binding to sphingolipids
|
|
AR096236A1
(es)
|
2013-05-09 |
2015-12-16 |
The Us Secretary Dept Of Health And Human Services Nat Inst Of Health Office Of Tech Transfer |
Anticuerpos de dominio simple vhh dirigidos a norovirus gi.1 y gii.4 y sus usos
|
|
NL1040254C2
(en)
|
2013-05-17 |
2014-11-24 |
Ablynx Nv |
Stable formulations of immunoglobulin single variable domains and uses thereof.
|
|
SG11201509618QA
(en)
|
2013-05-24 |
2015-12-30 |
Medimmune Llc |
Anti-b7-h5 antibodies and their uses
|
|
WO2014194293A1
(en)
|
2013-05-30 |
2014-12-04 |
Amplimmune, Inc. |
Improved methods for the selection of patients for pd-1 or b7-h4 targeted therapies, and combination therapies thereof
|
|
EP3003390B1
(en)
|
2013-06-06 |
2021-07-07 |
Pierre Fabre Médicament |
Anti-c10orf54 antibodies and uses thereof
|
|
AR096601A1
(es)
|
2013-06-21 |
2016-01-20 |
Novartis Ag |
Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
|
|
US9562101B2
(en)
|
2013-06-21 |
2017-02-07 |
Novartis Ag |
Lectin-like oxidized LDL receptor 1 antibodies and methods of use
|
|
JP6474797B2
(ja)
|
2013-06-27 |
2019-02-27 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
インターロイキン１５（ｉｌ−１５）アンタゴニスト並びに自己免疫疾患及び炎症性疾患の処置のためのその使用
|
|
WO2015001082A1
(en)
|
2013-07-05 |
2015-01-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Novel alternative splice transcripts for mhc class i related chain alpha (mica) and uses thereof
|
|
WO2015004632A1
(en)
|
2013-07-12 |
2015-01-15 |
Neotope Biosciences Limited |
Antibodies that recognize iapp
|
|
US9951131B2
(en)
|
2013-07-12 |
2018-04-24 |
Prothena Biosciences Limited |
Antibodies that recognize IAPP
|
|
EP3290922A1
(en)
|
2013-08-07 |
2018-03-07 |
Alexion Pharmaceuticals, Inc. |
Atypical hemolytic uremic syndrome (ahus) biomarker proteins
|
|
MX2016001969A
(es)
|
2013-08-14 |
2016-06-02 |
Novartis Ag |
Metodos para tratar la miositis por cuerpos de inclusion esporadica.
|
|
AR097306A1
(es)
|
2013-08-20 |
2016-03-02 |
Merck Sharp & Dohme |
Modulación de la inmunidad tumoral
|
|
TR201900665T4
(tr)
|
2013-11-28 |
2019-02-21 |
B Creative Sweden Ab |
Diyabetik nefropatinin tedavi yöntemi.
|
|
EP2883883A1
(en)
|
2013-12-16 |
2015-06-17 |
Cardio3 Biosciences S.A. |
Therapeutic targets and agents useful in treating ischemia reperfusion injury
|
|
CN105979965B
(zh)
|
2013-12-18 |
2021-07-09 |
杰特有限公司 |
治疗伤口的方法
|
|
CA3225453A1
(en)
|
2013-12-19 |
2015-06-25 |
Novartis Ag |
Human mesothelin chimeric antigen receptors and uses thereof
|
|
EP3087101B1
(en)
|
2013-12-20 |
2024-06-05 |
Novartis AG |
Regulatable chimeric antigen receptor
|
|
CN106029697B
(zh)
|
2013-12-20 |
2021-06-04 |
英特维特国际股份有限公司 |
具有经修饰的ch2-ch3序列的犬抗体
|
|
WO2015100409A2
(en)
|
2013-12-26 |
2015-07-02 |
Tufts University |
Methods, compositions and kits for treating a subject using a recombinant neutralizing binding protein
|
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
|
JP6687525B2
(ja)
|
2014-01-30 |
2020-04-22 |
ブイアイビー ブイゼットダブリュＶｉｂ Ｖｚｗ |
オピオイド受容体結合剤およびその使用
|
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
|
SG11201606624WA
(en)
|
2014-02-11 |
2016-09-29 |
Visterra Inc |
Antibody moleules to dengue virus and uses thereof
|
|
WO2015123687A1
(en)
|
2014-02-14 |
2015-08-20 |
Centrose, Llc |
Extracellular targeted drug conjugates
|
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
|
NZ631007A
(en)
|
2014-03-07 |
2015-10-30 |
Alexion Pharma Inc |
Anti-c5 antibodies having improved pharmacokinetics
|
|
EA201691765A1
(ru)
|
2014-03-14 |
2016-12-30 |
Новартис Аг |
Молекулы антител против lag-3 и их применения
|
|
US20170081411A1
(en)
|
2014-03-15 |
2017-03-23 |
Novartis Ag |
Regulatable chimeric antigen receptor
|
|
JP2017513818A
(ja)
|
2014-03-15 |
2017-06-01 |
ノバルティス アーゲー |
キメラ抗原受容体を使用する癌の処置
|
|
WO2015143414A2
(en)
|
2014-03-21 |
2015-09-24 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals that make single domain binding proteins
|
|
HK1231497A1
(zh)
|
2014-03-21 |
2017-12-22 |
瑞泽恩制药公司 |
表現不同結合特徵的vl抗原結合蛋白
|
|
US10562973B2
(en)
|
2014-04-08 |
2020-02-18 |
Prothena Bioscience Limited |
Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
|
|
TW201622746A
(zh)
|
2014-04-24 |
2016-07-01 |
諾華公司 |
改善或加速髖部骨折術後身體復原之方法
|
|
LT3689899T
(lt)
|
2014-04-25 |
2021-12-10 |
2Seventy Bio, Inc. |
Mnd promotorių chimerinių antigenų receptoriai
|
|
RU2741899C2
(ru)
|
2014-04-25 |
2021-01-29 |
Блубёрд Био, Инк. |
Улучшенные способы производства средств адоптивной клеточной терапии
|
|
US9388239B2
(en)
|
2014-05-01 |
2016-07-12 |
Consejo Nacional De Investigation Cientifica |
Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
|
|
EP3702369A1
(en)
|
2014-05-16 |
2020-09-02 |
Ablynx NV |
Immunoglobulin variable domains
|
|
SMT202100116T1
(it)
|
2014-05-28 |
2021-05-07 |
Agenus Inc |
Anticorpi anti-gitr e metodi di utilizzo degli stessi
|
|
RS61406B1
(sr)
|
2014-06-06 |
2021-03-31 |
Bluebird Bio Inc |
Poboljšane kompozicije t ćelija
|
|
NL2013007B1
(en)
|
2014-06-16 |
2016-07-05 |
Ablynx Nv |
Methods of treating TTP with immunoglobulin single variable domains and uses thereof.
|
|
NL2013661B1
(en)
|
2014-10-21 |
2016-10-05 |
Ablynx Nv |
KV1.3 Binding immunoglobulins.
|
|
EP3160991A2
(en)
|
2014-06-25 |
2017-05-03 |
Novartis AG |
Compositions and methods for long acting proteins
|
|
US20170290876A1
(en)
|
2014-06-25 |
2017-10-12 |
Novartis Ag |
Compositions and methods for long acting proteins
|
|
EP3161001A2
(en)
|
2014-06-25 |
2017-05-03 |
Novartis AG |
Antibodies specific for il-17a fused to hyaluronan binding peptide tags
|
|
AU2015292744C1
(en)
|
2014-07-21 |
2021-01-21 |
Novartis Ag |
Treatment of cancer using humanized anti-BCMA chimeric antigen receptor
|
|
US11542488B2
(en)
|
2014-07-21 |
2023-01-03 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
|
JP2017528433A
(ja)
|
2014-07-21 |
2017-09-28 |
ノバルティス アーゲー |
低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ
|
|
WO2016014576A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Treatment of cancer using a cd33 chimeric antigen receptor
|
|
US10641779B2
(en)
|
2014-07-22 |
2020-05-05 |
Vib Vzw |
Methods to select for agents that stabilize protein complexes
|
|
SG10201900455YA
(en)
|
2014-07-24 |
2019-02-27 |
Bluebird Bio Inc |
Bcma chimeric antigen receptors
|
|
WO2016016329A1
(en)
|
2014-07-29 |
2016-02-04 |
Vrije Universiteit Brussel |
Radio-labelled antibody fragments for use in the prognosis, diagnosis of cancer as well as for the prediction of cancer therapy response
|
|
CA2954359C
(en)
|
2014-07-29 |
2018-09-25 |
Vrije Universiteit Brussel |
Radio-labelled antibody fragments for use in the prevention and/or treatment of cancer
|
|
EP3174546B1
(en)
|
2014-07-31 |
2019-10-30 |
Novartis AG |
Subset-optimized chimeric antigen receptor-containing t-cells
|
|
NZ728425A
(en)
|
2014-08-07 |
2022-05-27 |
Novartis Ag |
Angiopoietin-like 4 antibodies and methods of use
|
|
TW201613977A
(en)
|
2014-08-07 |
2016-04-16 |
Novartis Ag |
Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
|
|
JP6919118B2
(ja)
|
2014-08-14 |
2021-08-18 |
ノバルティス アーゲー |
ＧＦＲα−４キメラ抗原受容体を用いる癌の治療
|
|
RU2020117196A
(ru)
|
2014-08-19 |
2020-10-15 |
Новартис Аг |
Химерный антигенный рецептор (car) против cd123 для использования в лечении злокачественных опухолей
|
|
MD4733C1
(ro)
|
2014-08-19 |
2021-07-31 |
Merck Sharp & Dohme Corp |
Anticorpi anti-TIGIT
|
|
JO3663B1
(ar)
|
2014-08-19 |
2020-08-27 |
Merck Sharp & Dohme |
الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
|
|
RU2718914C2
(ru)
|
2014-09-13 |
2020-04-15 |
Новартис Аг |
Сочетанные способы лечения с использованием ингибиторов alk
|
|
ES2891332T3
(es)
|
2014-09-17 |
2022-01-27 |
Novartis Ag |
Direccionamiento a células citotóxicas con receptores quiméricos para la inmunoterapia adoptiva
|
|
JP2017535528A
(ja)
|
2014-10-03 |
2017-11-30 |
ノバルティス アーゲー |
組み合わせ治療
|
|
MX2017003903A
(es)
|
2014-10-03 |
2017-09-15 |
Ntercept Llc |
Composiciones y metodos para inhibir la actividad biologica de biomoleculas solubles.
|
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
|
PT3204095T
(pt)
|
2014-10-10 |
2019-07-11 |
Ablynx Nv |
Dispositivo de inalação para usar na terapia com aerossóis de doenças respiratórias
|
|
KR20170093120A
(ko)
|
2014-10-10 |
2017-08-14 |
아블린쓰 엔.브이. |
Rsv 감염의 치료 방법
|
|
KR102513870B1
(ko)
|
2014-10-14 |
2023-03-23 |
노파르티스 아게 |
Pd-l1에 대한 항체 분자 및 그의 용도
|
|
WO2016061632A1
(en)
|
2014-10-23 |
2016-04-28 |
La Trobe University |
Fn14-binding proteins and uses thereof
|
|
US10858666B2
(en)
|
2014-11-05 |
2020-12-08 |
Biotalys |
Transgenic plants expressing a variable domain of a heavy chain antibody (VHH) that binds to a sphingolipid of a fungus
|
|
WO2016090034A2
(en)
|
2014-12-03 |
2016-06-09 |
Novartis Ag |
Methods for b cell preconditioning in car therapy
|
|
US11001625B2
(en)
|
2014-12-10 |
2021-05-11 |
Tufts University |
VHH based binding antibodies for anthrax and botulinum toxins and methods of making and using therefor
|
|
KR102693806B1
(ko)
|
2014-12-11 |
2024-08-09 |
피에르 파브르 메디카먼트 |
항-c10orf54 항체들 및 그들의 용도들
|
|
US20160168237A1
(en)
|
2014-12-12 |
2016-06-16 |
Alexion Pharmaceuticals, Inc. |
Method for treating a complement mediated disorder caused by an infectious agent in a patient
|
|
CN107207598B
(zh)
|
2014-12-12 |
2020-12-08 |
蓝鸟生物公司 |
Bcma嵌合抗原受体
|
|
UY36449A
(es)
|
2014-12-19 |
2016-07-29 |
Novartis Ag |
Composiciones y métodos para anticuerpos dirigidos a bmp6
|
|
HK1246329A1
(zh)
|
2014-12-19 |
2018-09-07 |
埃博灵克斯股份有限公司 |
半胱氨酸连接的纳米抗体二聚体
|
|
US20170340733A1
(en)
|
2014-12-19 |
2017-11-30 |
Novartis Ag |
Combination therapies
|
|
US10940212B2
(en)
|
2014-12-19 |
2021-03-09 |
Monash University |
IL-21 agonist antibodies and methods of treatment using same
|
|
EP3789039A1
(en)
|
2014-12-22 |
2021-03-10 |
The Rockefeller University |
Anti-mertk agonistic antibodies and uses thereof
|
|
CA2972597A1
(en)
|
2014-12-29 |
2016-07-07 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
|
SG10202007176TA
(en)
|
2014-12-30 |
2020-08-28 |
Celgene Corp |
Anti-cd47 antibodies and uses thereof
|
|
EP3240801B1
(en)
|
2014-12-31 |
2021-01-20 |
Checkmate Pharmaceuticals, Inc. |
Combination tumor immunotherapy
|
|
AU2016205197B2
(en)
|
2015-01-08 |
2021-10-21 |
Biogen Ma Inc. |
LINGO-1 antagonists and uses for treatment of demyelinating disorders
|
|
GB201501004D0
(en)
|
2015-01-21 |
2015-03-04 |
Cancer Rec Tech Ltd |
Inhibitors
|
|
US11161907B2
(en)
|
2015-02-02 |
2021-11-02 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
|
ES2791950T3
(es)
|
2015-02-03 |
2020-11-06 |
Ventana Med Syst Inc |
Ensayo histoquímico para evaluar la expresión del ligando de muerte programada 1 (PD-L1)
|
|
CN114133450B
(zh)
|
2015-02-03 |
2023-09-22 |
国家健康与医学研究院 |
抗-Rho GTPase的构象单域抗体及其用途
|
|
US20180022781A1
(en)
|
2015-02-13 |
2018-01-25 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Polypeptides for engineering integrase chimeric proteins and their use in gene therapy
|
|
US10301377B2
(en)
|
2015-02-24 |
2019-05-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use
|
|
WO2016135041A1
(en)
|
2015-02-26 |
2016-09-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Fusion proteins and antibodies comprising thereof for promoting apoptosis
|
|
EP3061826A1
(en)
|
2015-02-27 |
2016-08-31 |
Novartis AG |
Flavivirus replicons
|
|
DE112016001013T5
(de)
|
2015-03-03 |
2017-12-21 |
Kymab Limited |
Antikörper, verwendungen und verfahren
|
|
RU2758113C2
(ru)
|
2015-03-17 |
2021-10-26 |
Мемориал Слоан-Кеттеринг Кэнсер Сентер |
Антитела к muc16 и их применение
|
|
MA41795A
(fr)
|
2015-03-18 |
2018-01-23 |
Sarepta Therapeutics Inc |
Exclusion d'un exon induite par des composés antisens dans la myostatine
|
|
JP2018508224A
(ja)
|
2015-03-19 |
2018-03-29 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
抗原を結合する軽鎖可変領域を選択する非ヒト動物
|
|
WO2016151557A1
(en)
|
2015-03-25 |
2016-09-29 |
Alexion Pharmaceuticals, Inc. |
A method for measuring the protease activity of c5 convertase of the alternative complement pathway
|
|
WO2016151558A1
(en)
|
2015-03-25 |
2016-09-29 |
Alexion Pharmaceuticals, Inc. |
A method for measuring the protease activity of factor d of the alternative complement pathway
|
|
SG11201706882VA
(en)
|
2015-03-31 |
2017-09-28 |
Vhsquared Ltd |
Polypeptides
|
|
SG11201706840WA
(en)
|
2015-03-31 |
2017-09-28 |
Vhsquared Ltd |
Peptide construct having a protease-cleavable linker
|
|
IL254577B2
(en)
|
2015-03-31 |
2023-11-01 |
Vhsquared Ltd |
Polypeptides
|
|
CA2981398A1
(en)
|
2015-04-02 |
2016-10-06 |
Ablynx N.V. |
Bispecific cxcr4-cd4 polypeptides with potent anti-hiv activity
|
|
EP3954710A3
(en)
|
2015-04-02 |
2022-07-20 |
Intervet International B.V. |
Antibodies to canine interleukin-4 receptor alpha
|
|
US20180140602A1
(en)
|
2015-04-07 |
2018-05-24 |
Novartis Ag |
Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
|
|
US10851176B2
(en)
|
2015-04-13 |
2020-12-01 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods of administering neutralizing anti-protease nexin-1 antibodies to treat hemophilia A
|
|
US9778265B2
(en)
|
2015-04-16 |
2017-10-03 |
The United States Of America, As Represented By The Secretary Of The Navy |
Charged peptide appendage to facilitate oriented protein covalent immobilization
|
|
JP7114457B2
(ja)
|
2015-04-17 |
2022-08-08 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
キメラ抗原受容体発現細胞の有効性および増殖を改善するための方法
|
|
US20180112006A1
(en)
|
2015-04-17 |
2018-04-26 |
The General Hospital Corporation |
Agents, systems and methods for treating cancer
|
|
EP3286211A1
(en)
|
2015-04-23 |
2018-02-28 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
|
EP3292152A1
(en)
|
2015-05-07 |
2018-03-14 |
Agenus Inc. |
Anti-ox40 antibodies and methods of use thereof
|
|
US20180104331A1
(en)
|
2015-05-11 |
2018-04-19 |
The Johns Hopkins University |
Autoimmune antibodies for use in inhibiting cancer cell growth
|
|
CA3155409A1
(en)
|
2015-05-13 |
2016-11-17 |
Ablynx N.V. |
T cell recruiting polypeptides based on cd3 reactivity
|
|
PL3611192T3
(pl)
|
2015-05-13 |
2025-07-07 |
Ablynx N.V. |
Polipeptydy rekrutujące komórki T oparte na reaktywności TCR alfa/beta
|
|
WO2016187594A1
(en)
|
2015-05-21 |
2016-11-24 |
Harpoon Therapeutics, Inc. |
Trispecific binding proteins and methods of use
|
|
CN107614014B
(zh)
|
2015-05-28 |
2022-07-12 |
生物辐射实验室股份有限公司 |
亲和配体及其相关方法
|
|
SG10201913500TA
(en)
|
2015-05-29 |
2020-03-30 |
Agenus Inc |
Anti-ctla-4 antibodies and methods of use thereof
|
|
US10047155B2
(en)
|
2015-06-05 |
2018-08-14 |
Novartis Ag |
Antibodies targeting bone morphogenetic protein 9 (BMP9) and methods therefor
|
|
EP3307777A4
(en)
|
2015-06-11 |
2019-02-13 |
Wuxi Biologics (Shanghai) Co. Ltd. |
NOVEL ANTI-PD-L1 ANTIBODIES
|
|
EP3314260B1
(en)
|
2015-06-24 |
2021-04-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for detecting protein-protein interactions
|
|
JOP20200312A1
(ar)
|
2015-06-26 |
2017-06-16 |
Novartis Ag |
الأجسام المضادة للعامل xi وطرق الاستخدام
|
|
US11298433B2
(en)
|
2015-07-17 |
2022-04-12 |
Vrije Universiteit Brussel |
Radiolabelled antibody fragments for use in treating cancer
|
|
CN109476722A
(zh)
|
2015-07-21 |
2019-03-15 |
诺华股份有限公司 |
用于改善免疫细胞的功效和扩张的方法
|
|
LT3317301T
(lt)
|
2015-07-29 |
2021-07-26 |
Novartis Ag |
Kombinuotos terapijos, apimančios antikūno molekules prieš lag-3
|
|
WO2017019896A1
(en)
|
2015-07-29 |
2017-02-02 |
Novartis Ag |
Combination therapies comprising antibody molecules to pd-1
|
|
EP3878465A1
(en)
|
2015-07-29 |
2021-09-15 |
Novartis AG |
Combination therapies comprising antibody molecules to tim-3
|
|
EP3328393B1
(en)
|
2015-07-31 |
2023-12-20 |
Centrose, Llc |
Extracellular drug conjugates targeting cd20
|
|
EP3328399B1
(en)
|
2015-07-31 |
2023-12-27 |
Regents of the University of Minnesota |
Modified cells and methods of therapy
|
|
CA2994516A1
(en)
|
2015-08-03 |
2017-02-09 |
Novartis Ag |
Methods of treating fgf21-associated disorders
|
|
WO2017020291A1
(en)
|
2015-08-06 |
2017-02-09 |
Wuxi Biologics (Shanghai) Co. Ltd. |
Novel anti-pd-l1 antibodies
|
|
EP3331904B1
(en)
|
2015-08-07 |
2020-12-23 |
Merck Patent GmbH |
A transglutamine tag for efficient site-specific bioconjugation
|
|
EA201890468A1
(ru)
|
2015-08-11 |
2018-07-31 |
Уси Байолоджикс (Кайман) Инк. |
Новые антитела против белка pd-1
|
|
CN105384825B
(zh)
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
一种基于单域抗体的双特异性嵌合抗原受体及其应用
|
|
EP4014996A1
(en)
|
2015-08-31 |
2022-06-22 |
Helixmith Co., Ltd |
Anti-sialyl tn chimeric antigen receptors
|
|
EP3344656A1
(en)
|
2015-09-01 |
2018-07-11 |
Agenus Inc. |
Anti-pd-1 antibodies and methods of use thereof
|
|
US11747346B2
(en)
|
2015-09-03 |
2023-09-05 |
Novartis Ag |
Biomarkers predictive of cytokine release syndrome
|
|
EP3842457A1
(en)
|
2015-09-09 |
2021-06-30 |
Novartis AG |
Thymic stromal lymphopoietin (tslp)-binding molecules and methods of using the molecules
|
|
AU2016320748B2
(en)
|
2015-09-09 |
2019-05-02 |
Novartis Ag |
Thymic stromal lymphopoietin (TSLP)-binding antibodies and methods of using the antibodies
|
|
CA2999138C
(en)
|
2015-09-21 |
2024-05-21 |
Aptevo Research And Development Llc |
Cd3 binding polypeptides
|
|
US11203634B2
(en)
|
2015-10-07 |
2021-12-21 |
Alexion Pharmaceuticals, Inc. |
Methods of treating age-related macular degeneration in a patient comprising administering an anti-C5a antibody
|
|
EA201890908A1
(ru)
|
2015-10-09 |
2018-10-31 |
Сарепта Терапьютикс, Инк. |
Композиции и способы для лечения мышечной дистрофии дюшенна и сходных нарушений
|
|
CN105238759B
(zh)
*
|
2015-10-14 |
2019-05-24 |
吉日木图 |
抗驼乳重链IgG3单克隆抗体、含有所述单克隆抗体的试纸及其应用
|
|
CA3004790A1
(en)
|
2015-11-10 |
2017-05-18 |
Visterra, Inc. |
Lipopolysaccharide binding antibody-antimicrobial peptide conjugates and uses thereof
|
|
NO2768984T3
(GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
|
2015-11-12 |
2018-06-09 |
|
|
|
US20180327499A1
(en)
|
2015-11-13 |
2018-11-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Anti- nkg2d single domain antibodies and uses thereof
|
|
CA3004900C
(en)
|
2015-11-18 |
2021-08-10 |
Merck Sharp & Dohme Corp. |
Ctla4 binders
|
|
UA121914C2
(uk)
|
2015-11-18 |
2020-08-10 |
Мерк Шарп І Доум Корп. |
Молекула, що зв'язує pd1 і lag3
|
|
CA3006058A1
(en)
|
2015-11-25 |
2017-06-01 |
Visterra, Inc. |
Antibody molecules to april and uses thereof
|
|
EP3932945A1
(en)
|
2015-11-27 |
2022-01-05 |
Ablynx NV |
Polypeptides inhibiting cd40l
|
|
HK1253533A1
(zh)
|
2015-11-27 |
2019-06-21 |
Csl Limited |
Cd131结合蛋白及其应用
|
|
SI3383425T1
(sl)
|
2015-12-04 |
2020-11-30 |
Boehringer Ingelheim International Gmbh |
Biparatopični polipeptidi, ki antagonizirajo WNT-signaliziranje v tumorskih celicah
|
|
WO2017099712A1
(en)
|
2015-12-07 |
2017-06-15 |
Bluebird Bio, Inc. |
Improved t cell compositions
|
|
US10829562B2
(en)
|
2015-12-10 |
2020-11-10 |
Katholieke Universiteit Leuven |
Haemorrhagic disorder due to ventricular assist device
|
|
RU2018123481A
(ru)
|
2015-12-16 |
2020-01-20 |
Мерк Шарп И Доум Корп. |
Анти-lag3 антитела и антигенсвязывающие фрагменты
|
|
CN108697794A
(zh)
|
2015-12-17 |
2018-10-23 |
诺华股份有限公司 |
C-met抑制剂和抗pd-1抗体分子的组合及其用途
|
|
AU2016369537B2
(en)
|
2015-12-17 |
2024-03-14 |
Novartis Ag |
Antibody molecules to PD-1 and uses thereof
|
|
FI3390451T3
(fi)
|
2015-12-18 |
2025-03-28 |
Intervet Int Bv |
Kaninisoidut ihmisen vasta-aineet ihmisen ja koiraeläimen il-4r alfaa kohtaan
|
|
KR20180089510A
(ko)
|
2015-12-18 |
2018-08-08 |
노파르티스 아게 |
CD32b를 표적화하는 항체 및 그의 사용 방법
|
|
US11091556B2
(en)
|
2015-12-18 |
2021-08-17 |
Intervet Inc. |
Caninized human antibodies to human IL-4R alpha
|
|
EP3393504B1
(en)
|
2015-12-22 |
2025-09-24 |
Novartis AG |
Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy
|
|
JP2019500874A
(ja)
|
2015-12-28 |
2019-01-17 |
ノバルティス アーゲー |
キメラ抗原受容体発現細胞の作製方法
|
|
CA3013551A1
(en)
|
2016-02-05 |
2017-08-10 |
Orionis Biosciences Nv |
Clec9a binding agents and use thereof
|
|
CU20180088A7
(es)
|
2016-02-17 |
2019-05-03 |
Novartis Ag |
Anticuerpos anti tgfbeta 2
|
|
BR112018067679A2
(pt)
|
2016-03-04 |
2019-01-15 |
Novartis Ag |
células que expressam múltiplas moléculas do receptor de antígeno quimérico (car) e seu uso
|
|
US11248057B2
(en)
|
2016-03-07 |
2022-02-15 |
Vib Vzw |
CD20 binding single domain antibodies
|
|
JP7034489B2
(ja)
|
2016-03-15 |
2022-03-14 |
アイタブメッド （エイチケイ） リミテッド |
多重特異性Ｆａｂ融合タンパクおよびその使用
|
|
WO2017158396A1
(en)
|
2016-03-16 |
2017-09-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Cytidine deaminase inhibitors for the treatment of pancreatic cancer
|
|
WO2017162604A1
(en)
|
2016-03-21 |
2017-09-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for diagnosis and treatment of solar lentigo
|
|
CN109153728A
(zh)
|
2016-03-21 |
2019-01-04 |
埃尔斯塔治疗公司 |
多特异性和多功能分子及其用途
|
|
KR20180127971A
(ko)
|
2016-03-23 |
2018-11-30 |
맵스페이스 바이오사이언시즈 (쑤저우) 컴퍼니 리미티드 |
신규 항-pd-l1 항체
|
|
WO2017165778A1
(en)
|
2016-03-24 |
2017-09-28 |
Millennium Pharmaceuticals, Inc. |
Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments
|
|
WO2017165742A1
(en)
|
2016-03-24 |
2017-09-28 |
Millennium Pharmaceuticals, Inc. |
Methods of treating gastrointestinal immune-related adverse events in anti-ctla4 anti-pd-1 combination treatments
|
|
EP3433274A1
(en)
|
2016-03-25 |
2019-01-30 |
Visterra, Inc. |
Formulation of antibody molecules to dengue virus
|
|
WO2017176762A1
(en)
|
2016-04-06 |
2017-10-12 |
Nanotics, Llc |
Particles comprising subparticles or nucleic acid scaffolds
|
|
US20190120838A1
(en)
|
2016-04-13 |
2019-04-25 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and kits for the rapid detection of the escherichia coli o25b-st131 clone
|
|
EP3443002A4
(en)
|
2016-04-14 |
2019-12-04 |
Bluebird Bio, Inc. |
SYSTEMS FOR RECOVERED CHIMERIC ANTIGEN RECEPTORS
|
|
AU2017250304B2
(en)
|
2016-04-15 |
2023-08-17 |
Novartis Ag |
Compositions and methods for selective protein expression
|
|
US20170298119A1
(en)
|
2016-04-15 |
2017-10-19 |
Visterra, Inc. |
Antibody molecules to zika virus and uses thereof
|
|
CA3019588A1
(en)
|
2016-04-20 |
2017-10-26 |
Merck Sharp & Dohme Corp. |
Cmv neutralizing antigen binding proteins
|
|
WO2017182603A1
(en)
|
2016-04-22 |
2017-10-26 |
Université Libre de Bruxelles |
A new biomarker expressed in pancreatic beta cells useful in imaging or targeting beta cells
|
|
WO2017182605A1
(en)
|
2016-04-22 |
2017-10-26 |
Université Libre de Bruxelles |
A new biomarker expressed in pancreatic beta cells useful in imaging or targeting beta cells
|
|
CN109071647B
(zh)
|
2016-04-27 |
2022-11-22 |
诺华股份有限公司 |
抗生长分化因子15的抗体及其用途
|
|
DK3452507T3
(da)
|
2016-05-02 |
2022-11-14 |
Prothena Biosciences Ltd |
Tau-immunoterapi
|
|
CN109311968A
(zh)
|
2016-05-02 |
2019-02-05 |
埃博灵克斯股份有限公司 |
治疗rsv感染
|
|
EP3455245A2
(en)
|
2016-05-13 |
2019-03-20 |
Orionis Biosciences NV |
Therapeutic targeting of non-cellular structures
|
|
HUE053452T2
(hu)
|
2016-05-18 |
2021-07-28 |
Boehringer Ingelheim Int |
Anti-PD-1 és anti-LAG3 antitestek rák kezelésére
|
|
US10100106B2
(en)
|
2016-05-20 |
2018-10-16 |
Harpoon Therapeutics, Inc. |
Single domain serum albumin binding protein
|
|
WO2017201493A1
(en)
|
2016-05-20 |
2017-11-23 |
Harpoon Therapeutics, Inc. |
Single chain variable fragment cd3 binding proteins
|
|
US11623958B2
(en)
|
2016-05-20 |
2023-04-11 |
Harpoon Therapeutics, Inc. |
Single chain variable fragment CD3 binding proteins
|
|
US20190292259A1
(en)
|
2016-05-24 |
2019-09-26 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and pharmaceutical compositions for the treatment of non small cell lung cancer (nsclc) that coexists with chronic obstructive pulmonary disease (copd)
|
|
BR112018074463A2
(pt)
|
2016-05-27 |
2019-03-06 |
Agenus Inc. |
anticorpos anti-tim-3 e métodos de uso dos mesmos.
|
|
EP3463482B1
(en)
|
2016-06-07 |
2021-10-06 |
The Brigham and Women's Hospital, Inc. |
Methods relating to t peripheral helper cells in autoantibody-associated conditions
|
|
US11434269B2
(en)
|
2016-06-15 |
2022-09-06 |
Novartis Ag |
Methods for treating disease using inhibitors of bone morphogenetic protein 6 (BMP6)
|
|
WO2017223419A1
(en)
|
2016-06-24 |
2017-12-28 |
Ig Biosciences Corporation |
Prebiotic neutraceutical compositions and methods of treatment using the same
|
|
WO2018007442A1
(en)
|
2016-07-06 |
2018-01-11 |
Ablynx N.V. |
Treatment of il-6r related diseases
|
|
WO2018007999A1
(en)
|
2016-07-08 |
2018-01-11 |
Staten Biotechnology B.V. |
Anti-apoc3 antibodies and methods of use thereof
|
|
MX2019000327A
(es)
|
2016-07-13 |
2019-04-11 |
Biogen Ma Inc |
Regímenes de dosificación de antagonistas de lingo-1 y usos para el tratamiento de trastornos desmielinizantes.
|
|
CN110461315B
(zh)
|
2016-07-15 |
2025-05-02 |
诺华股份有限公司 |
使用与激酶抑制剂组合的嵌合抗原受体治疗和预防细胞因子释放综合征
|
|
WO2018014260A1
(en)
|
2016-07-20 |
2018-01-25 |
Nanjing Legend Biotech Co., Ltd. |
Multispecific antigen binding proteins and methods of use thereof
|
|
US20200148750A1
(en)
|
2016-07-21 |
2020-05-14 |
Emory University |
Ebola Virus Antibodies and Binding Agents Derived Therefrom
|
|
IL264486B2
(en)
|
2016-07-28 |
2025-04-01 |
Novartis Ag |
Combination therapies of chimeric antigen receptors and PD-1 inhibitors
|
|
NL2017267B1
(en)
|
2016-07-29 |
2018-02-01 |
Aduro Biotech Holdings Europe B V |
Anti-pd-1 antibodies
|
|
US20190161542A1
(en)
|
2016-08-01 |
2019-05-30 |
Novartis Ag |
Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
|
|
JP7464389B2
(ja)
|
2016-08-02 |
2024-04-09 |
ビステラ， インコーポレイテッド |
操作されたポリペプチドおよびその使用
|
|
NL2017270B1
(en)
|
2016-08-02 |
2018-02-09 |
Aduro Biotech Holdings Europe B V |
New anti-hCTLA-4 antibodies
|
|
BR112019002127A2
(pt)
|
2016-08-03 |
2019-09-17 |
Nextcure Inc |
proteína de fusão, vetor, célula, composição farmacêutica, e, uso da proteína de fusão
|
|
WO2018029182A1
(en)
|
2016-08-08 |
2018-02-15 |
Ablynx N.V. |
Il-6r single variable domain antibodies for treatment of il-6r related diseases
|
|
WO2018050833A1
(en)
|
2016-09-15 |
2018-03-22 |
Ablynx Nv |
Immunoglobulin single variable domains directed against macrophage migration inhibitory factor
|
|
KR20190049866A
(ko)
|
2016-09-20 |
2019-05-09 |
우시 바이올로직스 아일랜드 리미티드 |
신규한 항-ｐｃｓｋ９ 항체
|
|
EP4360714A3
(en)
|
2016-09-21 |
2024-07-24 |
Nextcure, Inc. |
Antibodies for siglec-15 and methods of use thereof
|
|
KR102644544B1
(ko)
|
2016-09-21 |
2024-03-11 |
넥스트큐어 인코포레이티드 |
Siglec-15를 위한 항체 및 이의 사용 방법
|
|
US11673971B2
(en)
|
2016-09-23 |
2023-06-13 |
Marengo Therapeutics, Inc. |
Multispecific antibody molecules comprising lambda and kappa light chains
|
|
CA3034105A1
(en)
|
2016-09-23 |
2018-03-29 |
Csl Limited |
Coagulation factor binding proteins and uses thereof
|
|
WO2018060453A1
(en)
|
2016-09-30 |
2018-04-05 |
Vhsquared Limited |
Compositions
|
|
EP3523331A1
(en)
|
2016-10-07 |
2019-08-14 |
Novartis AG |
Chimeric antigen receptors for the treatment of cancer
|
|
WO2018068201A1
(en)
|
2016-10-11 |
2018-04-19 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against ctla-4
|
|
JP7066696B2
(ja)
|
2016-10-11 |
2022-05-13 |
アジェナス インコーポレイテッド |
抗ｌａｇ－３抗体及びその使用方法
|
|
WO2018071624A1
(en)
|
2016-10-12 |
2018-04-19 |
Alexion Pharmaceuticals, Inc. |
Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of a kidney transplant
|
|
GB2605540B
(en)
|
2016-10-18 |
2022-12-21 |
Univ Minnesota |
Tumor infiltrating lymphocytes and methods of therapy
|
|
JP7173965B2
(ja)
|
2016-10-19 |
2022-11-16 |
アレクシオン ファーマシューティカルズ， インコーポレイテッド |
試料中の非結合Ｃ５ａの定量化方法
|
|
ES2848206T3
(es)
|
2016-10-19 |
2021-08-05 |
Alexion Pharma Inc |
Un método de cuantificar C5 sin unir en una muestra
|
|
EP3529262B1
(en)
|
2016-10-21 |
2021-07-21 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Methods for promoting t cells response
|
|
JP7128182B2
(ja)
|
2016-10-27 |
2022-08-30 |
アレクシオン ファーマシューティカルズ， インコーポレイテッド |
補体関連障害におけるＣ５ｂ－９沈着に関するアッセイ
|
|
WO2018078083A1
(en)
|
2016-10-28 |
2018-05-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New method for treating multiple myeloma
|
|
WO2018081578A1
(en)
|
2016-10-28 |
2018-05-03 |
Astute Medical, Inc. |
Use of antibodies to timp-2 for the improvement of renal function
|
|
EP3534947A1
(en)
|
2016-11-03 |
2019-09-11 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses & methods
|
|
NZ753088A
(en)
|
2016-11-04 |
2025-05-30 |
2Seventy Bio Inc |
Anti-bcma car t cell compositions
|
|
WO2018083538A1
(en)
|
2016-11-07 |
2018-05-11 |
Neuracle Scienc3 Co., Ltd. |
Anti-family with sequence similarity 19, member a5 antibodies and method of use thereof
|
|
CA3043515A1
(en)
|
2016-11-16 |
2018-05-24 |
Ablynx Nv |
T cell recruiting polypeptides capable of binding cd123 and tcr alpha/beta
|
|
IL309526B2
(en)
|
2016-11-17 |
2025-02-01 |
2Seventy Bio Inc |
TGFBeta signal converter
|
|
WO2018091720A1
(en)
|
2016-11-21 |
2018-05-24 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the prophylactic treatment of metastases
|
|
KR20210087108A
(ko)
|
2016-11-23 |
2021-07-09 |
하푼 테라퓨틱스, 인크. |
전립선 특이 막 항원 결합 단백질
|
|
BR112019010602A2
(pt)
|
2016-11-23 |
2019-12-17 |
Harpoon Therapeutics Inc |
proteínas trispecíficas para psma e métodos de uso
|
|
WO2018099968A1
(en)
|
2016-11-29 |
2018-06-07 |
Ablynx N.V. |
Treatment of infection by respiratory syncytial virus (rsv)
|
|
US10759855B2
(en)
|
2016-12-02 |
2020-09-01 |
Rigel Pharmaceuticals, Inc. |
Antigen binding molecules to TIGIT
|
|
MD3551660T2
(ro)
|
2016-12-07 |
2024-03-31 |
Agenus Inc |
Anticorpi anti-CTLA-4 și procedee de utilizare a acestora
|
|
AU2017370937A1
(en)
|
2016-12-07 |
2019-05-30 |
Biora Therapeutics, Inc. |
Gastrointestinal tract detection methods, devices and systems
|
|
AU2017373945B2
(en)
|
2016-12-07 |
2025-01-23 |
Agenus Inc. |
Antibodies and methods of use thereof
|
|
CA3045472A1
(en)
|
2016-12-14 |
2018-06-21 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with a smad7 inhibitor
|
|
WO2018112255A1
(en)
|
2016-12-14 |
2018-06-21 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with an immunosuppressant
|
|
EP3554343A1
(en)
|
2016-12-14 |
2019-10-23 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with an il-1 inhibitor
|
|
JP7150723B2
(ja)
|
2016-12-14 |
2022-10-11 |
ビオラ・セラピューティクス・インコーポレイテッド |
消化管疾病のインテグリン阻害薬による治療
|
|
US10980739B2
(en)
|
2016-12-14 |
2021-04-20 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
|
|
CN110430801B
(zh)
|
2016-12-14 |
2024-04-30 |
比奥拉治疗股份有限公司 |
使用tnf抑制剂治疗胃肠道疾病
|
|
WO2018112245A1
(en)
|
2016-12-14 |
2018-06-21 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with a jak inhibitor and devices
|
|
CN117045784A
(zh)
|
2016-12-14 |
2023-11-14 |
比奥拉治疗股份有限公司 |
使用利用可摄入装置释放的il-12/il-23抑制剂治疗胃肠道疾病
|
|
WO2018112237A1
(en)
|
2016-12-14 |
2018-06-21 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with an il-6r inhibitor
|
|
WO2018112223A1
(en)
|
2016-12-14 |
2018-06-21 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with a tlr modulator
|
|
EP3360898A1
(en)
|
2017-02-14 |
2018-08-15 |
Boehringer Ingelheim International GmbH |
Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer
|
|
CN110325550B
(zh)
|
2016-12-23 |
2024-03-08 |
诺华股份有限公司 |
因子xi抗体和使用方法
|
|
BR112019013096A2
(pt)
|
2016-12-23 |
2019-12-17 |
Visterra Inc |
polipeptídeos ligantes e métodos de preparo dos mesmos
|
|
EP3565560B1
(en)
|
2017-01-09 |
2024-05-29 |
OnkosXcel Therapeutics, LLC |
Predictive and diagnostic methods for prostate cancer
|
|
WO2018136626A1
(en)
|
2017-01-18 |
2018-07-26 |
Visterra, Inc. |
Antibody molecule-drug conjugates and uses thereof
|
|
JP2020505037A
(ja)
|
2017-01-19 |
2020-02-20 |
オープン モノクローナル テクノロジー，インコーポレイテッド |
複数の重鎖免疫グロブリン遺伝子座を有するトランスジェニックげっ歯類由来のヒト抗体
|
|
EP3574005B1
(en)
|
2017-01-26 |
2021-12-15 |
Novartis AG |
Cd28 compositions and methods for chimeric antigen receptor therapy
|
|
WO2018141753A1
(en)
|
2017-01-31 |
2018-08-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method for treating squamous cell carcinomas
|
|
CN110546160A
(zh)
|
2017-02-06 |
2019-12-06 |
奥里尼斯生物科学公司 |
靶向嵌合蛋白及其用途
|
|
EP3580237B1
(en)
|
2017-02-08 |
2025-05-14 |
Novartis AG |
Fgf21 mimetic antibodies and uses thereof
|
|
US20200291089A1
(en)
|
2017-02-16 |
2020-09-17 |
Elstar Therapeutics, Inc. |
Multifunctional molecules comprising a trimeric ligand and uses thereof
|
|
WO2018160731A1
(en)
|
2017-02-28 |
2018-09-07 |
Novartis Ag |
Shp inhibitor compositions and uses for chimeric antigen receptor therapy
|
|
US11535668B2
(en)
|
2017-02-28 |
2022-12-27 |
Harpoon Therapeutics, Inc. |
Inducible monovalent antigen binding protein
|
|
EP3589725A1
(en)
|
2017-02-28 |
2020-01-08 |
Vib Vzw |
Means and methods for oral protein delivery
|
|
EP3943940A1
(en)
|
2017-03-14 |
2022-01-26 |
NanoTag Biotechnologies GmbH |
Target detection using a monovalent antibody
|
|
CN114940713B
(zh)
|
2017-03-15 |
2024-04-30 |
清华大学 |
抗trkb抗体
|
|
WO2018167283A1
(en)
|
2017-03-17 |
2018-09-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling
|
|
CN119971025A
(zh)
|
2017-03-24 |
2025-05-13 |
诺华股份有限公司 |
用于预防和治疗心脏病的方法
|
|
AU2018244276A1
(en)
|
2017-03-27 |
2019-10-17 |
Celgene Corporation |
Methods and compositions for reduction of immunogenicity
|
|
EP3601531B1
(en)
|
2017-03-30 |
2023-06-07 |
Biora Therapeutics, Inc. |
Treatment of a disease of the gastrointestinal tract with live biotherapeutics
|
|
WO2018183934A1
(en)
|
2017-03-30 |
2018-10-04 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with a chst15 inhibitor
|
|
WO2018183931A1
(en)
|
2017-03-30 |
2018-10-04 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with il-10 or an il-10 agonist
|
|
EP4108183A1
(en)
|
2017-03-30 |
2022-12-28 |
Biora Therapeutics, Inc. |
Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
|
|
WO2018183932A1
(en)
|
2017-03-30 |
2018-10-04 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with a il-13 inhibitor
|
|
AU2018249493A1
(en)
|
2017-04-03 |
2019-09-19 |
Oncxerna Therapeutics, Inc. |
Methods for treating cancer using PS-targeting antibodies with immuno-oncology agents
|
|
WO2018185516A1
(en)
|
2017-04-05 |
2018-10-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treating cardiovascular toxicity induced by anti-cancer therapy
|
|
US20200088732A1
(en)
|
2017-04-13 |
2020-03-19 |
INSERM (Institut National de la Santé et de la Recherche Mèdicale) |
Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma
|
|
MA50956A
(fr)
|
2017-04-13 |
2020-10-14 |
Agenus Inc |
Anticorps anti-cd137 et procédés d'utilisation correspondants
|
|
WO2018189403A1
(en)
|
2017-04-14 |
2018-10-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of cancer
|
|
CA3058290A1
(en)
|
2017-04-18 |
2018-10-25 |
Universite Libre De Bruxelles |
Biomarkers and targets for proliferative diseases
|
|
WO2018195034A1
(en)
|
2017-04-19 |
2018-10-25 |
Alexion Pharmaceuticals, Inc. |
Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of a kidney transplant
|
|
AU2018256406A1
(en)
|
2017-04-19 |
2019-10-17 |
Marengo Therapeutics, Inc. |
Multispecific molecules and uses thereof
|
|
CN110506056A
(zh)
|
2017-04-21 |
2019-11-26 |
斯塔滕生物技术有限公司 |
抗apoc3抗体和其使用方法
|
|
WO2018201056A1
(en)
|
2017-04-28 |
2018-11-01 |
Novartis Ag |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
|
EP3615068A1
(en)
|
2017-04-28 |
2020-03-04 |
Novartis AG |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
|
WO2018201047A1
(en)
|
2017-04-28 |
2018-11-01 |
Elstar Therapeutics, Inc. |
Multispecific molecules comprising a non-immunoglobulin heterodimerization domain and uses thereof
|
|
DK3618863T3
(da)
|
2017-05-01 |
2023-08-21 |
Agenus Inc |
Anti-tigit-antistoffer og fremgangsmåder til anvendelse deraf
|
|
KR20200005635A
(ko)
|
2017-05-11 |
2020-01-15 |
브이아이비 브이지더블유 |
가변 면역글로불린 도메인의 글리코실화
|
|
AU2018266562A1
(en)
|
2017-05-12 |
2019-12-05 |
Augusta University Research Institute, Inc. |
Human alpha fetoprotein-specific T cell receptors and uses thereof
|
|
JOP20190256A1
(ar)
|
2017-05-12 |
2019-10-28 |
Icahn School Med Mount Sinai |
فيروسات داء نيوكاسل واستخداماتها
|
|
US10543271B2
(en)
|
2017-05-12 |
2020-01-28 |
Harpoon Therapeutics, Inc. |
Mesothelin binding proteins
|
|
CN115028727A
(zh)
|
2017-05-12 |
2022-09-09 |
哈普恩治疗公司 |
靶向msln的三特异性蛋白质及使用方法
|
|
WO2018222587A1
(en)
|
2017-05-30 |
2018-12-06 |
The Regents Of The University Of California |
NANOBODIES AGAINST CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) INHIBITORY FACTOR (Cif)
|
|
WO2018220080A1
(en)
|
2017-05-31 |
2018-12-06 |
Boehringer Ingelheim International Gmbh |
Polypeptides antagonizing wnt signaling in tumor cells
|
|
EP3630836A1
(en)
|
2017-05-31 |
2020-04-08 |
Elstar Therapeutics, Inc. |
Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
|
|
KR102740376B1
(ko)
|
2017-06-02 |
2024-12-09 |
메르크 파텐트 게엠베하 |
Adamts5, mmp13 및 아그레칸 결합성 폴리펩타이드
|
|
KR102752550B1
(ko)
|
2017-06-02 |
2025-01-10 |
메르크 파텐트 게엠베하 |
Adamts 결합성 면역글로불린
|
|
WO2018220235A1
(en)
|
2017-06-02 |
2018-12-06 |
Merck Patent Gmbh |
Mmp13 binding immunoglobulins
|
|
SG10202113337YA
(en)
|
2017-06-02 |
2021-12-30 |
Ablynx Nv |
Aggrecan binding immunoglobulins
|
|
JP2020521797A
(ja)
|
2017-06-02 |
2020-07-27 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
抗がん剤組み合わせ治療
|
|
EP3415010A1
(en)
|
2017-06-13 |
2018-12-19 |
Agrosavfe Nv |
Insect-controlling polypeptides and methods
|
|
GB201709379D0
(en)
|
2017-06-13 |
2017-07-26 |
Univ Leuven Kath |
Humanised ADAMTS13 binding antibodies
|
|
WO2018229715A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Compositions comprising anti-cd32b antibodies and methods of use thereof
|
|
WO2018236904A1
(en)
|
2017-06-19 |
2018-12-27 |
Surface Oncology, Inc. |
Combination of anti-cd47 antibodies and cell death-inducing agents, and uses thereof
|
|
US20200172628A1
(en)
|
2017-06-22 |
2020-06-04 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
CN110785187B
(zh)
|
2017-06-22 |
2024-04-05 |
诺华股份有限公司 |
针对cd73的抗体分子及其用途
|
|
MX2019015738A
(es)
|
2017-06-27 |
2020-02-20 |
Novartis Ag |
Regimen de dosificacion para anticuerpos anti-tim-3 y usos de los mismos.
|
|
WO2019000223A1
(en)
|
2017-06-27 |
2019-01-03 |
Nanjing Legend Biotech Co., Ltd. |
ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
|
|
WO2019005756A1
(en)
|
2017-06-28 |
2019-01-03 |
The Rockefeller University |
CONJUGATES AGONIST ANTIBODY ANTI-MERTK-MEDICINE
|
|
EP3645564A1
(en)
|
2017-06-28 |
2020-05-06 |
Novartis AG |
Methods for preventing and treating urinary incontinence
|
|
WO2019006418A2
(en)
|
2017-06-30 |
2019-01-03 |
Intima Bioscience, Inc. |
ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
|
|
SG10201913147WA
(en)
|
2017-07-11 |
2020-02-27 |
Compass Therapeutics Llc |
Agonist antibodies that bind human cd137 and uses thereof
|
|
BR112019028269A2
(pt)
|
2017-07-11 |
2020-07-14 |
Alexion Pharmaceuticals, Inc. |
polipeptídeos que se ligam ao componente c5 do complemento ou à albumina sérica e suas proteínas de fusão
|
|
WO2019012030A1
(en)
|
2017-07-13 |
2019-01-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
DHODH INHIBITOR AND CHK1 INHIBITOR FOR THE TREATMENT OF CANCER
|
|
EP3431496A1
(en)
|
2017-07-19 |
2019-01-23 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Anti- isoasp7 amyloid beta antibodies and uses thereof
|
|
EP3655436B1
(en)
|
2017-07-19 |
2025-10-15 |
Vib Vzw |
Serum albumin binding agents
|
|
JP2020527572A
(ja)
|
2017-07-20 |
2020-09-10 |
ノバルティス アーゲー |
抗ｌａｇ−３抗体の投薬量レジメンおよびその使用
|
|
WO2019016784A1
(en)
|
2017-07-21 |
2019-01-24 |
Universidade De Coimbra |
ANTI-NUCLEOLIN ANTIBODIES
|
|
EP3658581A1
(en)
|
2017-07-24 |
2020-06-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antibodies and peptides to treat hcmv related diseases
|
|
KR20230066126A
(ko)
|
2017-07-27 |
2023-05-12 |
알렉시온 파마슈티칼스, 인코포레이티드 |
고농도 항-c5 항체 제형
|
|
JP2020529605A
(ja)
|
2017-08-01 |
2020-10-08 |
コンパス セラピューティクス リミテッド ライアビリティ カンパニー |
濾過およびクロマトグラフィ用ポッドならびにその使用方法
|
|
US20200306516A1
(en)
|
2017-08-14 |
2020-10-01 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with glatiramer or a pharmaceutically acceptable salt thereof
|
|
WO2019035938A1
(en)
|
2017-08-16 |
2019-02-21 |
Elstar Therapeutics, Inc. |
MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
|
|
US11485781B2
(en)
|
2017-08-17 |
2022-11-01 |
Massachusetts Institute Of Technology |
Multiple specificity binders of CXC chemokines
|
|
WO2019051164A1
(en)
|
2017-09-07 |
2019-03-14 |
Augusta University Research Institute, Inc. |
ANTIBODIES AGAINST PROTEIN 1 OF PROGRAMMED CELL DEATH
|
|
SI3681911T1
(sl)
|
2017-09-11 |
2025-01-31 |
Monash University |
Proteini za vezavo na humani trombinski receptor, par4
|
|
JP7330174B2
(ja)
|
2017-09-20 |
2023-08-21 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
オートファジーをモジュレーションするための方法及び医薬組成物
|
|
ES2759622T3
(es)
|
2017-10-02 |
2020-05-11 |
Certest Biotec S L |
Anticuerpos anti-Dps y dispositivos de prueba para la detección de bacterias del género Campylobacter
|
|
CA3074032A1
(en)
|
2017-10-02 |
2019-04-11 |
Visterra, Inc. |
Antibody molecules to cd138 and uses thereof
|
|
WO2019075090A1
(en)
|
2017-10-10 |
2019-04-18 |
Tilos Therapeutics, Inc. |
ANTI-LAP ANTIBODIES AND USES THEREOF
|
|
IL315737A
(en)
|
2017-10-13 |
2024-11-01 |
Harpoon Therapeutics Inc |
B-cell maturation antigen-binding proteins
|
|
AU2018347582B2
(en)
|
2017-10-13 |
2025-08-28 |
Harpoon Therapeutics, Inc. |
Trispecific proteins and methods of use
|
|
CN111511766B
(zh)
|
2017-10-13 |
2024-06-07 |
Ose免疫疗法 |
修饰的抗SIRPa抗体及其应用
|
|
AU2018350370B2
(en)
|
2017-10-18 |
2023-05-04 |
Csl Limited |
Human serum albumin variants and uses thereof
|
|
KR20200072507A
(ko)
|
2017-10-19 |
2020-06-22 |
데비오팜 인터네셔날 에스 에이 |
암 치료를 위한 조합 제품
|
|
US20200370012A1
(en)
|
2017-10-25 |
2020-11-26 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
|
WO2019081983A1
(en)
|
2017-10-25 |
2019-05-02 |
Novartis Ag |
CD32B TARGETING ANTIBODIES AND METHODS OF USE
|
|
CN118512588A
(zh)
|
2017-10-26 |
2024-08-20 |
亚力兄制药公司 |
用于治疗阵发性夜间性血红蛋白尿(pnh)和非典型溶血性尿毒症综合征(ahus)的抗c5抗体的剂量和施用
|
|
US20210179709A1
(en)
|
2017-10-31 |
2021-06-17 |
Novartis Ag |
Anti-car compositions and methods
|
|
JP2021502063A
(ja)
|
2017-10-31 |
2021-01-28 |
フエー・イー・ベー・フエー・ゼツト・ウエー |
新規抗原結合性キメラタンパク質とその方法及び使用
|
|
JP7039694B2
(ja)
|
2017-10-31 |
2022-03-22 |
スターテン・バイオテクノロジー・ベー・フェー |
抗ａｐｏｃ３抗体およびその使用方法
|
|
US11718679B2
(en)
|
2017-10-31 |
2023-08-08 |
Compass Therapeutics Llc |
CD137 antibodies and PD-1 antagonists and uses thereof
|
|
US20190160102A1
(en)
|
2017-11-03 |
2019-05-30 |
Rubius Therapeutics, Inc. |
Compositions and methods related to therapeutic cell systems for tumor growth inhibition
|
|
WO2019099838A1
(en)
|
2017-11-16 |
2019-05-23 |
Novartis Ag |
Combination therapies
|
|
US11851497B2
(en)
|
2017-11-20 |
2023-12-26 |
Compass Therapeutics Llc |
CD137 antibodies and tumor antigen-targeting antibodies and uses thereof
|
|
WO2019104385A1
(en)
|
2017-11-29 |
2019-06-06 |
Csl Limited |
Method of treating or preventing ischemia-reperfusion injury
|
|
WO2019106126A1
(en)
|
2017-12-01 |
2019-06-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Mdm2 modulators for the diagnosis and treatment of liposarcoma
|
|
CN112236514A
(zh)
|
2017-12-05 |
2021-01-15 |
塞利亚德股份公司 |
改善细胞过继转移的持久性的组合物和方法
|
|
WO2019110667A1
(en)
|
2017-12-05 |
2019-06-13 |
Celyad S.A. |
Reducing fratricide of immune cells expressing nkg2d-based receptors
|
|
US20200377571A1
(en)
|
2017-12-08 |
2020-12-03 |
Elstar Therapeutics, Inc. |
Multispecific molecules and uses thereof
|
|
WO2019121872A1
(en)
|
2017-12-20 |
2019-06-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the diagnosis and treatment of liver cancer
|
|
WO2019129054A1
(zh)
|
2017-12-27 |
2019-07-04 |
信达生物制药(苏州)有限公司 |
三链抗体、其制备方法及其用途
|
|
WO2019129137A1
(zh)
|
2017-12-27 |
2019-07-04 |
信达生物制药(苏州)有限公司 |
抗lag-3抗体及其用途
|
|
WO2019129136A1
(zh)
|
2017-12-27 |
2019-07-04 |
信达生物制药(苏州)有限公司 |
抗pd-l1抗体及其用途
|
|
CN115925943A
(zh)
|
2017-12-27 |
2023-04-07 |
信达生物制药(苏州)有限公司 |
抗pd-l1抗体及其用途
|
|
CN109970856B
(zh)
|
2017-12-27 |
2022-08-23 |
信达生物制药(苏州)有限公司 |
抗lag-3抗体及其用途
|
|
JP7369127B2
(ja)
|
2017-12-28 |
2023-10-25 |
ナンジン レジェンド バイオテック カンパニー，リミテッド |
Ｔｉｇｉｔに対する単一ドメイン抗体及びその変異体
|
|
CN108218990B
(zh)
|
2017-12-29 |
2021-03-02 |
南京优迈生物科技有限公司 |
分离的抗体或其抗原结合片段及其在肿瘤治疗中的应用
|
|
WO2019139987A1
(en)
|
2018-01-09 |
2019-07-18 |
Elstar Therapeutics, Inc. |
Calreticulin binding constructs and engineered t cells for the treatment of diseases
|
|
US20190330591A1
(en)
|
2018-01-10 |
2019-10-31 |
Rubius Therapeutics, Inc. |
Amplifiable rnas for therapeutic cell systems
|
|
EP3740507A4
(en)
|
2018-01-15 |
2022-08-24 |
Nanjing Legend Biotech Co., Ltd. |
SINGLE DOMAIN ANTIBODIES AND VARIANTS THEREOF AGAINST PD-1
|
|
US11965191B2
(en)
|
2018-01-18 |
2024-04-23 |
California Institute Of Technology |
Programmable protein circuits in living cells
|
|
US10899823B2
(en)
|
2018-01-18 |
2021-01-26 |
California Institute Of Technology |
Programmable protein circuits in living cells
|
|
AU2019211326A1
(en)
|
2018-01-23 |
2020-09-10 |
Nextcure, Inc. |
B7-H4 antibodies and methods of use thereof
|
|
JP2021510594A
(ja)
|
2018-01-25 |
2021-04-30 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
臓器の虚血再灌流傷害を予防する方法における使用のためのｉｌ−３３のアンタゴニスト
|
|
WO2019148089A1
(en)
|
2018-01-26 |
2019-08-01 |
Orionis Biosciences Inc. |
Xcr1 binding agents and uses thereof
|
|
CA3090249A1
(en)
|
2018-01-31 |
2019-08-08 |
Novartis Ag |
Combination therapy using a chimeric antigen receptor
|
|
EP3746123A4
(en)
|
2018-02-01 |
2021-12-01 |
Memorial Sloan-Kettering Cancer Center |
ANTIBODIES DIRECTED AGAINST GALECTIN-3 AND THEIR METHODS OF USE
|
|
CA3090406A1
(en)
|
2018-02-05 |
2019-08-08 |
Orionis Biosciences, Inc. |
Fibroblast binding agents and use thereof
|
|
CN112004826B
(zh)
|
2018-02-05 |
2024-06-14 |
自由大学基金会 |
反向激动性抗us28抗体
|
|
EP3749696A1
(en)
|
2018-02-06 |
2020-12-16 |
Ablynx N.V. |
Methods of treating initial episode of ttp with immunoglobulin single variable domains
|
|
US11802303B2
(en)
|
2018-02-07 |
2023-10-31 |
Georgia Tech Research Corporation |
Methods for multiplexed cell isolation using DNA gates
|
|
WO2019155041A1
(en)
|
2018-02-12 |
2019-08-15 |
Vib Vzw |
Gβγ COMPLEX ANTIBODIES AND USES THEREOF
|
|
WO2019156566A1
(en)
|
2018-02-12 |
2019-08-15 |
Umc Utrecht Holding B.V. |
Bispecific molecules comprising gamma-delta tcr and t-cell or nk cell binding domain
|
|
WO2019158512A1
(en)
|
2018-02-13 |
2019-08-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the prognosis and the treatment of glioblastoma
|
|
WO2019160866A2
(en)
|
2018-02-13 |
2019-08-22 |
Checkmate Pharmaceuticals, Inc. |
Compositions and methods for tumor immunotherapy
|
|
CA3092421A1
(en)
|
2018-03-01 |
2019-09-06 |
Vrije Universiteit Brussel |
Human pd-l1-binding immunoglobulins
|
|
WO2019169229A1
(en)
|
2018-03-01 |
2019-09-06 |
Nextcure, Inc. |
Klrg1 binding compositions and methods of use thereof
|
|
NL2020520B1
(en)
|
2018-03-02 |
2019-09-12 |
Labo Bio Medical Invest B V |
Multispecific binding molecules for the prevention, treatment and diagnosis of neurodegenerative disorders
|
|
MX2020009507A
(es)
|
2018-03-13 |
2020-10-22 |
Smivet B V |
Anticuerpos de dominio individual que se unen a la neurotoxina del tetanos.
|
|
WO2019178269A2
(en)
|
2018-03-14 |
2019-09-19 |
Surface Oncology, Inc. |
Antibodies that bind cd39 and uses thereof
|
|
WO2019178364A2
(en)
|
2018-03-14 |
2019-09-19 |
Elstar Therapeutics, Inc. |
Multifunctional molecules and uses thereof
|
|
EP3765517A1
(en)
|
2018-03-14 |
2021-01-20 |
Elstar Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
US12202894B2
(en)
|
2018-03-20 |
2025-01-21 |
WuXi Biologics Ireland Limited |
Anti-TIM-3 antibodies
|
|
WO2019179365A1
(en)
|
2018-03-20 |
2019-09-26 |
WuXi Biologics Ireland Limited |
Novel anti-lag-3 antibody polypeptide
|
|
WO2019183499A1
(en)
|
2018-03-22 |
2019-09-26 |
Surface Oncology, Inc. |
Anti-il-27 antibodies and uses thereof
|
|
WO2019178645A1
(en)
|
2018-03-23 |
2019-09-26 |
Csl Limited |
Method of treating asthma
|
|
KR20210005597A
(ko)
|
2018-03-23 |
2021-01-14 |
유니베르시테 리브레 드 브룩크젤즈 |
Wnt 시그널링 작용제 분자
|
|
WO2019185723A1
(en)
|
2018-03-27 |
2019-10-03 |
Umc Utrecht Holding B.V. |
Targeted thrombolysis for treatment of microvascular thrombosis
|
|
WO2019184909A1
(zh)
|
2018-03-27 |
2019-10-03 |
信达生物制药(苏州)有限公司 |
新型抗体分子、其制备方法及其用途
|
|
EP3775206A1
(en)
|
2018-03-28 |
2021-02-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treating cancer
|
|
JP7346790B2
(ja)
|
2018-03-30 |
2023-09-20 |
ナンジン レジェンド バイオテック カンパニー，リミテッド |
Ｌａｇ‐３に対する単一ドメイン抗体およびその使用
|
|
WO2019193375A1
(en)
|
2018-04-04 |
2019-10-10 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of fzd7 inhibitors for the treatment of retinal neovascularization
|
|
KR20210006905A
(ko)
|
2018-04-09 |
2021-01-19 |
체크메이트 파마슈티칼스 |
바이러스-유사 입자 내로의 올리고뉴클레오타이드의 포장
|
|
WO2019200357A1
(en)
|
2018-04-12 |
2019-10-17 |
Surface Oncology, Inc. |
Biomarker for cd47 targeting therapeutics and uses therefor
|
|
WO2019197683A1
(en)
|
2018-04-13 |
2019-10-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting outcome and treatment of patients suffering from prostate cancer or breast cancer
|
|
US20210147547A1
(en)
|
2018-04-13 |
2021-05-20 |
Novartis Ag |
Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
|
|
WO2019207030A1
(en)
|
2018-04-26 |
2019-10-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting a response with an immune checkpoint inhibitor in a patient suffering from a lung cancer
|
|
WO2019210153A1
(en)
|
2018-04-27 |
2019-10-31 |
Novartis Ag |
Car t cell therapies with enhanced efficacy
|
|
US12048745B2
(en)
|
2018-05-01 |
2024-07-30 |
Augusta University Research Institute, Inc. |
Methods for detecting and reversing immune therapy resistance
|
|
WO2019211370A1
(en)
|
2018-05-03 |
2019-11-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treating cancer
|
|
WO2019211369A1
(en)
|
2018-05-03 |
2019-11-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treating cancer
|
|
CN119569873A
(zh)
|
2018-05-10 |
2025-03-07 |
纽洛可科学有限公司 |
抗序列相似家族19成员a5的抗体及其使用方法
|
|
WO2019217913A1
(en)
|
2018-05-10 |
2019-11-14 |
Sensei Biotherapeutics, Inc. |
Aspartate beta-hydroxylase chimeric antigen receptors and uses thereof
|
|
CA3100327A1
(en)
|
2018-05-14 |
2019-11-21 |
Harpoon Therapeutics, Inc. |
Binding moiety for conditional activation of immunoglobulin molecules
|
|
EP3569618A1
(en)
|
2018-05-19 |
2019-11-20 |
Boehringer Ingelheim International GmbH |
Antagonizing cd73 antibody
|
|
TW202003580A
(zh)
|
2018-05-21 |
2020-01-16 |
美商坎伯斯治療有限責任公司 |
用於增強nk細胞對標靶細胞之殺死之組合物及方法
|
|
WO2019226658A1
(en)
|
2018-05-21 |
2019-11-28 |
Compass Therapeutics Llc |
Multispecific antigen-binding compositions and methods of use
|
|
WO2019226050A2
(en)
|
2018-05-24 |
2019-11-28 |
Wageningen Universiteit |
Novel viral anti-infective reagents
|
|
TWI869346B
(zh)
|
2018-05-30 |
2025-01-11 |
瑞士商諾華公司 |
Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
|
|
ES2996257T3
(en)
|
2018-05-31 |
2025-02-12 |
Alexion Pharma Inc |
Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) in pediatric patients
|
|
WO2019232244A2
(en)
|
2018-05-31 |
2019-12-05 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
US11492409B2
(en)
|
2018-06-01 |
2022-11-08 |
Novartis Ag |
Binding molecules against BCMA and uses thereof
|
|
WO2019234099A1
(en)
|
2018-06-06 |
2019-12-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for diagnosing, predicting the outcome and treating a patient suffering from heart failure with preserved ejection fraction
|
|
WO2019234221A1
(en)
|
2018-06-08 |
2019-12-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for stratification and treatment of a patient suffering from chronic lymphocytic leukemia
|
|
TWI848953B
(zh)
|
2018-06-09 |
2024-07-21 |
德商百靈佳殷格翰國際股份有限公司 |
針對癌症治療之多特異性結合蛋白
|
|
EP3806888B1
(en)
|
2018-06-12 |
2024-01-31 |
Obsidian Therapeutics, Inc. |
Pde5 derived regulatory constructs and methods of use in immunotherapy
|
|
KR20210020932A
(ko)
|
2018-06-13 |
2021-02-24 |
노파르티스 아게 |
Bcma 키메라 항원 수용체 및 이의 용도
|
|
BR112020025439A2
(pt)
|
2018-06-14 |
2021-03-16 |
Bluebird Bio, Inc. |
Receptores de antígenos quiméricos cd79a
|
|
KR20210022004A
(ko)
|
2018-06-18 |
2021-03-02 |
안위타 바이오사이언시스, 인코포레이티드 |
항-메소텔린 작제물 및 이의 용도
|
|
CN112654394B
(zh)
|
2018-06-19 |
2025-07-11 |
阿塔盖有限责任公司 |
针对补体成分5的抗体分子和其用途
|
|
US20230041197A1
(en)
|
2018-06-20 |
2023-02-09 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with an immunomodulator
|
|
US12227565B2
(en)
|
2018-06-20 |
2025-02-18 |
Biora Therapeutics, Inc. |
Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
|
|
US12312394B2
(en)
|
2018-06-28 |
2025-05-27 |
Alexion Pharmaceuticals, Inc. |
Methods of producing anti-C5 antibodies
|
|
WO2020001526A1
(zh)
|
2018-06-29 |
2020-01-02 |
苏州智核生物医药科技有限公司 |
Pd-l1结合多肽及其用途
|
|
US11884729B2
(en)
|
2018-06-29 |
2024-01-30 |
ApitBio, Inc |
Anti-L1CAM antibodies and uses thereof
|
|
WO2020010250A2
(en)
|
2018-07-03 |
2020-01-09 |
Elstar Therapeutics, Inc. |
Anti-tcr antibody molecules and uses thereof
|
|
EP3820992A2
(en)
|
2018-07-11 |
2021-05-19 |
Actym Therapeutics, Inc. |
Engineered immunostimulatory bacterial strains and uses thereof
|
|
TW202019474A
(zh)
|
2018-07-11 |
2020-06-01 |
美商西建公司 |
抗bcma嵌合抗原受體之用途
|
|
WO2020016160A1
(en)
|
2018-07-16 |
2020-01-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method to treat neurological diseases
|
|
US20210290633A1
(en)
|
2018-07-19 |
2021-09-23 |
INSERM (Insstitut National de la Santé et de la Recherche Médicale) |
Combination for treating cancer
|
|
CA3106418A1
(en)
|
2018-07-20 |
2020-01-23 |
Pierre Fabre Medicament |
Receptor for vista
|
|
WO2020021465A1
(en)
|
2018-07-25 |
2020-01-30 |
Advanced Accelerator Applications (Italy) S.R.L. |
Method of treatment of neuroendocrine tumors
|
|
ES2738926A1
(es)
|
2018-07-26 |
2020-01-27 |
Univ Zaragoza |
Granulisina, metodo de obtencion y usos
|
|
WO2020028909A1
(en)
|
2018-08-03 |
2020-02-06 |
Brown University |
Oral formulations with increased uptake
|
|
US20210309746A1
(en)
|
2018-08-09 |
2021-10-07 |
Compass Therapeutics Llc |
Antibodies that bind cd277 and uses thereof
|
|
WO2020033925A2
(en)
|
2018-08-09 |
2020-02-13 |
Compass Therapeutics Llc |
Antibodies that bind cd277 and uses thereof
|
|
WO2020033923A1
(en)
|
2018-08-09 |
2020-02-13 |
Compass Therapeutics Llc |
Antigen binding agents that bind cd277 and uses thereof
|
|
US12391957B2
(en)
|
2018-08-17 |
2025-08-19 |
Icahn School Of Medicine At Mount Sinai |
Recombinant Newcastle disease viruses and uses thereof for the prevention of RSV disease or human metapneumovirus disease
|
|
US11453893B2
(en)
|
2018-08-30 |
2022-09-27 |
California Institute Of Technology |
RNA-based delivery systems with levels of control
|
|
WO2020047449A2
(en)
|
2018-08-31 |
2020-03-05 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
|
WO2020047320A1
(en)
|
2018-08-31 |
2020-03-05 |
California Institute Of Technology |
Synthetic protein circuits detecting signal transducer activity
|
|
LT3844267T
(lt)
|
2018-08-31 |
2025-10-10 |
|
Chimerinių antigenų receptorius ekspresuojančių ląstelių gaminimo metodai
|
|
KR20210056344A
(ko)
|
2018-09-04 |
2021-05-18 |
난징 유엠에이비-바이오파마 컴퍼티 리미티드 |
융합 단백질 및 그가 종양 및/또는 바이러스 감염을 치료하기 위한 약물 제조에서의 응용
|
|
GB201814451D0
(en)
|
2018-09-05 |
2018-10-17 |
Valerie Nicholas Carl Kristoffer |
Methods
|
|
GB2576914A
(en)
|
2018-09-06 |
2020-03-11 |
Kymab Ltd |
Antigen-binding molecules comprising unpaired variable domains produced in mammals
|
|
CN113195516B
(zh)
*
|
2018-09-11 |
2025-07-15 |
纳诺泰克生物技术公司 |
由特异性结合物识别的表位标签
|
|
US12195544B2
(en)
|
2018-09-21 |
2025-01-14 |
Harpoon Therapeutics, Inc. |
EGFR binding proteins and methods of use
|
|
CA3114038A1
(en)
|
2018-09-25 |
2020-04-02 |
Harpoon Therapeutics, Inc. |
Dll3 binding proteins and methods of use
|
|
EP3856772A1
(en)
|
2018-09-25 |
2021-08-04 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Use of antagonists of th17 cytokines for the treatment of bronchial remodeling in patients suffering from allergic asthma
|
|
US20220242957A1
(en)
|
2018-09-27 |
2022-08-04 |
Marengo Therapeutics, Inc. |
Csf1r/ccr2 multispecific antibodies
|
|
SG11202100935TA
(en)
|
2018-09-28 |
2021-02-25 |
Massachusetts Inst Technology |
Collagen-localized immunomodulatory molecules and methods thereof
|
|
WO2020070062A1
(en)
|
2018-10-01 |
2020-04-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of tim-3 inhibitors for the treatment of exacerbations in patients suffering from severe asthma
|
|
AU2019352017A1
(en)
|
2018-10-03 |
2021-05-06 |
Staten Biotechnology B.V. |
Antibodies specific for human and cynomolgus ApoC3 and methods of use thereof
|
|
WO2020070288A1
(en)
|
2018-10-05 |
2020-04-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and systems for controlling the agonistic properties of antibody variable domains by light
|
|
US11130802B2
(en)
|
2018-10-10 |
2021-09-28 |
Tilos Therapeutics, Inc. |
Anti-lap antibody variants
|
|
UY38407A
(es)
|
2018-10-15 |
2020-05-29 |
Novartis Ag |
Anticuerpos estabilizadores de trem2
|
|
WO2020080941A1
(en)
|
2018-10-16 |
2020-04-23 |
Umc Utrecht Holding B.V. |
Anti- low-density lipoprotein receptor-related protein 5/6 antibodies
|
|
US20210386788A1
(en)
|
2018-10-24 |
2021-12-16 |
Obsidian Therapeutics, Inc. |
Er tunable protein regulation
|
|
CN119405797A
(zh)
|
2018-10-30 |
2025-02-11 |
亚力兄制药公司 |
用于治疗阵发性睡眠性血红蛋白尿症(pnh)的抗c5抗体的皮下剂量和施用
|
|
EP3873455A1
(en)
|
2018-10-31 |
2021-09-08 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Method for treating t-helper type 2 mediated disease
|
|
WO2020097350A1
(en)
|
2018-11-08 |
2020-05-14 |
Orionis Biosciences, Inc. |
Modulation of dendritic cell lineages
|
|
GB201818477D0
(en)
|
2018-11-13 |
2018-12-26 |
Emstopa Ltd |
Tissue plasminogen activator antibodies and method of use thereof
|
|
EP3880716A4
(en)
|
2018-11-13 |
2022-08-03 |
Compass Therapeutics LLC |
MULTISPECIFIC BINDING CONSTRUCTS DIRECTED AGAINST CHECKPOINT MOLECULES AND ASSOCIATED USES
|
|
US12422441B2
(en)
|
2018-12-07 |
2025-09-23 |
Georgia Tech Research Corporation |
Antibodies that bind to natively folded myocilin
|
|
EP3894440A4
(en)
|
2018-12-13 |
2022-09-07 |
Surface Oncology, Inc. |
ANTI-IL-27 ANTIBODIES AND THEIR USES
|
|
US20220017611A1
(en)
|
2018-12-13 |
2022-01-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New anti tau svqivykpv epitope single domain antibody
|
|
JP2022513255A
(ja)
|
2018-12-20 |
2022-02-07 |
ノバルティス アーゲー |
ＨＤＭ２－ｐ５３相互作用阻害剤とＢＣＬ２阻害剤との組み合わせ及び癌を処置するためのその使用
|
|
KR20210108978A
(ko)
|
2018-12-21 |
2021-09-03 |
오제 이뮈노테라프틱스 |
이작용성 항-pd-1/il-7 분자
|
|
MX2021007274A
(es)
|
2018-12-21 |
2021-07-15 |
Ose Immunotherapeutics |
Molecula bifuncional anti-pd-1/sirpa.
|
|
WO2020127369A1
(en)
|
2018-12-21 |
2020-06-25 |
Ose Immunotherapeutics |
Bifunctional molecule directed against human pd-1
|
|
WO2020130838A2
(en)
|
2018-12-21 |
2020-06-25 |
Qvq Holding B.V. |
Antibodies for preventing or treating candidiasis
|
|
US20220073626A1
(en)
|
2019-01-03 |
2022-03-10 |
Institut National De La Santé Et De La Recheche Médicale (Inserm) |
Methods and pharmaceutical compositions for enhancing cd8+ t cell-dependent immune responses in subjects suffering from cancer
|
|
WO2020146627A1
(en)
|
2019-01-10 |
2020-07-16 |
California Institute Of Technology |
A synthetic system for tunable thresholding of protein signals
|
|
EP3911670B1
(en)
|
2019-01-15 |
2024-12-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Mutated interleukin-34 (il-34) polypeptides and uses thereof in therapy
|
|
JP7539897B2
(ja)
|
2019-01-16 |
2024-08-26 |
コンパス セラピューティクス リミテッド ライアビリティ カンパニー |
ヒトｃｄ１３７に結合する抗体の製剤およびその使用
|
|
WO2020148349A1
(en)
|
2019-01-16 |
2020-07-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Variants of erythroferrone and their use
|
|
TWI756621B
(zh)
|
2019-01-25 |
2022-03-01 |
大陸商信達生物製藥（蘇州）有限公司 |
新型雙特異性抗體分子以及同時結合pd-l1和lag-3的雙特異性抗體
|
|
GB201901608D0
(en)
|
2019-02-06 |
2019-03-27 |
Vib Vzw |
Vaccine adjuvant conjugates
|
|
WO2020165374A1
(en)
|
2019-02-14 |
2020-08-20 |
Ose Immunotherapeutics |
Bifunctional molecule comprising il-15ra
|
|
PH12021551840A1
(en)
|
2019-02-15 |
2022-03-21 |
Integral Molecular Inc |
Claudin 6 antibodies and uses thereof
|
|
CN113661175A
(zh)
|
2019-02-15 |
2021-11-16 |
整体分子公司 |
包含共同轻链的抗体及其用途
|
|
US10871640B2
(en)
|
2019-02-15 |
2020-12-22 |
Perkinelmer Cellular Technologies Germany Gmbh |
Methods and systems for automated imaging of three-dimensional objects
|
|
WO2020172596A1
(en)
|
2019-02-21 |
2020-08-27 |
Elstar Therapeutics, Inc. |
Anti-tcr antibody molecules and thereof
|
|
WO2020169707A1
(en)
|
2019-02-21 |
2020-08-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Foxo1 inhibitor for use in the treatment of latent virus infection
|
|
SG11202108955QA
(en)
|
2019-02-21 |
2021-09-29 |
Marengo Therapeutics Inc |
Antibody molecules that bind to nkp30 and uses thereof
|
|
SG11202109056TA
(en)
|
2019-02-21 |
2021-09-29 |
Marengo Therapeutics Inc |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
SG11202109061YA
(en)
|
2019-02-21 |
2021-09-29 |
Marengo Therapeutics Inc |
Multifunctional molecules that bind to t cell related cancer cells and uses thereof
|
|
AU2020224680B2
(en)
|
2019-02-21 |
2025-06-19 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to T cells and uses thereof to treat autoimmune disorders
|
|
EP3927371A1
(en)
|
2019-02-22 |
2021-12-29 |
Novartis AG |
Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors
|
|
AU2020228033A1
(en)
|
2019-02-26 |
2021-09-16 |
Inspirna, Inc. |
High-affinity anti-MERTK antibodies and uses thereof
|
|
EP3930757A1
(en)
|
2019-03-01 |
2022-01-05 |
President And Fellows Of Harvard College |
Methods and compositions for protein delivery
|
|
US20230026259A1
(en)
|
2019-03-08 |
2023-01-26 |
Obsidian Therapeutics, Inc. |
Ca2 compositions and methods for tunable regulation
|
|
EP4378485A3
(en)
|
2019-03-08 |
2024-08-28 |
LinXis B.V. |
Internalizing binding molecules targeting receptors involved in cell proliferation or cell differentiation
|
|
WO2020193740A1
(en)
|
2019-03-28 |
2020-10-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New strategy for treating pancreatic cancer
|
|
EP3947442A2
(en)
|
2019-03-28 |
2022-02-09 |
Danisco US Inc. |
Engineered antibodies
|
|
TWI877155B
(zh)
|
2019-03-29 |
2025-03-21 |
美商艾特加有限責任公司 |
Fgf23之抗體分子及其用途
|
|
EP3947419A4
(en)
|
2019-04-01 |
2023-05-24 |
Rush University Medical Center |
REAGENTS AND ASSAYS USING MODIFIED INTEGRIND DOMAINS
|
|
WO2020205409A1
(en)
|
2019-04-03 |
2020-10-08 |
President And Fellows Of Harvard College |
Ionic liquids for drug delivery
|
|
WO2020206233A1
(en)
|
2019-04-04 |
2020-10-08 |
Vanderbilt University |
Therapeutic antibodies for treating lung cancer
|
|
WO2020208082A1
(en)
|
2019-04-09 |
2020-10-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method for treating cmv related diseases
|
|
WO2020210678A1
(en)
|
2019-04-12 |
2020-10-15 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
|
CN119569849A
(zh)
|
2019-04-29 |
2025-03-07 |
康福治疗有限公司 |
用于跨膜蛋白尤其是gpcr的筛选方法和测定
|
|
US20220289837A1
(en)
|
2019-04-30 |
2022-09-15 |
Vib Vzw |
Cystic Fibrosis Transmembrane Conductance Regulator Stabilizing Agents
|
|
CA3135004A1
(en)
|
2019-05-13 |
2020-11-19 |
Regeneron Pharmaceuticals, Inc. |
Improved competitive ligand binding assays
|
|
EP3969569A1
(en)
|
2019-05-14 |
2022-03-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Regulatory t cells targeted by lymphotoxin alpha blocking agent and uses thereof
|
|
BR112021022874A2
(pt)
|
2019-05-14 |
2022-03-22 |
Harpoon Therapeutics Inc |
Proteínas de ligação epcam e métodos de uso
|
|
EP3969472A1
(en)
|
2019-05-16 |
2022-03-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method to treat type 2 inflammation or mast-cell dependent disease
|
|
EP3972634A2
(en)
|
2019-05-21 |
2022-03-30 |
Novartis AG |
Trispecific binding molecules against bcma and uses thereof
|
|
WO2020236797A1
(en)
|
2019-05-21 |
2020-11-26 |
Novartis Ag |
Variant cd58 domains and uses thereof
|
|
BR112021023048A2
(pt)
|
2019-05-21 |
2022-04-19 |
Novartis Ag |
Moléculas de ligação a cd19 e usos das mesmas
|
|
JP7600218B2
(ja)
|
2019-05-24 |
2024-12-16 |
サンヨウ バイオファーマシューティカルズ カンパニー リミテッド |
新規なｃｌｄｎ１８．２結合分子
|
|
WO2020239945A1
(en)
|
2019-05-28 |
2020-12-03 |
Vib Vzw |
Cancer treatment by targeting plexins in the immune compartment
|
|
WO2020239934A1
(en)
|
2019-05-28 |
2020-12-03 |
Vib Vzw |
Cd8+ t-cells lacking plexins and their application in cancer treatment
|
|
GB2584441A
(en)
|
2019-06-03 |
2020-12-09 |
Fenomark Diagnostics Ab |
Medical uses, methods and uses
|
|
JP2022535553A
(ja)
|
2019-06-04 |
2022-08-09 |
シャンハイ、ケンパーソー、バイオテクノロジー、カンパニー、リミテッド |
抗ｃｅａｃａｍ５モノクローナル抗体、その作製方法およびその使用
|
|
CU20210099A7
(es)
|
2019-06-12 |
2022-07-08 |
Novartis Ag |
Anticuerpos de receptor de péptido natriurético 1
|
|
BR112021025421A2
(pt)
|
2019-06-17 |
2022-02-01 |
Visterra Inc |
Moléculas de anticorpo humanizado para cd138 e os usos dos mesmos
|
|
US20220259295A1
(en)
|
2019-06-20 |
2022-08-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method useful in tolerance induction therapy and kits therefore
|
|
MX2021015762A
(es)
|
2019-06-21 |
2022-04-18 |
Sorriso Pharmaceuticals Inc |
Composiciones.
|
|
EP3986571A1
(en)
|
2019-06-21 |
2022-04-27 |
Sorriso Pharmaceuticals, Inc. |
Polypeptides
|
|
CA3144566A1
(en)
|
2019-06-21 |
2020-12-24 |
Sorriso Pharmaceuticals, Inc. |
Polypeptides
|
|
EP3990491A1
(en)
|
2019-06-26 |
2022-05-04 |
Massachusetts Institute of Technology |
Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
|
|
CN114466863A
(zh)
|
2019-07-01 |
2022-05-10 |
苏州康宁杰瑞生物科技有限公司 |
百日咳毒素结合蛋白
|
|
WO2021001539A1
(en)
|
2019-07-04 |
2021-01-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New strategy to detect and treat eosinophilic fasciitis
|
|
AU2020312686A1
(en)
|
2019-07-15 |
2022-02-03 |
Intervet International B.V. |
Caninized antibodies against canine CTLA-4
|
|
KR20220051177A
(ko)
|
2019-07-26 |
2022-04-26 |
비스테라, 인크. |
인터류킨-2 작용제 및 이의 용도
|
|
EP4010079A1
(en)
|
2019-08-05 |
2022-06-15 |
Stichting VU |
Identification and elimination of hcmv-infected cells
|
|
PE20221151A1
(es)
|
2019-08-30 |
2022-07-18 |
Agenus Inc |
Anticuerpos anti-cd96 y sus metodos de uso
|
|
TWI873176B
(zh)
|
2019-09-04 |
2025-02-21 |
美商建南德克公司 |
Ｃｄ８結合劑及其用途
|
|
US20220340975A1
(en)
|
2019-09-05 |
2022-10-27 |
INSERM (Institute National de la Santé et de la Recherche Médicale) |
Method of treatment and pronostic of acute myeloid leukemia
|
|
WO2021046451A1
(en)
|
2019-09-06 |
2021-03-11 |
Obsidian Therapeutics, Inc. |
Compositions and methods for dhfr tunable protein regulation
|
|
WO2021055329A1
(en)
|
2019-09-16 |
2021-03-25 |
Surface Oncology, Inc. |
Anti-cd39 antibody compositions and methods
|
|
WO2021053559A1
(en)
|
2019-09-18 |
2021-03-25 |
Novartis Ag |
Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
|
|
TW202124446A
(zh)
|
2019-09-18 |
2021-07-01 |
瑞士商諾華公司 |
與ｅｎｔｐｄ２抗體之組合療法
|
|
CA3151078A1
(en)
|
2019-09-25 |
2021-04-01 |
Surface Oncology, Inc. |
Anti-il-27 antibodies and uses thereof
|
|
US20220290151A1
(en)
|
2019-09-27 |
2022-09-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of müllerian inhibiting substance inhibitors for treating cancer
|
|
TW202126295A
(zh)
|
2019-09-27 |
2021-07-16 |
大陸商江蘇挪貝肽醫藥科技有限公司 |
一種治療心境障礙的方法
|
|
TWI878355B
(zh)
|
2019-10-02 |
2025-04-01 |
德商百靈佳殷格翰國際股份有限公司 |
用於癌症治療之多重專一性結合蛋白
|
|
EP3799881A1
(en)
|
2019-10-04 |
2021-04-07 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Single domain antibodies specifically binding globo - series glycans
|
|
US20240301054A1
(en)
|
2019-10-21 |
2024-09-12 |
Novartis Ag |
Tim-3 inhibitors and uses thereof
|
|
BR112022007376A2
(pt)
|
2019-10-21 |
2022-07-05 |
Novartis Ag |
Terapias de combinação com venetoclax e inibidores de tim-3
|
|
EP4048703A1
(en)
|
2019-10-21 |
2022-08-31 |
Vib Vzw |
Nanodisc-specific antigen-binding chimeric proteins
|
|
WO2021080682A1
(en)
|
2019-10-24 |
2021-04-29 |
Massachusetts Institute Of Technology |
Monoclonal antibodies that bind human cd161 and uses thereof
|
|
US20240148901A1
(en)
|
2019-10-28 |
2024-05-09 |
Georgia Tech Research Corporation |
Compositions and methods for prophylaxis of hiv
|
|
US20230002785A1
(en)
|
2019-10-28 |
2023-01-05 |
Georgia Tech Research Corporation |
Mrna-encoded antibodies for contraception
|
|
EP4054622A1
(en)
|
2019-11-05 |
2022-09-14 |
Celgene Corporation |
Uses of anti-bcma chimeric antigen receptors
|
|
BR112022009087A2
(pt)
|
2019-11-11 |
2022-07-26 |
Ibi Ag Innovative Bio Insecticides Ltd |
Nanocorpos para controle de insetos e usos dos mesmos
|
|
CN116249779A
(zh)
|
2019-11-12 |
2023-06-09 |
阿克蒂姆治疗有限公司 |
免疫刺激细菌递送平台及其用于递送治疗产物的用途
|
|
KR20220104766A
(ko)
|
2019-11-22 |
2022-07-26 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
약물 전달을 위한 이온성 액체
|
|
IL293215A
(en)
|
2019-11-26 |
2022-07-01 |
Novartis Ag |
Chimeric antigen receptors binding bcma and cd19 and uses thereof
|
|
WO2021105384A1
(en)
|
2019-11-27 |
2021-06-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Targeting the nls region of nupr1 protein to treat cancer
|
|
EP4065603A1
(en)
|
2019-11-27 |
2022-10-05 |
Vib Vzw |
Positive allosteric modulators of the calcium-sensing receptor
|
|
WO2021105391A1
(en)
|
2019-11-27 |
2021-06-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Combination comprising nupr1 inhibitors to treat cancer
|
|
EP4069372A1
(en)
|
2019-12-05 |
2022-10-12 |
Ose Immunotherapeutics |
Anti-clec-1a antibodies and antigen-binding fragment thereof
|
|
AU2020396204A1
(en)
|
2019-12-06 |
2022-07-28 |
Ablynx Nv |
Polypeptides comprising immunoglobulin single variable domains targeting TNFα and IL-23
|
|
US11897950B2
(en)
|
2019-12-06 |
2024-02-13 |
Augusta University Research Institute, Inc. |
Osteopontin monoclonal antibodies
|
|
WO2021110817A1
(en)
|
2019-12-06 |
2021-06-10 |
Ablynx Nv |
Polypeptides comprising immunoglobulin single variable domains targeting tnfa and ox40l
|
|
WO2021116182A1
(en)
|
2019-12-09 |
2021-06-17 |
Ablynx Nv |
Polypeptides comprising immunoglobulin single variable domains targeting il-13 and tslp
|
|
EP4072682A1
(en)
|
2019-12-09 |
2022-10-19 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Antibodies having specificity to her4 and uses thereof
|
|
GB201918279D0
(en)
|
2019-12-12 |
2020-01-29 |
Vib Vzw |
Glycosylated single chain immunoglobulin domains
|
|
WO2021122866A1
(en)
|
2019-12-17 |
2021-06-24 |
Ose Immunotherapeutics |
Bifunctional molecules comprising an il-7 variant
|
|
EP4077372A1
(en)
|
2019-12-20 |
2022-10-26 |
Vib Vzw |
Nanobody exchange chromatography
|
|
US11725048B2
(en)
|
2019-12-20 |
2023-08-15 |
Hudson Institute of Medical Research |
CXCL10 binding proteins and compositions thereof
|
|
US20230056470A1
(en)
|
2019-12-20 |
2023-02-23 |
Novartis Ag |
Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
|
|
EP4084821A4
(en)
|
2020-01-03 |
2024-04-24 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to cd33 and uses thereof
|
|
IL294330B1
(en)
|
2020-01-06 |
2025-07-01 |
Vaccinex Inc |
Anti-ccr8 antibodies and uses thereof
|
|
WO2021140205A1
(en)
|
2020-01-10 |
2021-07-15 |
Confo Therapeutics N.V. |
Methods for generating antibodies and antibody fragments and libraries comprising same
|
|
TWI869528B
(zh)
|
2020-01-13 |
2025-01-11 |
美商威特拉公司 |
C5ar1抗體分子及其用途
|
|
MX2022008845A
(es)
|
2020-01-17 |
2022-08-10 |
Univ Gent |
Anticuerpos de dominio unico de inmunoglobulina para la entrega de vacunas a traves de la mucosa.
|
|
BR112022012310A2
(pt)
|
2020-01-17 |
2022-09-06 |
Novartis Ag |
Combinação compreendendo um inibidor de tim-3 e um agente hipometilante para uso no tratamento de síndrome mielodisplásica ou leucemia mielomonocítica crônica
|
|
WO2021156490A2
(en)
|
2020-02-06 |
2021-08-12 |
Vib Vzw |
Corona virus binders
|
|
WO2021163618A1
(en)
|
2020-02-14 |
2021-08-19 |
Novartis Ag |
Method of predicting response to chimeric antigen receptor therapy
|
|
MX2022010175A
(es)
|
2020-02-21 |
2022-09-12 |
Harpoon Therapeutics Inc |
Proteinas de union a flt3 y metodos de uso.
|
|
BR112022016909A2
(pt)
|
2020-02-24 |
2022-12-06 |
Immatics Us Inc |
Métodos para a expansão de células t para o tratamento de câncer e malignidades associadas
|
|
CA3173090A1
(en)
|
2020-02-25 |
2021-09-02 |
Vib Vzw |
Leucine-rich repeat kinase 2 allosteric modulators
|
|
WO2021173674A1
(en)
|
2020-02-26 |
2021-09-02 |
A2 Biotherapeutics, Inc. |
Polypeptides targeting mage-a3 peptide-mhc complexes and methods of use thereof
|
|
PH12022552283A1
(en)
|
2020-02-27 |
2024-01-22 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
|
KR20220147109A
(ko)
|
2020-02-27 |
2022-11-02 |
노파르티스 아게 |
키메라 항원 수용체 발현 세포의 제조 방법
|
|
MX2022011080A
(es)
|
2020-03-10 |
2023-01-04 |
Massachusetts Inst Technology |
Metodos para generar celulas nk de tipo memoria modificadas y composiciones de las mismas.
|
|
AU2021232853A1
(en)
|
2020-03-10 |
2022-09-22 |
Massachusetts Institute Of Technology |
Compositions and methods for immunotherapy of NPM1c-positive cancer
|
|
DE102020111571A1
(de)
|
2020-03-11 |
2021-09-16 |
Immatics US, Inc. |
Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
|
|
KR20220152316A
(ko)
|
2020-03-12 |
2022-11-15 |
이뮨-온크 테라퓨틱스, 인코포레이티드 |
신규한 항-lilrb4 항체 및 유도체 생성물
|
|
US20240043530A1
(en)
|
2020-03-13 |
2024-02-08 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
PVRIG Binding Protein And Its Medical Uses
|
|
US11365239B2
(en)
|
2020-03-20 |
2022-06-21 |
Tsb Therapeutics (Beijing) Co., Ltd. |
Anti-SARS-COV-2 antibodies and uses thereof
|
|
IL296330A
(en)
|
2020-03-20 |
2022-11-01 |
Glaxosmithkline Ip Dev Ltd |
A method for the detection of polysorbates
|
|
US20230128499A1
(en)
|
2020-03-27 |
2023-04-27 |
Novartis Ag |
Bispecific combination therapy for treating proliferative diseases and autoimmune diseases
|
|
CN115397868A
(zh)
|
2020-03-30 |
2022-11-25 |
埃博灵克斯股份有限公司 |
用于产生和纯化多价免疫球蛋白单可变域的方法
|
|
CN113461817B
(zh)
|
2020-03-31 |
2025-04-18 |
苏州泽璟生物制药股份有限公司 |
一种抗人cd47抗体及其抗原结合片段、制备方法和应用
|
|
HUE069576T2
(hu)
|
2020-03-31 |
2025-03-28 |
Biotalys NV |
Gombaellenes polipeptidek
|
|
EP4126064A1
(en)
|
2020-04-03 |
2023-02-08 |
Visterra, Inc. |
Antibody molecule-drug conjugates and uses thereof
|
|
US20230272056A1
(en)
|
2020-04-09 |
2023-08-31 |
Merck Sharp & Dohme Llc |
Affinity matured anti-lap antibodies and uses thereof
|
|
AU2021257848A1
(en)
|
2020-04-15 |
2022-12-01 |
Voyager Therapeutics, Inc. |
Tau binding compounds
|
|
EP4135837A1
(en)
|
2020-04-16 |
2023-02-22 |
Assistance Publique, Hopitaux De Paris |
Methods for treating a complement mediated disorder caused by viruses
|
|
EP4144758A4
(en)
|
2020-04-22 |
2024-05-15 |
Mabwell (Shanghai) Bioscience Co., Ltd. |
SINGLE VARIABLE DOMAIN ANTIBODIES TARGETING AND DERIVED FROM HUMAN PROGRAMMED DEATH LIGAND 1 (PD-L1)
|
|
AU2021261420A1
(en)
|
2020-04-24 |
2022-12-01 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to T cell related cancer cells and uses thereof
|
|
CN116457368A
(zh)
|
2020-05-01 |
2023-07-18 |
匹兹堡大学联邦高等教育系统 |
用于鉴定纳米抗体和纳米抗体亲和力的组合物和方法
|
|
KR20230005952A
(ko)
|
2020-05-04 |
2023-01-10 |
임뮤노라이즌 엘티디. |
전구체 삼중-특이적 항체 구조체 및 그의 이용 방법
|
|
EP4149558A1
(en)
|
2020-05-12 |
2023-03-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New method to treat cutaneous t-cell lymphomas and tfh derived lymphomas
|
|
WO2021229104A1
(en)
|
2020-05-15 |
2021-11-18 |
Université de Liège |
Anti-cd38 single-domain antibodies in disease monitoring and treatment
|
|
CN116249555A
(zh)
|
2020-05-19 |
2023-06-09 |
勃林格殷格翰国际有限公司 |
用于癌症治疗的结合分子
|
|
JP2023526529A
(ja)
|
2020-05-19 |
2023-06-21 |
アンスティテュ・クリー |
サイトカイン放出症候群の診断及び処置の方法
|
|
EP3916088A1
(en)
|
2020-05-28 |
2021-12-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Fusion proteins comprising the sars-cov-2 3clpro catalytic domain and their uses for screening anti-sars-cov-2 agents
|
|
EP4157923A2
(en)
|
2020-05-29 |
2023-04-05 |
President And Fellows Of Harvard College |
Living cells engineered with polyphenol-functionalized biologically active nanocomplexes
|
|
CR20220611A
(es)
|
2020-06-02 |
2023-06-07 |
Arcus Biosciences Inc |
Anticuerpos anti-tigit
|
|
CN111647077B
(zh)
|
2020-06-02 |
2021-02-09 |
深圳市因诺赛生物科技有限公司 |
新型冠状病毒(sars-cov-2)刺突蛋白结合分子及其应用
|
|
CA3185455A1
(en)
|
2020-06-11 |
2021-12-16 |
Novartis Ag |
Zbtb32 inhibitors and uses thereof
|
|
JP2023530919A
(ja)
|
2020-06-17 |
2023-07-20 |
ヤンセン バイオテツク，インコーポレーテツド |
多能性幹細胞の製造のための材料及び方法
|
|
WO2021255204A1
(en)
|
2020-06-18 |
2021-12-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New strategy for treating pancreatic cancer
|
|
WO2021262999A1
(en)
|
2020-06-24 |
2021-12-30 |
Visterra, Inc. |
Antibody molecules to april and uses thereof
|
|
CN115884986A
(zh)
|
2020-06-29 |
2023-03-31 |
Inserm(法国国家健康医学研究院) |
抗蛋白s单域抗体和包含其的多肽
|
|
WO2022003156A1
(en)
|
2020-07-02 |
2022-01-06 |
Oncurious Nv |
Ccr8 non-blocking binders
|
|
US12077576B2
(en)
|
2020-07-02 |
2024-09-03 |
Trustees Of Tufts College |
VHH polypeptides that bind to Clostridium difficile toxin b and methods of use thereof
|
|
US20240247076A1
(en)
|
2020-07-03 |
2024-07-25 |
Suzhou Alphamab Co., Ltd. |
Coagulation factor xi (fxi) binding protein
|
|
JP2023534214A
(ja)
|
2020-07-16 |
2023-08-08 |
ノバルティス アーゲー |
抗ベータセルリン抗体、その断片、及び多重特異性結合分子
|
|
CN113956357B
(zh)
|
2020-07-21 |
2024-02-20 |
苏州智核生物医药科技有限公司 |
Cd8结合多肽及其用途
|
|
CN116348487A
(zh)
|
2020-07-23 |
2023-06-27 |
欧萨尔普罗席纳有限公司 |
抗淀粉样β抗体
|
|
WO2022026592A2
(en)
|
2020-07-28 |
2022-02-03 |
Celltas Bio, Inc. |
Antibody molecules to coronavirus and uses thereof
|
|
EP4189061A1
(en)
|
2020-07-31 |
2023-06-07 |
Biotalys NV |
Methods of increasing recombinant protein yields
|
|
EP4196139A2
(en)
|
2020-08-12 |
2023-06-21 |
Actym Therapeutics, Inc. |
Immunostimulatory bacteria-based vaccines, therapeutics, and rna delivery platforms
|
|
WO2022040631A1
(en)
|
2020-08-21 |
2022-02-24 |
Immatics US, Inc. |
Methods for isolating cd8+ selected t cells
|
|
CN116917316A
(zh)
|
2020-08-26 |
2023-10-20 |
马伦戈治疗公司 |
与NKp30结合的抗体分子及其用途
|
|
CN116249718A
(zh)
|
2020-08-26 |
2023-06-09 |
马伦戈治疗公司 |
结合至钙网蛋白的多功能性分子及其用途
|
|
KR20230074487A
(ko)
|
2020-08-26 |
2023-05-30 |
마렝고 테라퓨틱스, 인크. |
Trbc1 또는 trbc2를 검출하는 방법
|
|
WO2022043557A1
(en)
|
2020-08-31 |
2022-03-03 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
|
EP4204020A1
(en)
|
2020-08-31 |
2023-07-05 |
Advanced Accelerator Applications International S.A. |
Method of treating psma-expressing cancers
|
|
US20230365675A1
(en)
|
2020-09-14 |
2023-11-16 |
Vor Biopharma Inc. |
Single domain antibodies against cd33
|
|
WO2022060806A1
(en)
|
2020-09-16 |
2022-03-24 |
Obsidian Therapeutics, Inc. |
Compositions and methods for expression of anti-bcma chimeric antigen receptors with small molecule-regulated il15 in t cells
|
|
JP2023541934A
(ja)
|
2020-09-16 |
2023-10-04 |
リンクシス ベスローテン フェンノートシャップ |
内在化結合分子
|
|
EP4216943A1
(en)
|
2020-09-24 |
2023-08-02 |
Vib Vzw |
Combination of p2y6 inhibitors and immune checkpoint inhibitors
|
|
WO2022063957A1
(en)
|
2020-09-24 |
2022-03-31 |
Vib Vzw |
Biomarker for anti-tumor therapy
|
|
IL301581A
(en)
|
2020-09-25 |
2023-05-01 |
Ablynx Nv |
Polypeptides comprising immunoglobulin single variable domains targeting il-13 and ox40l
|
|
TW202228775A
(zh)
|
2020-10-14 |
2022-08-01 |
美商維里迪恩醫療股份有限公司 |
用於治療甲狀腺眼病之組合物及方法
|
|
CN117043186A
(zh)
|
2020-10-21 |
2023-11-10 |
勃林格殷格翰国际有限公司 |
用于治疗眼部疾病的激动性TrkB结合分子
|
|
WO2022084399A1
(en)
|
2020-10-21 |
2022-04-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
C-terminal sparc fragments for treating cancer
|
|
JP2023550309A
(ja)
|
2020-11-04 |
2023-12-01 |
セルジーン コーポレーション |
以前に抗がんアルキル化剤療法を受けた患者におけるｃａｒ ｔ細胞療法
|
|
AU2021374083A1
(en)
|
2020-11-06 |
2023-06-01 |
Novartis Ag |
Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies
|
|
KR20230104651A
(ko)
|
2020-11-06 |
2023-07-10 |
노파르티스 아게 |
Cd19 결합 분자 및 이의 용도
|
|
CN112480248B
(zh)
|
2020-11-24 |
2023-05-05 |
三优生物医药(上海)有限公司 |
与cld18a2特异性结合的分子
|
|
WO2022117572A2
(en)
|
2020-12-02 |
2022-06-09 |
Oncurious Nv |
An ltbr agonist in combination therapy against cancer
|
|
WO2022117569A1
(en)
|
2020-12-02 |
2022-06-09 |
Oncurious Nv |
A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
|
|
PH12023500013A1
(en)
|
2020-12-04 |
2024-03-11 |
Tidal Therapeutics Inc |
Ionizable cationic lipids and lipi nanoparticles, and methods of synthesis and use thereof
|
|
US12098178B2
(en)
|
2020-12-04 |
2024-09-24 |
Visterra, Inc. |
Methods of using interleukin-2 agents
|
|
US20240016936A1
(en)
|
2020-12-04 |
2024-01-18 |
Celgene Corporation |
Uses of chimeric antigen receptor (car) t-cell therapies in combination with inhibitors of inflammation-related soluble factors
|
|
WO2022130182A1
(en)
|
2020-12-14 |
2022-06-23 |
Novartis Ag |
Reversal binding agents for anti-natriuretic peptide receptor 1 (npr1) antibodies and uses thereof
|
|
JP2023554097A
(ja)
|
2020-12-17 |
2023-12-26 |
オーエスイー・イミュノセラピューティクス |
二機能性抗ｐｄ１／ｉｌ－７分子
|
|
US20240092919A1
(en)
|
2020-12-18 |
2024-03-21 |
Ablynx N. V. |
T cell recruiting polypeptides based on tcr alpha/beta reactivity
|
|
CA3205422A1
(en)
|
2020-12-18 |
2022-06-23 |
Ablynx Nv |
Polypeptides comprising immunoglobulin single variable domains targeting glypican-3 and t cell receptor
|
|
TW202239763A
(zh)
|
2020-12-18 |
2022-10-16 |
比利時商艾伯霖克斯公司 |
包含靶向ＩＬ－６和ＴＮＦ－α的免疫球蛋白單可變結構域的多肽
|
|
GB202020502D0
(en)
|
2020-12-23 |
2021-02-03 |
Vib Vzw |
Antibody composistion for treatment of corona virus infection
|
|
WO2022136650A1
(en)
|
2020-12-24 |
2022-06-30 |
Oncurious Nv |
Murine cross-reactive human ccr8 binders
|
|
WO2022136649A1
(en)
|
2020-12-24 |
2022-06-30 |
Oncurious Nv |
Non-blocking human ccr8 binders
|
|
US20240076391A1
(en)
|
2020-12-24 |
2024-03-07 |
Oncurious Nv |
Human ccr8 binders
|
|
CA3208934A1
(en)
|
2021-01-20 |
2022-07-28 |
Visterra, Inc. |
Interleukin-2 mutants and uses thereof
|
|
JP2024505049A
(ja)
|
2021-01-29 |
2024-02-02 |
ノバルティス アーゲー |
抗ｃｄ７３及び抗ｅｎｔｐｄ２抗体のための投与方式並びにその使用
|
|
GB2603166A
(en)
|
2021-01-29 |
2022-08-03 |
Thelper As |
Therapeutic and Diagnostic Agents and Uses Thereof
|
|
KR20230152035A
(ko)
|
2021-02-01 |
2023-11-02 |
에쓰티 피에이치아이 테라퓨틱스 컴퍼니 리미티드 |
표적 단백질 분해 시스템 및 이의 응용
|
|
EP4288095A1
(en)
|
2021-02-05 |
2023-12-13 |
Vib Vzw |
Sarbecovirus binders
|
|
WO2022170063A1
(en)
|
2021-02-05 |
2022-08-11 |
Salubris Biotherapeutics, Inc. |
Il-15 fusion proteins and methods of making and using same
|
|
CN117794566A
(zh)
|
2021-02-05 |
2024-03-29 |
Vib研究所 |
沙贝病毒结合剂
|
|
US20240229154A9
(en)
|
2021-02-12 |
2024-07-11 |
Institut National de la Santé et de la Recherche Médicale |
Method for prognosis and treating a patient suffering from cancer
|
|
EP4294407A1
(en)
|
2021-02-17 |
2023-12-27 |
Vib Vzw |
Inhibition of slc4a4 in the treatment of cancer
|
|
EP4294516A1
(en)
|
2021-02-19 |
2023-12-27 |
Vib Vzw |
Cation-independent mannose-6-phosphate receptor binders
|
|
CA3209052A1
(en)
|
2021-02-19 |
2022-08-25 |
Rafael Cristian CASELLAS |
Single domain antibodies that neutralize sars-cov-2
|
|
BR112023016706A2
(pt)
|
2021-02-19 |
2023-10-31 |
Seoul Nat Univ R&Db Foundation |
Anticorpo ou um fragmento de ligação ao antígeno do mesmo, molécula de ácido nucleico, métodos para produzir um anticorpo ou um fragmento de ligação ao antígeno do mesmo e para detectar agrupamento de diferenciação 47 ou determinar uma quantidade de agrupamento de diferenciação 47 em uma amostra, e, uso do anticorpo ou de um fragmento de ligação ao antígeno do mesmo
|
|
BR112023016713A2
(pt)
|
2021-02-19 |
2023-10-31 |
Seoul Nat Univ R&Db Foundation |
Anticorpo ou um fragmento de ligação ao antígeno do mesmo, molécula de ácido nucleico, métodos para produzir um anticorpo ou um fragmento de ligação ao antígeno do mesmo e para detectar agrupamento de diferenciação 47 ou determinar uma quantidade de agrupamento de diferenciação 47 em uma amostra, e, uso do anticorpo ou de um fragmento de ligação ao antígeno do mesmo
|
|
EP4296284A4
(en)
|
2021-02-19 |
2025-03-05 |
SHAPERON Inc. |
BISPECIFIC SINGLE DOMAIN ANTIBODY AGAINST PD-L1 AND CD47 AND USE THEREOF
|
|
US20240310266A1
(en)
|
2021-03-18 |
2024-09-19 |
Novartis Ag |
Biomarkers for cancer and methods of use thereof
|
|
GB202104104D0
(en)
|
2021-03-24 |
2021-05-05 |
Liliumx Ltd |
Platform and method
|
|
WO2022199804A1
(en)
|
2021-03-24 |
2022-09-29 |
Vib Vzw |
Nek6 inhibition to treat als and ftd
|
|
JP2024514530A
(ja)
|
2021-04-02 |
2024-04-02 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
切断型ｃｄｃｐ１に対する抗体およびその使用
|
|
AU2022252997A1
(en)
|
2021-04-07 |
2023-09-28 |
Century Therapeutics, Inc. |
Compositions and methods for generating gamma-delta t cells from induced pluripotent stem cells
|
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
|
|
CA3214661A1
(en)
|
2021-04-07 |
2022-10-13 |
Century Therapeutics, Inc. |
Combined artificial cell death/reporter system polypeptide for chimeric antigen receptor cell and uses thereof
|
|
CN117441010A
(zh)
|
2021-04-07 |
2024-01-23 |
世纪治疗股份有限公司 |
从诱导多能干细胞产生α-βT细胞的组合物和方法
|
|
GB2623199A
(en)
|
2021-04-08 |
2024-04-10 |
Marengo Therapeutics Inc |
Multifunctional molecules binding to TCR and uses thereof
|
|
US20240369570A1
(en)
|
2021-04-09 |
2024-11-07 |
Stichting Radboud Universiteit |
Off the shelf proximity biotinylation enzyme
|
|
EP4320156A1
(en)
|
2021-04-09 |
2024-02-14 |
Ose Immunotherapeutics |
Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains
|
|
MX2023011964A
(es)
|
2021-04-09 |
2024-01-08 |
Ose Immunotherapeutics |
Nuevo andamio para moléculas bifuncionales con propiedades mejoradas.
|
|
US20240190993A1
(en)
|
2021-04-14 |
2024-06-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New method to improve the anti-tumoral activity of macrophages
|
|
US20240228659A1
(en)
|
2021-04-14 |
2024-07-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New method to improve nk cells cytotoxicity
|
|
IL307598A
(en)
|
2021-04-16 |
2023-12-01 |
Juno Therapeutics Inc |
T-cell therapy in patients who have had a previous stem cell transplant
|
|
US20220372168A1
(en)
|
2021-05-04 |
2022-11-24 |
Regeneron Pharmaceuticals, Inc. |
Multispecific fgf21 receptor agonists and their uses
|
|
AU2022270170A1
(en)
|
2021-05-07 |
2023-09-21 |
Surface Oncology, LLC |
Anti-il-27 antibodies and uses thereof
|
|
WO2022242892A1
(en)
|
2021-05-17 |
2022-11-24 |
Université de Liège |
Anti-cd38 single-domain antibodies in disease monitoring and treatment
|
|
CN117769434A
(zh)
|
2021-05-20 |
2024-03-26 |
黛安瑟斯医疗运营公司 |
与C1s结合的抗体和其用途
|
|
WO2022253910A1
(en)
|
2021-06-02 |
2022-12-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
A new method to treat an inflammatory skin disease
|
|
JP2024523436A
(ja)
|
2021-06-16 |
2024-06-28 |
上海▲シン▼湾生物科技有限公司 |
Ａｘｌタンパク質を標的とする抗体及びその抗原結合断片、その調製方法と使用
|
|
WO2022263507A1
(en)
|
2021-06-17 |
2022-12-22 |
Boehringer Ingelheim International Gmbh |
Novel tri-specific binding molecules
|
|
EP4359437A2
(en)
|
2021-06-22 |
2024-05-01 |
Merck Patent GmbH |
Vhh-based nkp30 binders
|
|
US20240287501A1
(en)
|
2021-06-23 |
2024-08-29 |
Vib Vzw |
Means and Methods for Selection of Specific Binders
|
|
CN114230665B
(zh)
|
2021-06-23 |
2024-03-22 |
苏州智核生物医药科技有限公司 |
CD8α结合多肽及其用途
|
|
WO2022269473A1
(en)
|
2021-06-23 |
2022-12-29 |
Janssen Biotech, Inc. |
Materials and methods for hinge regions in functional exogenous receptors
|
|
WO2023274183A1
(zh)
|
2021-06-29 |
2023-01-05 |
江苏先声药业有限公司 |
Cd16抗体及其应用
|
|
EP4370160A1
(en)
|
2021-07-15 |
2024-05-22 |
President And Fellows Of Harvard College |
Compositions and methods relating to cells with adhered particles
|
|
JP7727086B2
(ja)
|
2021-07-30 |
2025-08-20 |
山▲東▼先声生物制▲薬▼有限公司 |
抗ｐｖｒｉｇ／抗ｔｉｇｉｔ二重特異性抗体及び応用
|
|
WO2023016828A2
(en)
|
2021-07-30 |
2023-02-16 |
Vib Vzw |
Cation-independent mannose-6-phosphate receptor binders for targeted protein degradation
|
|
EP4380691A1
(en)
|
2021-08-06 |
2024-06-12 |
Institut Régional du Cancer de Montpellier (ICM) |
Methods for the treatment of cancer
|
|
TW202320850A
(zh)
|
2021-08-10 |
2023-06-01 |
美商維里迪恩醫療股份有限公司 |
用於治療甲狀腺眼病之組合物、劑量及方法
|
|
WO2023023227A1
(en)
|
2021-08-20 |
2023-02-23 |
Alexion Pharmaceuticals, Inc. |
Methods for treating sickle cell disease or beta thalassemia using complement alternative pathway inhibitors
|
|
WO2023023220A1
(en)
|
2021-08-20 |
2023-02-23 |
Alexion Pharmaceuticals, Inc. |
Methods for treating sickle cell disease or beta thalassemia using a complement alternative pathway inhibitor
|
|
KR20240049318A
(ko)
|
2021-08-24 |
2024-04-16 |
지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 |
Fap/cd40 결합 분자 및 이의 의학적 용도
|
|
TW202317644A
(zh)
|
2021-09-15 |
2023-05-01 |
大陸商江蘇恆瑞醫藥股份有限公司 |
一種含抗ｐｖｒｉｇ／ｔｉｇｉｔ雙特異性抗體的醫藥組成物
|
|
WO2023041985A2
(en)
|
2021-09-15 |
2023-03-23 |
New York University In Abu Dhabicorporation |
Compositions that block activation of the sars-cov-2 replication and transcription complex (rtc) and methods of use thereof
|
|
EP4403574A1
(en)
|
2021-09-15 |
2024-07-24 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Protein specifically binding to pd-1 and pharmaceutical use thereof
|
|
EP4401715A1
(en)
|
2021-09-17 |
2024-07-24 |
Institut Curie |
Bet inhibitors for treating pab1 deficient cancer
|
|
WO2023044483A2
(en)
|
2021-09-20 |
2023-03-23 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
|
EP4405680A1
(en)
|
2021-09-20 |
2024-07-31 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods for improving the efficacy of hdac inhibitor therapy and predicting the response to treatment with hdac inhibitor
|
|
US20240401146A1
(en)
|
2021-10-06 |
2024-12-05 |
Institut National de la Santé et de la Recherche Médicale |
Methods for predicting and improving the efficacy of mcl-1 inhibitor therapy
|
|
WO2023057601A1
(en)
|
2021-10-06 |
2023-04-13 |
Biotalys NV |
Anti-fungal polypeptides
|
|
KR20240082406A
(ko)
|
2021-10-08 |
2024-06-10 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
약물 전달을 위한 이온성 액체
|
|
AU2022364888A1
(en)
|
2021-10-14 |
2024-05-30 |
Latticon (Suzhou) Biopharmaceuticals Co., Ltd. |
Novel antibody-cytokine fusion protein, preparation method therefor and use thereof
|
|
WO2023073099A1
(en)
|
2021-10-28 |
2023-05-04 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method to improve phagocytosis
|
|
WO2023078906A1
(en)
|
2021-11-03 |
2023-05-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method for treating acute myeloid leukemia
|
|
EP4177266A1
(en)
|
2021-11-05 |
2023-05-10 |
Katholieke Universiteit Leuven |
Neutralizing anti-sars-cov-2 human antibodies
|
|
WO2023079137A1
(en)
|
2021-11-05 |
2023-05-11 |
Katholieke Universiteit Leuven |
Neutralizing anti-sars-cov-2 human antibodies
|
|
EP4429682A2
(en)
|
2021-11-09 |
2024-09-18 |
Actym Therapeutics, Inc. |
Immunostimulatory bacteria for converting macrophages into a phenotype amenable to treatment, and companion diagnostic for identifying subjects for treatment
|
|
EP4429692A1
(en)
|
2021-11-09 |
2024-09-18 |
Ose Immunotherapeutics |
Identification of clec-1 ligand and uses thereof
|
|
EP4180518A1
(en)
|
2021-11-12 |
2023-05-17 |
Istituto Europeo di Oncologia S.r.l. |
T cells and uses thereof
|
|
US20250034559A1
(en)
|
2021-11-17 |
2025-01-30 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
|
US20250019708A1
(en)
|
2021-11-19 |
2025-01-16 |
Institut Curie |
Methods for the treatment of hrd cancer and brca-associated cancer
|
|
WO2023089191A1
(en)
|
2021-11-22 |
2023-05-25 |
Ablynx N.V. |
Obtaining sequence information for target multivalent immunoglobulin single variable domains
|
|
WO2023089159A1
(en)
|
2021-11-22 |
2023-05-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New strategy targeting stroma/tumor cell crosstalk to treat a cancer
|
|
US20250001013A1
(en)
|
2021-11-24 |
2025-01-02 |
Novartis Ag |
Modulators of adeno-associated virus transduction and uses thereof
|
|
WO2023097254A1
(en)
|
2021-11-24 |
2023-06-01 |
Visterra, Inc. |
Engineered antibody molecules to cd138 and uses thereof
|
|
CN118339179A
(zh)
|
2021-11-29 |
2024-07-12 |
江苏恒瑞医药股份有限公司 |
经修饰的蛋白或多肽
|
|
JP2024544057A
(ja)
|
2021-11-30 |
2024-11-27 |
蘇州康寧傑瑞生物科技有限公司 |
血栓塞栓性疾患を予防及び／又は治療する方法
|
|
TW202333772A
(zh)
|
2021-12-01 |
2023-09-01 |
美商威特拉公司 |
使用介白素-2藥劑之方法
|
|
JP2024541668A
(ja)
|
2021-12-03 |
2024-11-08 |
山▲東▼先声生物制▲薬▼有限公司 |
抗ｂｃｍａナノ抗体及びその応用
|
|
WO2023099763A1
(en)
|
2021-12-03 |
2023-06-08 |
Institut Curie |
Sirt6 inhibitors for use in treating resistant hrd cancer
|
|
US11767366B1
(en)
|
2021-12-15 |
2023-09-26 |
Interius Biotherapeutics, Inc. |
Pseudotyped viral particles, compositions comprising the same, and uses thereof
|
|
KR20240122867A
(ko)
|
2021-12-17 |
2024-08-13 |
아블린쓰 |
TCRαβ, CD33, 및 CD123을 표적화하는 면역글로불린 단일 가변 도메인을 포함하는 폴리펩티드
|
|
CN118510805A
(zh)
|
2021-12-31 |
2024-08-16 |
山东先声生物制药有限公司 |
一种gprc5d抗体及其应用
|
|
EP4209508A1
(en)
|
2022-01-11 |
2023-07-12 |
Centre national de la recherche scientifique |
Nanobodies for the deneddylating enzyme nedp1
|
|
EP4463479A1
(en)
|
2022-01-12 |
2024-11-20 |
Vib Vzw |
Human ntcp binders for therapeutic use and liver-specific targeted delivery
|
|
GB202201137D0
(en)
|
2022-01-28 |
2022-03-16 |
Thelper As |
Therapeutic and diagnostic agents and uses thereof
|
|
WO2023147470A2
(en)
|
2022-01-28 |
2023-08-03 |
Georgiamune Inc. |
Antibodies to programmed cell death protein 1 that are pd-1 agonists
|
|
US20250129387A1
(en)
|
2022-02-02 |
2025-04-24 |
Biotalys NV |
Methods for genome editing
|
|
EP4476250A1
(en)
|
2022-02-07 |
2024-12-18 |
Vib Vzw |
Engineered stabilizing aglycosylated fc-regions
|
|
JP2025505650A
(ja)
|
2022-02-07 |
2025-02-28 |
ビステラ， インコーポレイテッド |
抗イディオタイプ抗体分子及びその使用
|
|
KR20240150434A
(ko)
|
2022-02-11 |
2024-10-15 |
헨켈 아게 운트 코. 카게아아 |
α-메틸렌-γ-부티로락톤의 합성 방법
|
|
US20250144042A1
(en)
|
2022-02-22 |
2025-05-08 |
Brown University |
Compositions and methods to achieve systemic uptake of particles following oral or mucosal administration
|
|
AU2023240232A1
(en)
|
2022-03-23 |
2024-10-10 |
Bodhi Bio Llc |
Antigen-specific therapy for autoimmune diseases
|
|
WO2023187657A1
(en)
|
2022-03-30 |
2023-10-05 |
Novartis Ag |
Methods of treating disorders using anti-natriuretic peptide receptor 1 (npr1) antibodies
|
|
CN119487069A
(zh)
|
2022-04-11 |
2025-02-18 |
Vor生物制药股份有限公司 |
结合剂及其使用方法
|
|
CN119013290A
(zh)
|
2022-04-13 |
2024-11-22 |
Ose免疫疗法公司 |
用于选择性清除抗体的新型分子
|
|
EP4508082A1
(en)
|
2022-04-13 |
2025-02-19 |
Vib Vzw |
An ltbr agonist in combination therapy against cancer
|
|
US20250249278A1
(en)
|
2022-04-14 |
2025-08-07 |
Institut National de la Santé et de la Recherche Médicale |
Methods for controlling the tumor cell killing by light
|
|
US20240092921A1
(en)
|
2022-04-25 |
2024-03-21 |
Visterra, Inc. |
Antibody molecules to april and uses thereof
|
|
WO2023212587A1
(en)
|
2022-04-28 |
2023-11-02 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Recombinant polypeptides comprising single-domain antibodies targeting herv-k subtype hml-2
|
|
EP4519324A1
(en)
|
2022-05-02 |
2025-03-12 |
UMC Utrecht Holding B.V. |
Single domain antibodies for the detection of plasmin-cleaved vwf
|
|
KR20250006959A
(ko)
|
2022-05-02 |
2025-01-13 |
아르커스 바이오사이언시즈 인코포레이티드 |
항-tigit 항체 및 이의 용도
|
|
CN119032105A
(zh)
|
2022-05-07 |
2024-11-26 |
北京拓界生物医药科技有限公司 |
松弛素或类似物的融合蛋白及其医药用途
|
|
EP4522630A1
(en)
|
2022-05-10 |
2025-03-19 |
Institut National de la Santé et de la Recherche Médicale |
Syncitin-1 fusion proteins and uses thereof for cargo delivery into target cells
|
|
EP4522183A2
(en)
|
2022-05-11 |
2025-03-19 |
Celgene Corporation |
Methods and uses related to t cell therapy and production of same
|
|
EP4522649A1
(en)
|
2022-05-11 |
2025-03-19 |
Regeneron Pharmaceuticals, Inc. |
Multispecific binding molecule proproteins and uses thereof
|
|
US20250295809A1
(en)
|
2022-05-13 |
2025-09-25 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
|
US20250282874A1
(en)
|
2022-05-17 |
2025-09-11 |
Suzhou Transcenta Therapeutics Co., Ltd. |
Bifunctional protein, and preparation thereof and use thereof
|
|
WO2023222825A1
(en)
|
2022-05-18 |
2023-11-23 |
Vib Vzw |
Sarbecovirus spike s2 subunit binders
|
|
WO2023224715A1
(en)
|
2022-05-19 |
2023-11-23 |
Massachusetts Institute Of Technology |
Car cells targeting an inserted ligand
|
|
AU2023271380A1
(en)
|
2022-05-19 |
2024-12-05 |
Shaperon Inc. |
Bispecific humanized single domain antibody to pd-l1 and cd47, and use thereof
|
|
WO2023230548A1
(en)
|
2022-05-25 |
2023-11-30 |
Celgene Corporation |
Method for predicting response to a t cell therapy
|
|
US20240025987A1
(en)
|
2022-05-25 |
2024-01-25 |
Surface Oncology, Inc. |
Use of anti-il-27 antibodies
|
|
US20240026001A1
(en)
|
2022-05-25 |
2024-01-25 |
Surface Oncology, Inc. |
Use of anti-il-27 antibodies
|
|
CN119301276A
(zh)
|
2022-05-30 |
2025-01-10 |
Ose免疫疗法 |
Il7r调节剂活性的生物标志物
|
|
CN119233996B
(zh)
|
2022-05-31 |
2025-08-26 |
明济生物制药（北京）有限公司 |
抗cd40抗体和抗pd-l1×cd40双特异抗体及其应用
|
|
CN119317648A
(zh)
|
2022-06-06 |
2025-01-14 |
山东先声生物制药有限公司 |
靶向bcma、gprc5d和t细胞的多特异性抗体及其应用
|
|
WO2023240124A1
(en)
|
2022-06-07 |
2023-12-14 |
Regeneron Pharmaceuticals, Inc. |
Pseudotyped viral particles for targeting tcr-expressing cells
|
|
JP2025519477A
(ja)
|
2022-06-07 |
2025-06-26 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
Ｔ細胞活性を調節するための多重特異性分子及びその使用
|
|
JP2025523403A
(ja)
|
2022-06-08 |
2025-07-23 |
タイダル・セラビューティクス・インコーポレイテッド |
イオン化可能なカチオン性脂質及び脂質ナノ粒子、並びにその合成方法及び使用
|
|
US20240109965A1
(en)
|
2022-06-14 |
2024-04-04 |
Ablynx N.V. |
Immunoglobulin single variable domains targeting t cell receptor
|
|
EP4299124A1
(en)
|
2022-06-30 |
2024-01-03 |
Universite De Montpellier |
Anti-mglur2 nanobodies for use as biomolecule transporter
|
|
EP4299125A1
(en)
|
2022-06-30 |
2024-01-03 |
Universite De Montpellier |
Anti-mglur2 biparatopic nanobodies and uses thereof
|
|
WO2024003873A1
(en)
|
2022-06-30 |
2024-01-04 |
Intrexon Actobiotics Nv D/B/A Precigen Actobio |
Single variable domain antibodies against tumor necrosis factor-alpha
|
|
JP2025523630A
(ja)
|
2022-07-04 |
2025-07-23 |
ブイアイビー ブイゼットダブリュ |
血液－脳脊髄液関門通過抗体
|
|
CN119630707A
(zh)
|
2022-07-08 |
2025-03-14 |
诺和诺德股份有限公司 |
能够替代fviii(a)的高效isvd化合物
|
|
US12098400B2
(en)
|
2022-07-08 |
2024-09-24 |
Novo Nordisk A/S |
Highly potent ISVD compounds capable of substituting for FVIII(A)
|
|
IL317689A
(en)
|
2022-07-15 |
2025-02-01 |
Boehringer Ingelheim Int |
Binding molecules for cancer treatment
|
|
JP2025525566A
(ja)
|
2022-07-18 |
2025-08-05 |
アブリンクス エン．ヴェー． |
Ｃｘ３ｃｒ１結合化合物、その使用及び関連する方法
|
|
US20250188492A1
(en)
|
2022-07-22 |
2025-06-12 |
Janssen Biotech, Inc. |
Enhanced Transfer of Genetic Instructions to Effector Immune Cells
|
|
TW202409288A
(zh)
|
2022-07-25 |
2024-03-01 |
美商英特瑞斯生物療法公司 |
突變多肽、包含該等突變多肽之組合物及其用途
|
|
EP4562036A1
(en)
|
2022-07-27 |
2025-06-04 |
Ablynx NV |
Polypeptides binding to a specific epitope of the neonatal fc receptor
|
|
WO2024028347A1
(en)
|
2022-08-01 |
2024-02-08 |
Ose Immunotherapeutics |
Heterodimeric fc-clec-1 fusion molecule and uses thereof
|
|
JP2025525886A
(ja)
|
2022-08-02 |
2025-08-07 |
オーエスイー・イミュノセラピューティクス |
Ｃｄ２８に対する多機能性分子
|
|
WO2024030976A2
(en)
|
2022-08-03 |
2024-02-08 |
Voyager Therapeutics, Inc. |
Compositions and methods for crossing the blood brain barrier
|
|
WO2024028476A1
(en)
|
2022-08-05 |
2024-02-08 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the treatment of th2-mediated diseases
|
|
WO2024037910A1
(en)
|
2022-08-17 |
2024-02-22 |
Institut National de la Santé et de la Recherche Médicale |
Syk inhibitors for use in the treatment of cancer
|
|
KR20250071294A
(ko)
|
2022-08-22 |
2025-05-21 |
압데라 테라퓨틱스 인크. |
Dll3 결합 분자 및 이의 용도
|
|
EP4580658A1
(en)
|
2022-08-31 |
2025-07-09 |
Institut National de la Santé et de la Recherche Médicale |
Method to generate more efficient car-t cells
|
|
TW202417490A
(zh)
|
2022-08-31 |
2024-05-01 |
美商艾力克森製藥公司 |
用於治療鐮狀細胞病的融合多肽之劑量及投與
|
|
JP2025529210A
(ja)
|
2022-09-01 |
2025-09-04 |
ユニバーシティ・オブ・ジョージア・リサーチ・ファウンデイション・インコーポレイテッド |
アポリポタンパク質ｌ１を導いて哺乳動物の細胞死を誘導するための組成物及び方法
|
|
JP2025529318A
(ja)
|
2022-09-06 |
2025-09-04 |
アレクシオン ファーマシューティカルズ， インコーポレイテッド |
造血幹細胞移植関連血栓性微小血管症（ｈｓｃｔ－ｔｍａ）を有する患者における診断及び予後バイオマーカプロファイル
|
|
EP4584299A2
(en)
|
2022-09-07 |
2025-07-16 |
Quantitative Biosciences, Inc. |
Fentanyl-specific single variable-domain antibodies and use in a continuous agglutination assay
|
|
CN120112550A
(zh)
|
2022-09-09 |
2025-06-06 |
耶鲁大学 |
蛋白水解靶向抗体及其使用方法
|
|
IL319121A
(en)
|
2022-09-15 |
2025-04-01 |
Voyager Therapeutics Inc |
Tau-binding compounds
|
|
AU2023342547A1
(en)
|
2022-09-15 |
2025-03-06 |
Novartis Ag |
Treatment of autoimmune disorders using chimeric antigen receptor therapy
|
|
EP4594348A1
(en)
|
2022-09-27 |
2025-08-06 |
Vib Vzw |
Antivirals against human parainfluenza virus
|
|
KR20250131767A
(ko)
|
2022-09-28 |
2025-09-03 |
발린크 테라퓨틱스 리미티드 |
다가 단백질 및 스크리닝 방법
|
|
TW202430561A
(zh)
|
2022-09-30 |
2024-08-01 |
法商賽諾菲公司 |
抗cd28抗體
|
|
WO2024074713A1
(en)
|
2022-10-07 |
2024-04-11 |
Institut National de la Santé et de la Recherche Médicale |
Method to generate improving car-t cells
|
|
WO2024083843A1
(en)
|
2022-10-18 |
2024-04-25 |
Confo Therapeutics N.V. |
Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders
|
|
CN120322456A
(zh)
|
2022-10-28 |
2025-07-15 |
嘉和生物药业有限公司 |
新型抗ctla4抗体
|
|
WO2024096735A1
(en)
|
2022-10-31 |
2024-05-10 |
Stichting Amsterdam UMC |
Single domain anti-cd169 antibodies
|
|
EP4613768A1
(en)
|
2022-11-02 |
2025-09-10 |
Suzhou Alphamab Co., Ltd |
Gipr binding protein and use thereof
|
|
WO2024101989A1
(en)
|
2022-11-08 |
2024-05-16 |
Stichting Amsterdam UMC |
Activation inducible antigen receptors for adoptive immunotherapy
|
|
CN120584135A
(zh)
|
2022-11-10 |
2025-09-02 |
英姆维亚公司 |
结合dr5和muc16的细胞毒性双特异性抗体及其用途
|
|
EP4619156A1
(en)
|
2022-11-15 |
2025-09-24 |
Imec VZW |
Method and system for droplet manipulation
|
|
EP4622670A1
(en)
|
2022-11-21 |
2025-10-01 |
Dianthus Therapeutics OpCo, Inc. |
Antibodies that bind to c1s and uses thereof
|
|
TW202421667A
(zh)
|
2022-11-29 |
2024-06-01 |
大陸商江蘇恆瑞醫藥股份有限公司 |
Ｃｌｄｎ１８．２／４－１ｂｂ結合蛋白及其醫藥用途
|
|
IL319951A
(en)
|
2022-11-30 |
2025-05-01 |
Integral Molecular Inc |
Antibodies targeting claudin 6, including its bispecific formats
|
|
KR20250114116A
(ko)
|
2022-12-01 |
2025-07-28 |
제너레이션 바이오 컴퍼니 |
세포 표적화를 위한 스텔스 지질 나노입자 조성물
|
|
WO2024123963A2
(en)
|
2022-12-07 |
2024-06-13 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing monoclonal antibodies against western, eastern, and venezuelan equine encephalitis virus (eev)
|
|
WO2024126363A1
(en)
|
2022-12-12 |
2024-06-20 |
Institut National de la Santé et de la Recherche Médicale |
Image-based high-content screening methods for identifying compounds targeting apicomplexan parasites
|
|
AR131388A1
(es)
|
2022-12-15 |
2025-03-12 |
Univ Aarhus |
Activación sintética de receptores transmembrana multiméricos
|
|
WO2024133301A1
(en)
|
2022-12-19 |
2024-06-27 |
Umc Utrecht Holding B.V. |
Btn2a1 binding peptide
|
|
US12195546B2
(en)
|
2022-12-19 |
2025-01-14 |
Sanofi |
CD28/OX40 bispecific antibodies
|
|
CN120380024A
(zh)
|
2022-12-21 |
2025-07-25 |
建新公司 |
抗pd-1×4-1bb结合蛋白
|
|
WO2024133937A1
(en)
|
2022-12-22 |
2024-06-27 |
Biotalys NV |
Methods for genome editing
|
|
WO2024133723A1
(en)
|
2022-12-22 |
2024-06-27 |
Institut National de la Santé et de la Recherche Médicale |
Methods for decreasing therapeutic acquired resistance to chemotherapy and/or radiotherapy
|
|
CN120476149A
(zh)
|
2022-12-23 |
2025-08-12 |
成都恩沐生物科技有限公司 |
靶向gprc5d的多特异性多肽复合物
|
|
AR131494A1
(es)
|
2022-12-23 |
2025-03-26 |
Ablynx Nv |
Vehículos de conjugación a base de proteína
|
|
WO2024145551A1
(en)
|
2022-12-29 |
2024-07-04 |
Biotalys NV |
Agrochemical compositions
|
|
WO2024140939A2
(zh)
|
2022-12-29 |
2024-07-04 |
苏州创胜医药集团有限公司 |
含有治疗性抗体的药物制剂及其用途
|
|
WO2024141638A1
(en)
|
2022-12-30 |
2024-07-04 |
Biotalys NV |
Self-emulsifiable concentrate
|
|
WO2024141641A2
(en)
|
2022-12-30 |
2024-07-04 |
Biotalys NV |
Secretion signals
|
|
WO2024141645A1
(en)
|
2022-12-30 |
2024-07-04 |
Biotalys N.V. |
Agglomerate
|
|
WO2024143925A1
(ko)
|
2022-12-30 |
2024-07-04 |
연세대학교 산학협력단 |
Rnase a에 특이적으로 결합하는 항체 또는 펩티드, 및 rnase a 검출 면역분석 장치 및 방법 그리고 rnase a 포집 방법
|
|
KR20250133913A
(ko)
|
2023-01-09 |
2025-09-09 |
베이징 투오 지에 바이오파마수티컬 컴퍼니 리미티드 |
TGFβ1 결합 분자, GARP-TGFβ1 결합 분자 및 이의 의학적 용도
|
|
IL321915A
(en)
|
2023-01-09 |
2025-09-01 |
Odyssey Therapeutics Inc |
Anti-TNFR2 antigen-binding proteins and their uses
|
|
US20240247069A1
(en)
|
2023-01-13 |
2024-07-25 |
Regeneron Pharmaceuticals, Inc. |
Fgfr3 binding molecules and methods of use thereof
|
|
TW202434629A
(zh)
|
2023-01-26 |
2024-09-01 |
愛爾蘭商歐薩爾普羅席納有限公司 |
以抗類澱粉β (ABETA)抗體治療神經病症之方法
|
|
WO2024156881A1
(en)
|
2023-01-27 |
2024-08-02 |
Vib Vzw |
CD8b-BINDING POLYPEPTIDES
|
|
WO2024156888A1
(en)
|
2023-01-27 |
2024-08-02 |
Vib Vzw |
Cd163-binding conjugates
|
|
WO2024165500A1
(en)
|
2023-02-06 |
2024-08-15 |
Merck Patent Gmbh |
Vhh-based nkp46 binders
|
|
WO2024168061A2
(en)
|
2023-02-07 |
2024-08-15 |
Ayan Therapeutics Inc. |
Antibody molecules binding to sars-cov-2
|
|
WO2024165710A1
(en)
|
2023-02-09 |
2024-08-15 |
Seni-Preps B.V. |
Immunoglobulin single variable domains that inhibit urease and use thereof
|
|
KR20250133776A
(ko)
|
2023-02-10 |
2025-09-08 |
아뮤닉스 파마슈티컬스, 인크. |
전립선-특이적 막 항원(psma)을 표적화하는 조성물 및 이의 제조 방법 및 사용 방법
|
|
CN120712282A
(zh)
|
2023-02-17 |
2025-09-26 |
阿布林克斯有限公司 |
结合新生儿fc受体的多肽
|
|
WO2024175787A1
(en)
|
2023-02-24 |
2024-08-29 |
Vrije Universiteit Brussel |
Anti-inflammatory pannexin 1 channel inhibitors
|
|
AR132064A1
(es)
|
2023-03-06 |
2025-05-21 |
Beigene Switzerland Gmbh |
Anticuerpos anti-cldn6 y métodos de uso
|
|
WO2024184810A1
(en)
|
2023-03-06 |
2024-09-12 |
Beigene Switzerland Gmbh |
Anti-cldn6 and anti-cd3 multispecific antibodies and methods of use
|
|
TW202436345A
(zh)
|
2023-03-06 |
2024-09-16 |
瑞士商百濟神州瑞士有限責任公司 |
抗ｃｄ３多特異性抗體及使用方法
|
|
WO2024184476A1
(en)
|
2023-03-07 |
2024-09-12 |
Institut Curie |
Ung/udg inhibition in brca-associated cancer
|
|
WO2024184479A1
(en)
|
2023-03-08 |
2024-09-12 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the treatment of food allergy
|
|
AU2024234615A1
(en)
|
2023-03-14 |
2025-08-21 |
Odyssey Therapeutics, Inc. |
Anti-cd25 antigen-binding proteins and uses thereof
|
|
WO2024189171A1
(en)
|
2023-03-14 |
2024-09-19 |
Aarhus Universitet |
Genetically altered nfr5 receptor kinases
|
|
WO2024194402A1
(en)
|
2023-03-21 |
2024-09-26 |
Institut Curie |
Farnesyl transferase inhibitor for use in methods for the treatment of hrd cancer
|
|
WO2024194401A1
(en)
|
2023-03-21 |
2024-09-26 |
Institut Curie |
Vps4b inhibitor for use in methods for the treatment of hrd cancer
|
|
WO2024194673A1
(en)
|
2023-03-21 |
2024-09-26 |
Institut Curie |
Methods for the treatment of dedifferentiated liposarcoma
|
|
WO2024197296A1
(en)
|
2023-03-23 |
2024-09-26 |
Bodhi Bio Llc |
Compositions and methods for antigen-specific therapy
|
|
WO2024200332A1
(en)
|
2023-03-24 |
2024-10-03 |
Sanofi |
Asthma treatment by blocking il-13 and tslp
|
|
EP4435005A1
(en)
|
2023-03-24 |
2024-09-25 |
Sanofi |
Asthma treatment by blocking il-13 and tslp
|
|
WO2024200846A1
(en)
|
2023-03-30 |
2024-10-03 |
272BIO Limited |
Gnrh-binding polypeptides and uses thereof
|
|
WO2024208816A1
(en)
|
2023-04-03 |
2024-10-10 |
Vib Vzw |
Blood-brain barrier crossing antibodies
|
|
WO2024213782A1
(en)
|
2023-04-13 |
2024-10-17 |
Institut Curie |
Methods for the treatment of t-cell acute lymphoblastic leukemia
|
|
WO2024224323A1
(en)
|
2023-04-24 |
2024-10-31 |
King Abdullah University Of Science Of Technology |
Compositions, systems and methods for multiplex detection of target biomarkers in a sample
|
|
WO2024226829A2
(en)
|
2023-04-26 |
2024-10-31 |
Yale University |
Enpp3-binding molecules, compositions formed therefrom, and methods of use thereof for the treatment of cancer
|
|
TW202509060A
(zh)
|
2023-05-08 |
2025-03-01 |
法商賽諾菲公司 |
免疫球蛋白單可變結構域的醣基化
|
|
WO2024231348A1
(en)
|
2023-05-11 |
2024-11-14 |
Vib Vzw |
Slc4a4/nbce1 inhibitors
|
|
WO2024238565A1
(en)
|
2023-05-15 |
2024-11-21 |
Vor Biopharma Inc. |
Egf-like module containing mucin-like hormone-like 2 (erm2) binding agents and methods of use thereof
|
|
WO2024238790A1
(en)
|
2023-05-17 |
2024-11-21 |
Odyssey Therapeutics, Inc. |
Modified single-domain antibodies
|
|
WO2024240162A1
(en)
|
2023-05-23 |
2024-11-28 |
Shanghai Allygen Biologics Co., Ltd. |
Pd-l1 and trop-2 targeting conjugates comprising effector molecules and uses thereof
|
|
WO2024243340A1
(en)
|
2023-05-23 |
2024-11-28 |
Sana Biotechnology, Inc. |
Tandem fusogens and related lipid particles
|
|
WO2024251783A1
(en)
|
2023-06-05 |
2024-12-12 |
Sanofi |
Predicting thermal stabilities of immunoglobulin single variable domains using machine-learning models
|
|
WO2024251826A1
(en)
|
2023-06-05 |
2024-12-12 |
Vib Vzw |
Glyco-engineered antibody-drug-conjugates comprising an oxime linker
|
|
WO2024251983A1
(en)
|
2023-06-09 |
2024-12-12 |
Merck Patent Gmbh |
Il-18 mimetics
|
|
WO2024251981A1
(en)
|
2023-06-09 |
2024-12-12 |
Umc Utrecht Holding B.V. |
Detecting and/or modulating susceptibility to btn2a1 and/or btn3a1 targeting therapeutics
|
|
WO2024256527A1
(en)
|
2023-06-13 |
2024-12-19 |
Institut National de la Santé et de la Recherche Médicale |
Use of a cxcl 10 inhibitor for the treatment of transplant vasculopathy
|
|
WO2024259305A1
(en)
|
2023-06-14 |
2024-12-19 |
The Broad Institute, Inc. |
Vhh polypeptides that bind to mesothelin, compositions and methods of use thereof
|
|
WO2024261235A1
(en)
|
2023-06-22 |
2024-12-26 |
Ablynx Nv |
Chimeric proteins for modulating cytokine receptor activity
|
|
WO2024261338A1
(en)
|
2023-06-22 |
2024-12-26 |
Ablynx Nv |
Immunoglobulin single variable domains targeting pd-l1
|
|
WO2024261344A1
(en)
|
2023-06-23 |
2024-12-26 |
Vib Vzw |
Novel binders targeting the multi-drug resistant pathogen acinetobacter baumannii
|
|
TW202515917A
(zh)
|
2023-06-29 |
2025-04-16 |
美商奧迪希治療公司 |
抗trailr2抗原結合蛋白及其用途
|
|
EP4483951A1
(en)
|
2023-06-30 |
2025-01-01 |
Université de Liège |
Single-domain antibody for inhibition of neutrophil elastase activity
|
|
US20250034260A1
(en)
|
2023-07-05 |
2025-01-30 |
Sanofi |
Fcrn antagonists for treatment of igg-related diseases and disorders
|
|
WO2025007195A1
(en)
|
2023-07-05 |
2025-01-09 |
CSL Innovation Pty Ltd |
Methods of treating or preventing a complication of sickle cell disease
|
|
WO2025014774A1
(en)
|
2023-07-07 |
2025-01-16 |
Viridian Therapeutics, Inc. |
Methods of treating active and chronic thyroid eye disease
|
|
WO2025024645A1
(en)
|
2023-07-25 |
2025-01-30 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Rapid method for producing antibodies
|
|
WO2025034806A1
(en)
|
2023-08-08 |
2025-02-13 |
Wisconsin Alumni Research Foundation |
Single-domain antibodies and variants thereof against fibroblast activation protein
|
|
WO2025032112A1
(en)
|
2023-08-08 |
2025-02-13 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the treatment of type 2-mediated diseases
|
|
WO2025032158A1
(en)
|
2023-08-08 |
2025-02-13 |
Institut National de la Santé et de la Recherche Médicale |
Method to treat tauopathies
|
|
WO2025032213A1
(en)
|
2023-08-10 |
2025-02-13 |
Ose Immunotherapeutics |
Identification of hla-dra as a ligand of clec-1 and uses thereof
|
|
WO2025036848A1
(en)
|
2023-08-11 |
2025-02-20 |
Wuxi Biologics (Shanghai) Co., Ltd. |
Anti-muc16 antibodies and uses thereof
|
|
EP4512243A1
(en)
|
2023-08-21 |
2025-02-26 |
Kymab Limited |
Binding molecules
|
|
TW202525843A
(zh)
|
2023-09-04 |
2025-07-01 |
法商賽諾菲公司 |
用於治療表現磷脂醯肌醇蛋白聚糖-3之腫瘤的多肽
|
|
WO2025059487A2
(en)
|
2023-09-15 |
2025-03-20 |
Othair Prothena Limited |
Cell penetrating agents and uses thereof
|
|
GB202314424D0
(en)
|
2023-09-20 |
2023-11-01 |
Cambridge Entpr Ltd |
A conjugate
|
|
WO2025061919A1
(en)
|
2023-09-22 |
2025-03-27 |
Ablynx Nv |
Bi- and multivalent albumin binders
|
|
WO2025068393A1
(en)
|
2023-09-27 |
2025-04-03 |
Institut Curie |
Methods for the treatment of fibrotic related diseases
|
|
WO2025073765A1
(en)
|
2023-10-03 |
2025-04-10 |
Institut National de la Santé et de la Recherche Médicale |
Methods of prognosis and treatment of patients suffering from melanoma
|
|
WO2025073890A1
(en)
|
2023-10-06 |
2025-04-10 |
Institut National de la Santé et de la Recherche Médicale |
Method to capture circulating tumor extracellular vesicles
|
|
WO2025078418A1
(en)
|
2023-10-10 |
2025-04-17 |
Nano Tag Biotechnologies Gmbh |
Humanized single-domain antibodies binding to epitope tags
|
|
WO2025078401A1
(en)
|
2023-10-11 |
2025-04-17 |
BioNTech SE |
Agents and methods for targeted delivery of immune effector cells
|
|
WO2025078851A1
(en)
|
2023-10-11 |
2025-04-17 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Methods of treating cognitive deficit
|
|
NL2036011B1
(en)
|
2023-10-12 |
2025-04-30 |
Synapse Res Institute |
Molecules for reversing anti-coagulant activity of direct oral anticoagulants
|
|
TW202515903A
(zh)
|
2023-10-12 |
2025-04-16 |
瑞士商百濟神州瑞士有限責任公司 |
手術前後基於抗ｐｄ－１之治療
|
|
WO2025080751A2
(en)
|
2023-10-13 |
2025-04-17 |
Odyssey Therapeutics, Inc. |
Anti-cdh17 antigen-binding proteins and uses thereof
|
|
WO2025093541A1
(en)
|
2023-10-31 |
2025-05-08 |
Ose Immunotherapeutics |
Combination of interleukin 7 and tumour associated antigen vaccine
|
|
WO2025093683A1
(en)
|
2023-11-03 |
2025-05-08 |
Neuvasq Biotechnologies Sa |
Wnt7 signaling agonists
|
|
WO2025099632A1
(en)
|
2023-11-08 |
2025-05-15 |
Sanofi |
Cd25 based lysosomal degrader and uses thereof
|
|
WO2025109176A1
(en)
|
2023-11-22 |
2025-05-30 |
Exevir Bio Bv |
Optimized sarbecovirus spike s2 subunit binders and compositions comprising the same
|
|
US20250296991A1
(en)
|
2023-12-01 |
2025-09-25 |
Ablynx N.V. |
Precision activated polypeptides
|
|
WO2025122634A1
(en)
|
2023-12-05 |
2025-06-12 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
|
WO2025125577A1
(en)
|
2023-12-14 |
2025-06-19 |
Vib Vzw |
Antibodies against influenza b virus
|
|
WO2025136985A1
(en)
|
2023-12-17 |
2025-06-26 |
Viridian Therapeutics, Inc. |
Compositions, doses, and methods for treatment of thyroid eye disease
|
|
WO2025132833A1
(en)
|
2023-12-20 |
2025-06-26 |
Institut National de la Santé et de la Recherche Médicale |
Anti trypsin-3 single domain antibody
|
|
WO2025133252A1
(en)
|
2023-12-22 |
2025-06-26 |
Ablynx Nv |
Immunoglobulin single variable domains targeting ceacam5
|
|
EP4574981A1
(en)
|
2023-12-22 |
2025-06-25 |
Biotalys NV |
Anti-fungal vhh antibodies
|
|
WO2025133166A1
(en)
|
2023-12-22 |
2025-06-26 |
Ablynx Nv |
Protein-based carriers for site-specific amine conjugation
|
|
WO2025133253A2
(en)
|
2023-12-22 |
2025-06-26 |
Ablynx Nv |
Protein-based conjugation carriers for intranuclear delivery
|
|
WO2025151496A1
(en)
|
2024-01-09 |
2025-07-17 |
Viridian Therapeutics, Inc. |
Compositions and methods for treatment of thyroid eye disease
|
|
WO2025151502A1
(en)
|
2024-01-09 |
2025-07-17 |
Viridian Therapeutics, Inc. |
Modified antibodies
|
|
WO2025151492A1
(en)
|
2024-01-09 |
2025-07-17 |
Viridian Therapeutics, Inc. |
Compositions and methods for treatment of thyroid eye disease
|
|
WO2025154056A1
(en)
|
2024-01-21 |
2025-07-24 |
Ibi-Ag Innovative Bio Insecticides Ltd. |
Anti-insect cda nanobodies and uses thereof
|
|
WO2025154058A1
(en)
|
2024-01-21 |
2025-07-24 |
Ibi-Ag Innovative Bio Insecticides Ltd. |
Anti-insect hsp70 nanobodies and uses thereof
|
|
WO2025160546A1
(en)
|
2024-01-26 |
2025-07-31 |
The Johns Hopkins University |
Dendrimer conjugate compositions for intracellular delivery of antibodies and antibody fragments
|
|
WO2025162980A1
(en)
|
2024-01-30 |
2025-08-07 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the treatment of breast cancer using a jnk-1 inhibitor
|
|
WO2025168716A1
(en)
|
2024-02-07 |
2025-08-14 |
Eyebiotech Limited |
Compositions, doses, and methods for treatment of ocular diseases
|
|
WO2025174825A2
(en)
|
2024-02-12 |
2025-08-21 |
Aera Therapeutics, Inc. |
Delivery compositions
|
|
WO2025178959A1
(en)
|
2024-02-20 |
2025-08-28 |
University Of Georgia Research Foundation, Inc. |
Single-domain antibodies and variants thereof against tab1
|
|
WO2025176777A1
(en)
|
2024-02-20 |
2025-08-28 |
Institut Curie |
Dut inhibition in homologous recombination deficiency cancer
|
|
WO2025181155A1
(en)
|
2024-02-26 |
2025-09-04 |
Vib Vzw |
Human beta-glucocerebrosidase binders and uses thereof
|
|
WO2025184208A1
(en)
|
2024-02-27 |
2025-09-04 |
Bristol-Myers Squibb Company |
Anti-ceacam5 antibodies and uses thereof
|
|
US20250269052A1
(en)
|
2024-02-27 |
2025-08-28 |
Bristol-Myers Squibb Company |
Anti-ceacam5 antibody drug conjugates
|
|
WO2025191018A1
(en)
|
2024-03-13 |
2025-09-18 |
Institut National de la Santé et de la Recherche Médicale |
Mrgpre binding agent for use in the treatment of inflammatory and pain disorders
|
|
WO2025196308A1
(en)
|
2024-03-22 |
2025-09-25 |
Vib Vzw |
Means and methods for displaying fc-containing proteins on cells and selection thereof
|
|
WO2025207946A1
(en)
|
2024-03-28 |
2025-10-02 |
Genzyme Corporation |
Polypeptides binding to a specific epitope of the transferrin receptor 1
|